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1Section A. Introduction
Background
Substantial progress has been made in the past decade to improve tuberculosis (TB) 
outcomes and control, particularly with the development and implementation of new 
diagnostic tests and treatment regimens [1–3]. Addressing the global TB epidemic is 
in line with the goals of Universal Health Coverage (UHC) to provide health care for 
all, without financial adversity. However, funding for TB still needs to be increased in 
order to reach global targets. Estimating the costs of TB interventions is an essential 
component to planning, prioritizing and managing the funding of TB services [4]. 
The ‘Reference Case for Estimating the Costs of Global Health Services and 
Interventions’ [5] (referred to hereafter as the ‘Reference Case’) encourages consistent 
adherence to core principles when collecting data to estimate the costs of health 
services. As a guiding document, it also presents the different costing methodologies 
that can be utilized, indicating the strengths and weaknesses of each, and provides 
a set of principles to improve global health costing. In this set of guidelines, we draw 
on the Reference Case principles to outline the main steps for costing TB services. 
Researchers can develop specific protocols which draw from these steps depending on 
the purpose of their costing study. For example, cost methods may vary depending on 
the time available, size or scope of a study. 
Throughout this document, we use the Value TB Study as an illustration of how a TB 
costing study can be undertaken. Value TB was funded by The Bill and Melinda Gates 
Foundation (https://datacompass.lshtm.ac.uk/817/). The purpose of the Value TB 
Study was to assess the service delivery costs of all TB interventions in five countries 
(Kenya, Ethiopia, India, Philippines and Georgia) in order to update current data and 
inform users of the cost data, such as modellers and policy makers. The primary aim of 
Value TB was to enable National Tuberculosis Programmes (NTPs) and their funders 
to allocate their resources, both to and within TB, in an efficient and fair way. We also 
include a set of costing instruments called the Value TB Costing Tool Suite (including 
Data Collection and Data Entry components) which can be adapted depending on 
the costing protocol developed. The complementary Value TB Costing Tool Suite can be 
found on the Global Health Cost Consortium (GHCC) and World Health Organization 
(WHO) websites (https://ghcosting.org/ and https://www.who.int/tb/publications/
en/), and a detailed explanation of these tools can be found in Appendix 8 of these 
guidelines.
Section A. Introduction
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Aim of the guidelines
The aim of these guidelines is to provide a step-by-step guide for those who need to 
conduct primary data collection to estimate the cost of delivering TB interventions 
and produce a standard set of unit costs. These guidelines take the reader from 
protocol design to cost data analysis. They provide practical advice on how to collect 
cost data for specific chosen purposes, perform analysis and disseminate data. These 
guidelines do not cover how to assess cost savings for TB interventions over time, 
as the focus of the guidelines is the production of unit costs through a cost analysis 
rather than undertaking economic modelling. They also do not touch on assessing 
cost-effectiveness of programmes or interventions, or the analytics required to 
produce cost functions. Rather, they assist with the collection and estimation of a 
standard set of unit costs as this relates to making estimates of economics costs, 
setting budgets, financial planning, understanding TB programmes and responding 
to the introduction of new technologies as they emerge. Several guidelines have 
previously been developed for TB costing. This set of guidelines  specifically updated 
and built on existing work by Floyd [6–9]. 
Who should use these guidelines?
These guidelines are intended for experienced producers of cost data who may know 
less about how to cost TB services. This manual is TB-specific and allows costing work 
to be adapted to context and purpose. While this guidance can be used for those who 
have not costed health services previously, where this is the case we would advise 
using the Reference Case as a complementary resource [5].
The primary user may be the costing coordinator based in the NTP, a primary 
investigator or a manager at a facility. For the co-ordinator of studies, particular 
reference should be made to Section C – Study Design and Set Up. Section C covers 
the necessary steps in establishing the study, including defining the purpose of the 
study, setting up a study team to perform the data collection and analysis, gaining 
ethical approval and establishing the study aims and objectives. This guidance is also 
designed to support those collecting data in the field. In this case, the focus should 
be on Section D, which highlights the important aspects in TB cost data collection, 
including understanding the production process, adapting the Data Collection Tool, 
mapping data sources and measuring resource use. 
Structure of the guidelines
The guidelines are structured into the following stages in a costing study: pre-data 
collection activities (initial conceptualization, defining the interventions, setting up 
country links/selection of study partners, establishing country teams, study protocol 
formation and submission of protocol for ethical approval, training and piloting); 
data collection at the facility level (and the community level if required), data 
collection at above-facility level; and post-data collection activities (data analysis, 
preparation of reports, papers and a publicly accessible database, dissemination of 
data). Accordingly, the guidelines have the following four sections:
Section B: Defining the TB Interventions to be costed 
This encompasses a brief overview of TB interventions, with additional detail in 
Appendix 2.
3Section C: Study Design and Set Up 
Section C focuses on study design aspects and how to set up a TB costing study, 
highlighting key steps in the process. 
Section D: Data Collection: Resource and Service Use Measurement; 
Pricing and Valuation
Section D outlines the features of data collection and the production process, details 
costing approaches and provides an introduction to the Value TB Costing Tool Suite. 
These features include: the scope, methods, sampling, data sources, timing of data 
collection and adjustments to data.
Section E: Data Analysis, Presenting Results and Dissemination of 
Cost Data
Section E speaks to the data analysis stage where one assesses the unit costs that 
have been generated. It also addresses the need to look at the drivers of cost, variation 
in costs, sensitivity analyses one may want to undertake to assess uncertainty and 
how to disseminate this information effectively in a transparent manner to the users 
of TB unit costs. 
Additionally, appendices can be found in the final section:
Section F: Appendices 
Appendix 8 describes the corresponding Value TB Costing Tool Suite, how to make best 
use of these tools and how to adapt them to specific contexts.
Appendix 11 provides case studies to illustrate steps for learning how things are 
practically and pragmatically done when costing TB services. 
Section A. Introduction
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Section B. Defining TB interventions
Standardized unit costs for TB interventions
In order to enable cross-country comparisons of TB costs and extrapolate costs across 
settings, it is important to develop a set of standardized unit costs for TB services. 
This was done as part of the GHCC, contained here in Appendix 3 [5]. Appendix 3 
outlines the main TB intervention categories (under the heading Intervention), 
intervention details and standardized cost units that should be reported.
The main classes of intervention for TB are: 
A. Vaccination (which includes Bacille Calmette-Guérin (BCG) Vaccination)
B. TB case detection and diagnosis, which includes the intervention types of passive, 
active and intensified case finding (PCF, ACF and ICF)
C. TB treatment
D. TB prevention
E. TB infection control
F. TB programme above site services (which comprises policy, planning, coordination 
and management for TB services)
Over time there may be further adoption of future technologies and thus interventions 
to be included, for instance if new vaccine candidates are developed. 
To ensure comparability of costs, Appendix 3 also provides details of different 
options for intervention implementation, including: an open field for any specific 
intervention modality (e.g. centralized, decentralized etc.), the technologies utilized 
for that particular intervention (such as first line treatment, or type of diagnostic), 
the delivery platform ownership and type (such as private facilities, public clinics and 
hospitals), and the population that is covered, for instance adults with pulmonary TB, 
HIV comorbidity or children (which can be further separated into demographic and 
clinical details). For TB treatment, the particular phase should be indicated (start-up, 
implementation, intensive or continuation). If a new intervention for TB care emerges 
and requires costing, it should be described in a similar manner (platform, population 
covered etc). 
For each intervention, a standardized unit cost is presented (unit cost per recipient/
person reached) in order to standardize the outputs of TB costing studies to provide 
comparability and generalizability. Further breakdowns of unit costs are indicated: an 
optional quality adjusted unit cost per recipient, and unit costs for the list of outputs 
required to deliver the intervention or services. The activity and other total cost 
breakdowns, input category breakdown and mandatory reported inputs are listed by 
intervention. 
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Fig. 1. Standard unit costs
Passive case finding
Intervention ‘unit’ cost
Direct and ancillary 
service ‘unit’ costs Activity costs
Cost per person 
diagnosed (with either 
drug sensitive or drug 
resistant TB) 
Quantity (visits) * Cost per 
outpatient visit
Quantity (visits) * Cost 
per inpatient visit (e.g. for 
children needing fine-
needle biopsy)
Quantity * Cost of patient 
support visit 
Only included if within the 
health sector
Quantity (number of tests) 
* Cost per test (defined 
per technology: Symptom 
Screen; Xpert® MTB/RIF; 
Microscopy LED; X-ray 
(chest x-ray); Digital X-ray 
(chest x-ray); rapid HIV Test 
etc.)
Quantity (minutes) * Cost per minute 
(personnel time includes time of clinical 
and non-clinical staff) 
Quantity (square metre per minute) 
* Cost per square metre per minute 
(infrastructure including building, 
equipment, furniture, overhead inputs 
including administration, cleaning, kitchen, 
utilities, security, laundry, monitoring 
and evaluation/pharmacovigilance, 
maintenance, training)
Quantity (minutes) * Cost per minute 
(personnel time see above)
Quantity (square metre per minute) 
* Cost per square metre per minute 
(infrastructure and overhead cost see 
above)
Quantity (minutes) * Cost per minute 
(personnel time includes time of health 
care or social care worker)
Quantity (square metre per minute) * 
Cost per square metre per minute for 
counseling visit (infrastructure and 
overheads see above)
Quantity * Cost of cash transfer (includes 
the actual cash transfer itself)
Quantity * infrastructure cost surrounding 
administration of the transfer (personnel 
time, infrastructure, overhead inputs, 
information technology and banking fees, 
etc.)
Quantity (minutes) * Cost per minute 
(personnel time of laboratory staff) 
Quantity (number of tests) * cost of 
‘technology’ (infrastructure, consumables, 
chemicals and reagents, overhead inputs, 
biosafety, quality assurance (national, 
regional, supranational), monitoring and 
evaluation, transportation of samples, 
transport for reporting results back to the 
patient, training of laboratory workers to 
operate that technology (both capital and 
recurrent)
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Figure 1 shows one diagrammatic example of a unit cost per recipient for PCF (from 
Table 3, Appendix 2). It explores the possible activities that make up the direct and 
ancillary unit costs in term the intervention unit cost.
When starting a costing study, it is important to describe the intervention and all 
the outputs and inputs required to produce the intervention (the production process). 
For example, in the instance of TB Treatment (Table 1), one would first define the 
intervention unit costs e.g. the Cost per person completing treatment for children 
with pulmonary TB having taken first line treatment in the context of a hospital 
delivering TB care). This intervention ‘unit’ cost can be broken down into the direct 
(mean cost per output) and ancillary (mean cost per additional output that supports 
the delivery of health services). The direct and ancillary service ‘unit’ costs can be 
further broken down into activity costs, which are the costs for each action required 
to provide services. The activity costs are in turn determined by the quantity of input 
multiplied by price (see Table 3 in Appendix 2).
To cost an intervention, it is necessary to understand and describe this production 
process and build up the cost from the different components to ensure the cost is not 
biased. Much of the work of costing involves describing this detail, often together 
with TB service planners. For instance, for drug sensitive TB (DS-TB) treatment, one 
needs to include the cost of all the capital items/assets or providing outpatient visits 
(building, training, vehicle, equipment and furniture unit costs) to the recurrent cost 
per visit (overhead utility costs and staff costs). The cost per DS-TB treatment visit is 
then added to the diagnostic test cost per DS-TB treatment case and then the drug 
cost per DS-TB treatment case. To determine the total cost of treating a DS-TB case, 
the cost per visit would be multiplied by the average number of visits made added to 
the diagnostic test cost and drug costs multiplied by the number of tests performed 
and drugs received respectively. Generic descriptions of the TB interventions are 
given in Appendix 2 which can be adapted as needed to define the interventions in 
the setting selected. 
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Section C. Study objectives and set-up
Overview
This section addresses how to determine the broad objectives and scope of the costing 
study, as well as the study set up. It briefly describes the various steps with examples 
from recent costing studies with a focus on the study methodology and design. 
Depending on the aim of the study, the steps may take a different order than laid out 
here (in Figures 2 and 3). In practice a TB costing study involves the following pre-
data collection activities. 
Fig. 2. Example of activities for national costing study (example of Value TB)
Pre-data collection activities
n The initial conceptualization of the study – deciding the research purpose
n Setting up the core research team
n Planning meetings to define TB costing needs, ascertain study objectives, agree on activities 
and responsibilities
n Identification of funding sources for the study
n Where relevant, sampling of countries
n Where relevant establishing links with sampled potential countries and investigating their 
interest
n Where relevant, initial country visits to set up country teams with the NTP
n Develop country budgets and initial study timeframe planning
n Any relevant contracts to partners issued
n Writing specific country protocols
n Ethical approval processes
n Establish technical advisory group (national and international)
n Training of research staff, primarily research assistants
n Adaptation and piloting the data collection tools
2. Setting up 
country links/ 
selection of 
study partners 
and establishing 
country  
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4. Study protocol 
formation and 
submission of 
protocol for 
ethical  
approval
5. Training  
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Pre-data collection activities
Initial conceptualization and defining the study team (three to six months)
1. The first step will be the initial conceptualization of the research purpose and scope 
as well as setting up the core research team who will oversee the study. Applications 
for funding may need to be made at this stage. If an external international study 
team is involved, this is the time to establish links in potential countries and 
investigate their interest. 
2. The core research team should hold planning meetings to define TB costing needs, 
develop a study question, ascertain study aim and specific objectives, and agree on 
activities, roles and responsibilities of each of the members.
3. If a multi-country study is selected, at this stage researchers will need to collate 
global data so that sampling of countries can be undertaken (e.g. sampling of high 
TB burden countries by region).
4. Inclusion of study partners (NTP, local research group, other researchers, technical 
assistance support) should be considered. When funding is awarded, sub-contracts 
from the study lead to other partners may also be required, which may take 
additional time. 
Study protocol formation and submission of protocol for ethical approval (three to 
six months)
5. A protocol development workshop can be an effective platform to develop a 
common vision, establish the purpose of the costing and decide what is within 
(and out of) the study scope at the start of the costing study. Specific roles and 
responsibilities of the team members can be considered. Protocol development 
should be initiated, as well as proposed budget and timeline. 
6. At this point, all relevant information that is available at the country level for TB 
services for the sampling frame for site selection should be collated.
7. Country adaptation of existing tools and inclusion of specific country protocols 
(standard operating procedures) is required.
8. Protocols need to be submitted in a timely manner for appropriate ethical approval. 
While an expedited review can be requested if no patient records will be used, with 
patient observation the process of review may take longer.
9. A technical advisory group (national and/or international) should be established 
to assist with decision-making and strategic direction.
Training and piloting (two months)
10. Once ethical approval is given, a study pilot can be undertaken. Together with 
initial training, this process can take around two months. The analysis of the study 
pilot can help fine-tuning of generic tools (such as the Value TB Costing Tool Suite) 
and direct the data collection.
11. Throughout the process, training is necessary to familiarize data collectors with 
the tool, the purpose, scope and aim of the study.
1. Initial 
conceptualization
2. Setting up 
country links/ 
selection of 
study partners 
and establishing 
country  
teams
4. Study protocol 
formation and 
submission of 
protocol for 
ethical  
approval
5. Training  
and piloting
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Initial conceptualization and defining  
the study team
Overview
A costing study is initiated where a need for primary costing has been identified based 
on what the cost estimates are going to be used for, and the level of availability of 
existing cost data. There may be some cases where a country would not need a primary 
costing to be undertaken for instance if cost data already available is detailed, recent 
and of good enough quality for the required purpose (see Reference Case [5] for further 
details). 
1. Understanding the purpose of the costing study
The first step in any costing study is to identify what the costs are needed for and 
defining the purpose of the TB costing study [5]. Costing can be done with a specific 
purpose in mind. For instance, costing could be applied if a new technology (e.g. 
loop-mediated isothermal amplification (LAMP)) is being rolled out and one wants 
to assess cost and cost-effectiveness in a particular setting (e.g. an urban district in 
the Republic of Congo). Alternately, the purpose for the study can be more general, for 
instance costing all TB interventions in a particular country (e.g. treatment costs in 
Yemen) to inform resource allocation between different TB interventions. 
Methods used to estimate the cost of health interventions or ‘costing’ will depend 
on the purpose of the study. To reduce expenditures, any primary data-derived 
cost estimate ideally should be able to be used for multiple purposes. However, in 
practice, costing studies are often commissioned with a specific purpose in mind, 
and the methodological choices will be driven by that purpose. Each purpose may 
require different approaches to definition and measurement (i.e. the unit of the costs 
reported). There are several groupings of potential purposes that are outlined below. 
A. Economic evaluation and/or priority setting
Certain cost estimates assess allocative efficiency of either single or multiple TB 
interventions. Allocative efficiency is achieved by maximizing health impact among 
different (competing) health care interventions within a given (restricted) health 
budget. There are various approaches and processes that help decision-makers assess 
allocative efficiency of investment in TB interventions. These include cost-effectiveness 
analysis and benefit cost analysis. Assessing the cost-effectiveness of alternative uses 
of resources is now recognized as a core piece of information for decisions around 
whether to invest in new technologies or set priorities across different strategies 
and interventions, and as part of the WHO TB guideline development. For example, 
cost-effectiveness can inform the design of health care benefit packages provided 
by governments or insurers. As many low-income countries move towards national 
insurance schemes, these assessments can estimate reimbursement levels.
B. Medium- and long-term financial planning, budget impact and resource 
requirements estimation
Cost estimates are also used to predict expenditures in the medium (three to five 
years) and longer term. Examples include using costs to inform budget impact 
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analyses and budgets for national strategic plans; support medium-term expenditure 
frameworks; develop financial plans for investment cases; and produce ‘global price 
tags’. These analyses support national planning but can be used in both national and 
global fundraising efforts for increased investment in a specific global health area. 
For example, since 2009, the South African government has collected cost data to 
predict the medium- and long-term costs to the South African national public sector 
antiretroviral treatment (ART) programme, which was then used to advocate for 
increasing funding for ART. 
C. Budgeting and price-setting
Cost data may also be useful to those planning both the incomes and expenditures 
of health providers (or funders). Costs can predict expenditures by specific budget 
holders and help to set prices for specific services. Budget settings would include annual 
programme budgeting by managers for routine health services, or a specific provider, 
or could refer to an investment case for a specific study or a funding application. 
For some organizations, such as insurance companies or private providers, budgets 
involve planning incomes, and prices for specific goods and services for the coming 
year and costs are core elements in this process. 
D. Technical efficiency analyses
Costs can also be used to explore differences and drivers of technical efficiency 
between providers and/or modes of delivery (integrated services, platforms, level 
of decentralization, etc.) for health interventions or services. Technical efficiency 
analyses are usually conducted through the comparison or analysis of costs over 
multiple sites, or by comparing actual costs to benchmarks. Technical efficiency can 
be defined as assessing the best way of spending a given (limited) budget to produce 
a set of TB services. Cost data from studies that help to estimate technical efficiency 
can also help identify the minimum efficient scale of operation or providing insights 
into areas of efficient or inefficient practices. For example, WHO, the United Nations 
Children’s Fund (UNICEF), and Gavi, the Vaccine Alliance, use unit cost data to 
identify and design efficient supply chain logistic systems in immunization activities.
For each of these purposes, there may be different theoretical and practical reasons 
that a certain type of cost or methodological approach is preferred. For example, 
where countries are moving towards UHC, the need to generate reimbursement rates 
and to understand the comparative value of new technologies (i.e., applying economic 
evaluation/and or priority setting) creates a demand for unit cost data that are 
comparable across diseases and health services, follow a standardized methodology, 
and reflect economic cost.
In contrast, cost data for technical efficiency studies may need larger sample sizes, 
have a different perspective, and need additional information about cost determinants 
collected to enable analysis. For the purposes of financial planning and resource 
requirement estimates, financial costs are generally needed rather than economic 
costs (see Principle 3 [5]), and disaggregation of prices and quantities in unit cost 
reporting is helpful. The Reference Case [5] explains which type of cost can be used 
for which purpose.
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2. Establishing the research team 
The core research team may be set up before, during, or after deciding the costing 
purpose. This is the group that will oversee the study, define the scope, and bear 
primary responsibility for applying for or sourcing funding for the study. The core 
research team will also develop a study question, plan study aims and objectives, 
decide what the study activities will entail and identify the roles and responsibilities 
of each team member. The core research team may be comprised of individuals in the 
country of interest or outside of the country or countries included in the study (as was 
the case with Value TB).
Careful consideration should be given to appropriate study team composition and 
roles and responsibilities. A range of skills sets may be required. For instance, the 
primary investigator will need experience in protocol writing, ethical applications, 
managing teams, TB and costing generally; those in the field doing the data collection 
should be organized, keep well-documented notes and records, be able to understand 
and disentangle different clinical TB procedures and processes, enquire and interview, 
and report back to the study co-ordinator. The study co-ordinator should have good 
oversight of the data collection process, and be able to provide additional guidance and 
training if needed and to identify any errors in data collection as they arise. Appendix 
10 contains a sample terms of reference for the costing team.
Box 1. Selecting a study team for Value TB
Core Research Team
For Value TB, it was important to select individuals with extensive previous TB costing experience and a current 
interest in the field, to oversee the study to its completion. Three institutions were selected to be involved: the 
London School of Hygiene and Tropical Medicine (LSHTM); the Global TB Programme at WHO; and the Health 
Economics Unit, University of Cape Town (HEU UCT). 
Setting up country links/selection of study partners and establishing country teams
At a country level, the NTP took responsibility for the TB costing, supported by the core team of seven researchers 
from the three institutions listed above. The NTP was responsible for selecting the principal investigator (PI) within 
the country (this role was given either to someone within the NTP with prior costing knowledge or to an external 
principal investigator (PI) from a consultancy or academic institution in the country with experience in TB costing 
such as a health economist). In Kenya, this PI role was shared between a senior member of the NTP (National 
Tuberculosis, Leprosy and Lung Disease Program (NTLP-P)) and a senior health economist and researcher at Kenya 
Medical Research Institute Wellcome Trust (KEMRI-WT). 
The country PI formulated the country specific protocol (with input from the broader team) and ensured its timely 
submission to ethical committees. The PI supported by the NTP focal point for the study also communicated 
with public and private facilities to ensure that permission had been obtained, and that data collection would be 
welcome. Piloting and training were organized by both the country PI as well as the core research team.
The PI and NTP were responsible for assigning the remainder of the within-country research team, generally 
comprised of research assistants and data managers hired by the PI. Research assistants’ main roles were data 
collection at the facilities and centrally (when data such as salary grades were not available at the facility) as 
well as data cleaning and some primary analysis. If a data manager was employed, his/her role was to manage 
incoming data and to ensure the quality of this data.
In addition to the core country team, a national advisory committee or task force was established to provide inputs 
in the initial stages as well as later stages of data analysis and dissemination. This task force met initially to discuss 
results, and were contacted regarding specific issues as needed. 
An international advisory panel was also established, hosted by the WHO Task Force on Impact Measurement. The 
rest of the panel was made up of members (advisors and stakeholders) linked to the GHCC, as well as others who 
are involved in the economics of TB. The members comprise a mix of global agencies, TB economic modelers, NTP 
representatives and ‘costing experts’. A 36-month duration of funding was applied for through the Bill and Melinda 
Gates Foundation.
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When deciding an appropriate timeframe and timeline, planners should consider the 
trade-off between the number of staff hired and the amount of time needed for data 
collection. Generally, it takes a trained data collector one week to collect good quality 
TB cost data at a facility (this of course will vary based on the facility size, the way 
records are stored at the facility and the number of interventions to be costed at a 
given facility). However, as more staff are involved the role of a coordinator becomes 
even more crucial as facilities will be seen in parallel, and multiple data points will 
need to be checked for consistency and errors. With larger groups of data collectors, 
there may be a need for greater investment in ongoing training.
Study protocol formation and submission of 
protocol for ethical approval 
Overview
This section summarizes the main elements of a draft study protocol; a draft protocol 
outline is provided in Appendix 6. The protocol has been developed as part of the 
Value TB study which closely follows the Reference Case [5] as a guiding document. 
The Value TB study design and methodology can be applied in small (<10 sites) or large 
(>10 sites) costing studies. 
Study protocols outline objectives, present the detailed study design, develop a 
timeline and budget. Objectives and scope are described below, with more detail on 
the methods used presented in Section C. The process should closely involve cost data 
users from the start, and ideally the initial draft of the protocol should be developed 
through a workshop to facilitate a participatory process. These initial stages can 
be time-consuming if starting from scratch. However, adapting the protocol in 
Appendix 6 and associated Value TB Costing Tool Suite can accelerate the study design 
phase considerably. 
1. Specifying the study objectives   
The primary output from a costing study is a dataset of unit costs; this dataset 
should be constructed along the lines outlined in Annex 3 of the Reference Case and 
Appendix 3. For the Value TB study, the output was a nationally representative set 
unit costs (when feasible) for the delivery of TB interventions and services in five 
countries. The dataset should be eventually made available in a disaggregated form, 
as this facilitates future analysis and decision-making at the country level and by 
researchers. Breakdowns of data presented in Value TB include:
n prices and quantities of inputs by site;
n costs broken down by activity and level (service-level versus above-service level);
n economic and financial costs by provider/payer (i.e. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria (GFATM) versus NTP-funded interventions/resources); 
and
n ‘real world’ and ‘per protocol’ costs where possible (see Principle 3).
Section C. Study objectives and set-up
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2. Perspective of the evaluation 
These guidelines have been developed to guide costing of TB interventions from the 
perspective of the providers of health services. The provider perspective takes the 
point of view of the provision of services; the costs are those incurred by a hospital, 
clinic or TB facility providing the services. WHO has developed a ‘Tuberculosis patient 
cost surveys’ handbook which will guide the user in collecting patient costs relating 
to TB [10]. A patient perspective assesses the costs from the patients’ perspective, 
and considers direct patient costs such as medical out-of-pocket payments or non-
medical expenses (transport, relocation costs), as well as indirect costs which relate to 
productivity losses such as time off work. Some data can be easily collected at the same 
time or may include the same information, such as time with a healthcare provider, 
and so it can be worthwhile to include both the provider and patient perspective in a 
study (i.e. a societal perspective).
3. Site selection/sampling
There are several different approaches to sampling. Random sampling ensures 
that the sample is representative of the population it characterizes, i.e. that each 
individual in a population has an equal chance of being drawn. In order to obtain 
a random sample a sampling frame is necessary. A method for stratified random 
sampling using a sampling frame is described below. The strata are the subgroups 
that should be represented which should also be mutually exclusive. There are other 
non-random methods for sampling such as convenience and purposive. The advantage 
of convenience sampling is that selection is based on easy inclusion or willingness 
to participate, although this can introduce bias. Purposive sampling can be suitable 
if it is necessary to include something that is rare in the broader population (such 
as patients with extensively drug-resistant TB (XDR-TB)) but may not be desirable if 
more broad costing is being done (i.e. DS-TB pulmonary TB). In principle the sample 
size of a costing can be determine with a set precision in mind [11]. 
Depending on the purpose of the cost estimation, the sampling frame may involve 
the selection of countries, geographical regions within countries, sites within regions, 
patients within sites, and different client groups. The purpose will also determine the 
most appropriate sampling method and size. For example, some financial planning 
processes will require the collection of data from different site types. For economic 
evaluation, the aim is usually to compare the ‘intervention’ with the ‘comparator’ and 
this will determine the method used. For the sampling process, the first step is to 
Box 2. Study objectives 
The XTEND study had the overall goal of understanding how Xpert® MTB/RIF should best be used under conditions 
of national roll-out by determining its effectiveness and cost-effectiveness and modelling these data to project the 
impact at a population level in South Africa.a 
This goal required empirical costing in a ‘real world’ setting. The objective for the costing component of the XTEND 
project was therefore:
To estimate the unit cost per test and total costs per laboratory for Xpert® MTB/RIF and microscopy tests during Xpert® 
MTB/RIF roll-out.
a Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, et al. Cost-effectiveness of Xpert MTB/RIF for tuberculosis 
diagnosis in South Africa: a real-world cost analysis and economic evaluation. The Lancet Global Health. 2017;5(7): e710-e719.
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synthesize information that is available at the country level for relevant TB services 
to outline the sampling frame (from which the eventual site selection is made).
Due to logistical challenges and budget constraints, most cost estimates in low- and 
middle-income countries have been typically conducted on a small number of sites or 
locations (<10), though in recent years, larger studies have emerged, particularly in 
HIV. Where large studies have occurred, they have demonstrated a high variation of 
costs, suggesting that the common practice of estimating costs on a small sample may 
produce highly unrepresentative results [15]. However, even if a few sites are selected, 
explicit consideration (and transparency) of the sampling frame and selection method 
can at least assist others apply cost estimates to other settings.
Depending on the structure of the health system in one’s setting, developing the 
sampling frame will require determining where the interventions of interest take 
place. For instance, a screening for TB symptoms might take place in a clinic as an 
Box 3. Sampling in large (>10 facilities) costing study: 
example from Value TB site selection/sampling 
Given the objective of the Value TB study (to assess the costs of all TB interventions in five countries in order to 
update current data and inform users of the cost data, such as modellers and policy makers), sampling was done 
on two levels. 
The first level was to select countries based on five criteria: budget, study team capacity, data availability, 
representativeness and feasibility. 
In terms of budget, the sample size for participating countries was agreed upon with the funder based on budgetary 
considerations. Data collection was budgeted to take place in five countries. Countries with the highest burden of 
TB, TB and HIV coinfection and multidrug-resistant TB (MDR-TB) were prioritized. Only one country with extensive 
hospitalization due to MDR-TB was selected and hospital costing was simplified due to the limited study team 
capacity and limited time.
To assess data availability among the countries of interest, published literature was mapped from the GHCC 
database (https://ghcosting.org/pages/data/ucsr/app/) by type of intervention. Countries were excluded where data 
were considered recent and sufficient.
Selecting a wide range of countries is helpful when only a few can be studied. In this case, rather than comparing 
randomly chosen countries, countries were selected to represent a range of income levels and geographical 
regions. 
Finally, feasibility was considered when selecting the order in which countries were approached. Feasibility 
included both local NTP interest in the study and capacity to collaborate (on-going research platforms/
partnerships); both aspects are critical to ensure cost data produced is relevant and useful to countries so that it 
ultimately contributes to decision making processes. 
The second level of sampling/selection took place within the five countries. Preliminary data was collected 
regarding the TB interventions offered at different facilities levels, population density of regions, and TB 
notifications etc. 
The focus of the facility selection was to obtain a sample of facilities to estimate unit costs for a comprehensive 
set of TB interventions and, where feasible, to calculate a nationally representative unit cost. Again, budget played 
a role in the selection of 24–30 facilities per country. The selected facilities followed a standardized sampling 
strategy shared across the five countries. Three regions were purposively sampled to reflect a high, medium and 
low burden of TB respectively based on population size and cases of TB as well as urbanicity as a proxy for spread 
of facilities/accessibility of services. 
A stratified random sampling approach was used to obtain a sample of facilities within the following strata: level of 
care, ownership (public, private), and diagnostic interventions available (availability of Xpert® MTB/RIF, microscopy 
and none) to ensure a representation of facilities in each stratum (facilities with very low volume of TB services 
were excluded). These strata were selected as they represent important determinants of cost variation. If a facility 
refused to take part in the study, a substitute facility from the same strata was selected from a ‘substitution’ list. 
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outpatient whereas a microscopy test would take place in a laboratory either at the 
clinic or peripherally.
Consideration should also be given to how to access data for the target population 
and the epidemiological context in one’s setting. For the intervention(s) being costed, 
coverage level or phase should be noted: the cost may differ if an intervention has just 
been piloted or is well-established. 
4. Timeframe and budgeting
The costing study timeline is usually around six months or longer (Figure 3). Costing 
selected TB services in a smaller sample (less than 10 sites) should take less than a 
year. However, costing all TB services in a nationally representative sample (such as 
in the example of Value TB) using the current TB guidelines and Value TB Costing Tool 
Suite (described in Appendix 8) will take approximately one year. 
The average budget for one Value TB country, for approximately 20 sites (taking around 
12 months) was in the region of US$100 000 (excluding external technical support 
from core research team). This includes around a third for travel funds, training and 
meeting funds; and the rest for staff (two co-principal investigators spending 5% and 
10% of their time respectively; a study co-ordinator working 10%; a data manager 
working 10%; and four research assistance/data collectors working 25% each for the 
year).
Fig. 3. Example of timeline for national costing study (example of Value TB)
n Conceptualization
n Country links
n Country teams
n Protocol formation and ethical approval
n Training and piloting
n Data collection, preparation and analysis
n Dissemination 
YEAR 2
YEAR 1
5. Ethical consideration/approval
As costing work requires review of medical records and interviews with staff, costing 
studies require ethical approval. If a costing study is done alongside a larger existing 
study which already has such approval (such as a study collecting widespread 
epidemiological data on TB with a costing component), expedited ethical approval 
may be sought or, if the TB costing work is included in the existing study, this may be 
combined with the proposal sent for ethical approval. If a study is a stand-alone TB 
costing study, then ethical approval will need to be sought from all relevant parties. 
Ethical approval can take time to obtain depending on the setting and whether 
patient records or observation of patients during TB care are included (the ethical 
approval can take anywhere from one to six months). This needs to be considered 
when planning the overall study and timeline.
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Box 4. Ethical approval for Value TB 
In the case of Value TB, ethical approval was obtained from the three institutions involved (LSHTM; Global TB 
Programme, WHO; Health Economics Unit UCT). In addition, ethical approval was granted by the medical ethical 
committees within the five relevant countries for instance in Kenya through the Kenya Medical Research Institute 
(KEMRI) and WHO African Regional Office. Permission to gain access to the selected facilities was requested in 
each of the five countries. In Kenya this was done by approaching the Ministry of Health at a County Level with a 
letter applying for entry (with letters of ethical approval attached), and then at a facility level through telephone 
communications with the facility managers stating that the relevant ethical approval and County Level permissions 
had been obtained. The NTPs were central to the facilitation of this process as well as to data collection teams 
accessing facilities.
Section C. Study objectives and set-up
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Section D. Designing data collection
Understanding the production process
In the costing approach, describing the outputs of interest (see Tables 2 and 3) allows 
planners to consider what needs to be estimated in terms of the cost per activity 
broken down into cost per output. Activities can occur at different platforms, for 
instance at health facilities, or as outreach, mobile or household visits.
The first step consists of establishing and defining the interventions that require 
costing. While the protocol will describe TB service delivery process as per country 
guidelines and the “generic” Data Collection Tool (from the Value TB Costing Tool Suite) 
will be adapted accordingly, data collectors will need to reassess the production process 
of each TB service at a given facility. Where interventions are placed will depend on 
the delivery mechanism and will vary by setting. For example, an intervention may be 
housed within the health system level, at different facility types, in the community, 
or in facilities such as non-governmental organizations (NGOs), or faith-based 
organizations. 
At the facility level, possible TB interventions include: vaccination; TB case detection 
and diagnosis; PCF, ACF and ICF; TB treatment; TB prevention; TB infection control. 
Above the facility level, TB interventions include: development of strategic plans, 
programme reviews, national and regional meetings, surveys, management and 
information systems, supervision, procurement and supply chain management, 
transportation of specimens, advocacy, technical assistance, training, accreditation 
and quality assurance of laboratories, community media, information, education and 
communication (IEC) campaigns or any partnership activities (see Appendix 2).
For each intervention, data collectors will then need to understand the workflow of 
the ‘facility’ (health facility, laboratory, pharmacy, community outreach etc.) (see 
Figure 4 and Appendix 11; Case Study 1 as examples). This entails asking questions 
and observing practices (how services are provided and by whom) and the structure 
of how the services are delivered. A good starting point is a discussion with the clinic 
manager or TB nurse or laboratory manager about the facility. 
For instance, within a health facility at an introductory meeting questions could 
include:
n Where are patients seen?
n Is space shared between TB and other services?
n If TB and HIV care are integrated, how (ie. physically, temporally, clinically)?
n Are TB patients kept separate from other patients?
n Where do patients wait?
n Which staff attend to the patients?
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n Is staff time shared between TB and other services (such as outpatient care, 
curative medicine, noncommunicable diseases (NCDs)/chronic care, maternal and 
child health, family planning, ART)?
n Which days are TB services offered (every day or only selected days)?
n Do patients make appointments or come on an ad hoc basis?
n How often do patients come for treatment?
n Do patients come with a treatment support partner, or can send one to collect 
medicine?
n Where are tests sent?
n What is the process for referring tests (do they send a letter with a patient, phone 
the laboratory/private facility)?
n How are results returned?
n Is transport or vehicles provided to staff or patients?
n How often has training occurred in the previous year?
n How many TB patients are seen on average in a day?
A process flow diagram can be helpful at this stage (often drawn immediately after the 
site visit) and this can then be used to validate the process by asking the staff to look 
at the diagram and confirm that it is accurate representation of what happens within 
the facility (see Figure 4). This is then used to ensure that all aspects are being costed 
and to better understand cost estimates within the context of the facility.
Section D. Designing data collection
Fig. 4. Example of a process flow diagram for smear microscopy in a laboratory
Smear microscopy process in laboratory
Room 1
(reception)
Personnel: Data clerk
Room 2 
(laboratory)
Personnel: Laboratory 
technician
Room 3
(dark room with 
microscope)
Personnel: Senior 
laboratory technician
n Specimens delivered to laboratory
n Patient information entered into database and 
processing sheet printed
n Printed barcodes attached to sputum containers 
n Batch of 15 decontamination of sputum in a biosafety cabinet
n Preparation of slides
n Adding of chemicals and reagents
n Multitasking when slides are drying
n Batch of 15 decontamination of sputum in a biosafety cabinet
n Preparation of slides
n Adding of chemicals and reagents
n Multitasking when slides are drying
n Reading of all slides for the day (5 sets 
of batches of 15)
n No multitasking during this reading 
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Within a laboratory, it is useful to speak to the laboratory manager and to observe 
the tests being processed (which is slightly more straightforward as there are no 
patients present). Some laboratories keep standard operating procedures that record 
the diagnosis delivery process, which can then be verified through an interview with 
the laboratory manager who has an overview of TB diagnostic services.
This process of workflow mapping can help data collectors to identify inputs, or 
resources, which need to be measured. Figure 5 shows the capital and recurrent 
inputs to consider at each level of the health system. The platform refers to the type 
Fig. 5. Capital and recurrent inputs
Platform Capital costs (input) Recurrent costs (input)
Public health facilities (including 
TB Care, HIV care, Hospital 
general, Hospital TB) and 
laboratories
Private health facilities 
(including TB Care, HIV care, 
Hospital general, Hospital TB) 
and laboratories
National TB Programme
Ministry of Health
Non-governmental 
organizations
Households
Community
Mobile
Prisons
Schools (through health facility 
outreach)
Building space
Quantities: Size of department/ 
clinic/room/area/building 
Prices: Value if sold today
Vehicles (transportation)
Quantities: Number of vehicles
Prices: Current market value of 
all vehicles 
Equipment and furniture
Quantities: Inventory of 
equipment and furniture
Prices: Current price/ 
replacement cost for the listed 
equipment and furniture
Training (the effects of which 
will last more than one year)
Quantities: Duration of training, 
number of participants trained, 
number of trainers
Prices: Training fee per 
participant (venue, catering, 
training materials, training staff 
salaries, per diem)
Above service level cost 
Quantities: Number of facilities 
served
Prices: Expenditure on above 
service level activities such as 
NTP support, TB drug delivery
Recurrent expenditure/ 
Overhead inputs
Quantities: Per facility
Price: Annual expenditure
Personnel (Staff costs)
Quantities: Staff time on task(s) 
measured using timesheets/ 
observation/interview
Prices: Salaries/wages of staff
Supplies
Quantities: Quantity of 
consumables used
Price: Annual expenditure/price 
of consumables etc
Drugs 
Quantities: Number and type of 
drugs/regimen used
Price: Current price of 
medication
Diagnostic tests
Quantities: Number and type of 
diagnostic tests/supplies used
Price: Current price of 
diagnostic test/supplies
Other
This could include calibration 
of instruments, chemicals and 
reagents, administration of cash 
transfer, quality assurance, 
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of facility or structure (such as community outreach, visits at the household level, 
or schools) used to administer TB. The prices and quantities for both capital and 
recurrent inputs are outlined in Figure 5 to illustrate which prices and quantities of 
items should be collected in the different platforms.
Mapping of interventions
After fully defining the interventions and classifying them according to the GHCC 
intervention definitions [5], the available interventions and technologies in each 
facility level should be mapped. This will establish where the relevant interventions 
will be captured when conducting the costing at the facility. A new blank Data 
Collection Tool should be used for each facility (see Appendix 8).
The facility costing tool has been organized to capture the description of the health 
facility, followed by service utilization and overhead items. It also includes default 
lists of staff type, equipment, consumables, chemicals and reagents and drugs used in 
the TB interventions provided at the facility. The quantities and costs of each item can 
be inputted into these lists. Additional items can also be added to the lists. 
Defining inputs
Another consideration involves which inputs need to be included in order to work 
out the unit cost from the provider perspective. The broad groupings are capital and 
recurrent categories with specific inputs in these categories (Figure 5). Depending on 
the platform costed, these can include capital (building space; vehicles (transporta-
tion); equipment and furniture; training (the effects of which will last more than one 
year) and recurrent inputs (recurrent expenditure/overhead inputs, personnel (staff 
costs) and supplies) that make up a visit cost. Input costs of diagnostic testing and 
medication (drugs) are added subsequently, as these are the most likely to change or 
need updating. 
Costing approaches
There are a number of core principles laid out in the Reference Case on how to measure 
and value inputs. The two main (but complementary) approaches to estimating costs 
are bottom-up and top-down (see Principle 7 in the Reference Case [5]). Perfect 
efficiency as represented by guideline or normative costing in a system is rare in real 
health systems, and it is much more likely that the costs in the real world reflect some 
inefficiency both in capacity and production. In order to capture real world costs, we 
can use bottom-up costing of real world services to capture process inefficiency and 
top-down costing to also capture capacity inefficiency (see Figure 6). If both time and 
resources are available to the study team, both top-down and bottom-up should be 
undertaken in order to have a range of costs for most efficient practice (bottom-up) to 
a cost that includes inefficiency (top-down).
Bottom-up costing
Bottom-up is a detailed approach to costing which involves detailed measurement 
of all resources used in the provision of a specific health service or intervention. 
This involves the “ingredients” approach where all resources (i.e. inputs) utilized or 
consumed in the production of a service are costed separately. Bottom-up costing can 
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use interviews (as a minimum), time-in-motion style data collection, observation, or 
work sampling techniques of health providers. Methods of estimating building space, 
staff, equipment and furniture are detailed here, with further detail on all inputs 
provided in Appendix 8.
Estimating resource use
Estimating resources used requires assessing the quantities of inputs. This may be 
from routine data, patient file abstraction or alongside a study. The methods used to 
estimate the levels of inputs used in an intervention can bias estimates, and therefore 
should be reported. For instance, observation can be biased in that it may suffer from 
the Hawthorne effect of observation bias, where more efficient practice is presented 
due to an awareness of being studied. The methodological specification is to report 
the source of data, report the approach used to sample or fill missing data and justify 
why the approach was selected given the potential for bias caused by misreporting or 
incomplete data [5]. 
Measurement and valuation of space 
The size of all the buildings at the facility should be reported in square metres (m2). 
The best-case scenario is if the facility has a record of the size in square metres or 
better still a map with the dimensions and floor plan. If this is unavailable, one of the 
following options for estimating the facility size can be used: 
n value of the building, obtained by sourcing the current replacement value;
n original facility records inflated to the current value;
n insurance valuation of the building;
n tax forms for the building or government rate for stamp duty;
n cost of recent renovations;
n rental value from lease agreement;
n where total land space is known but building size is not, estimation of the 
proportion of land that the building occupies; or
n physical measurement of the space with a laser distance measurer or a tape measure 
or street mapping software (e.g. Google Earth).
Fig. 6. Estimating efficiency
Capacity 
efficiency
Production
process efficiency
Perfect 
efficiency
23
Measurement of equipment and furniture
This is generally done through an itemized count or reliance on an existing detailed 
list per department. 
Measurement of staff time
Calculation of quantities of staff time using a bottom-up approach can be assessed 
through either an observation or interview. This is calculated by multiplying the price 
of staff time per minute (derived from their cost of employment and the number of 
minutes they work for in a year) by the number of minutes for a TB service collected 
through either observation (ideal) or interview (as a minimum). 
Valuing resources
Once all resources have been identified for each facility/place, these need to be 
quantified and valued. Figure 4 illustrates how this could be done for both capital and 
recurrent costs. Examples of prices for different inputs have been given. If research 
costs are part of the intervention there may be a need to include these, however that is 
up to the judgement of the researcher. Data sources should be listed, for instance NTP 
under the Ministry of Health or TB clinical records etc.
Valuation, especially for economic costs, is important as it is a way of making unit costs 
comparable. Current prices for consumables, medical equipment may be obtained 
from the records kept by a facility or from a medical supplier. Pricing for furniture 
and equipment may be kept at a facility level or more likely will need to be requested 
from a furniture or medical equipment supplier. See the Reference Case [5] for further 
detail on exchange rates, discount rates, etc.
Estimation of total costs
Total costs are estimated through the multiplication of unit costs with the total 
utilization for the period of interest. 
Top-down costing
The top-down approach is a more aggregative method which involves estimating the 
cost of delivering a TB service (e.g. a hospitalization for a TB patient) by using a national 
average figure or expenditure accounts from a facility. The top-down approach involves 
preferably the step-wise allocation of the facility expenditure by various departments 
(usually of a complex organization) to specific cost centres of interest. Criteria used 
to allocate shared resources should be explicit and reflect usage of each input. Where 
allocations have been made ‘top-down’, either to sites or within sites to services, or 
above-service delivery or overhead costs have been allocated, the criteria used and the 
relevant data sources of the allocation factors should be explained.
As indicated in previous work, one can cost resources within a laboratory through 
top-down methods [13]. The top-down approach utilizing expenditure for different 
cost centres, departments or inputs considers inefficiency. The example of staff time is 
given here, while more detail for other inputs is provided in Appendix 8.
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Measurement of staff time top-down
Top-down costing methods use the proportion of time for each TB output calculated 
from timesheets and the expenditure of facilities on TB services for staff (as derived 
from their cost of employment). Timesheets and interview may have an overestimation 
or underestimation of time being spent on tasks depending on staff ability to recall 
work practices and workload. 
Valuing resources top-down
For salary information, facility expenditure and overhead costs (such as administra-
tion, cleaning, kitchen, utilities, security, laundry, monitoring and evaluation, phar-
macovigilance, maintenance), information is often obtained from a central level, for 
instance the finance department of a Minstry of Health.
Fig. 7. Top-down allocation of costs within a laboratory
Total cost of LED microscopy tests for TB (area of 
innermost circle only) 
500 LED microscopy tests processed for TB; 1000 TB 
tests (all types) processed
Allocation factor 500/1000=0.5
Total cost of TB diagnostics (area of two innermost 
circles) 
e.g. 1000 TB tests (all types) processed; 5000 all tests 
processed (TB and other)
Allocation factor 1000/5000=0.2 
Total cost of TB diagnostics $100000*0.2=$20000
Total cost of all tests performed in laboratory (TB and 
other) (entire surface area of circle)
e.g. $100000
In a top-down costing of light emitting diode (LED) microscopy for TB diagnosis in a 
laboratory, the cost of the microscopy department would be separated from the total 
TB diagnostic costs for the laboratory using an allocation factor (such as the number 
of microscopy tests using LED divided by the total number of all TB tests processed 
in that laboratory multiplied by the total TB diagnostic cost for the laboratory). A 
separate allocation procedure may be needed to separate out the cost of processing 
TB diagnostic tests, if the cost of all diagnostic tests in the laboratory, TB-related 
and all others, are aggregated (see Figure 7). The allocation factor could be the total 
number of TB tests processed divided by the total number of all tests processed in the 
laboratory.
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The Standardized Value TB Costing Tool Suite
In conjunction with this set of guidelines, a generic Value TB Costing Tool Suite has been 
developed in Microsoft Excel spreadsheets with aligning instructions in Microsoft 
Word (see Appendix 8). The Value TB Costing Tool Suite encompasses all the aspects 
one needs to consider for costing a variety of TB interventions in any country setting, 
which should be adapted to specific country contexts. 
The Value TB Costing Tool Suite consists of a list of all data required for costing (for 
submission to ethics), a Data Collection Tool (a unit cost generation tool), a separate 
Data Entry Tool, and draft informed consent forms. The rationale for having two 
instruments, one for data collection and one for unit cost generation stems from the 
need to simplify the data collection itself, leaving the data analyst to use the Data 
Entry Tool to clean data reported by research assistants/data collectors (through the 
Data Collection Tool) and to generate unit costs for the facility. 
The Data Collection Tool can be used by research assistants to collect data for one 
facility. The tool will essentially allow recording of quantity and price data collected 
from the facility for each of the TB interventions that are present in a given facility. 
The Data Collection Tool collects the necessary bottom-up and top-down ingredients. 
In terms of bottom-up costing this relates to the prices and quantities. The quantities 
include time spent on tasks by health care workers, training, building space utilized 
for tasks, the equipment, drugs and supplies used etc. Prices include the prices for 
these items, the price of staff time per minute (derived from their cost of employment 
and the number of minutes they work for in a year), time spent on training, the price 
of space, equipment, drugs and supplies, etc. For top-down costing this relates to the 
expenditure of facilities on TB services on staff, training, buildings, equipment, drugs 
supplies, and the service statistics or utilization by patients (to work out the allocation 
to TB services). 
The Data Entry Tool will be used by data analysts to clean and copy data from the Data 
Collection Tool, and generates unit costs and other intermediary results for a facility. 
The Data Entry Tool takes all these ingredients and produces unit costs of delivering 
each TB service using both bottom-up and top-down methodologies. For bottom-up 
this means taking the prices and quantities for all inputs (staff time, training, building 
space, equipment, drugs and supplies) and calculating the bottom-up unit costs. 
For top-down costing, this entails calculating the unit cost for all inputs (recurrent 
expenditure (overhead costs), staff time, training, building space, equipment, drugs 
and supplies) based on step-down accounting using allocations based on space or 
service statistics (as described in Appendix 8).
The Value TB Costing Tool Suite and accompanying instructions can easily be adapted 
to any costing of TB service delivery exercise. When submitting the protocol to the 
ethics review board, one can include a draft interview questionnaire and a list of 
the other types of data that are planned to be collected. Consent form sheets also 
need to be submitted to ethics – these will be required from all staff interviewed and 
providing data to the data collector. Samples of facility information and consent form 
sheets have been provided (see Appendix 12). Format and content that is appropriate 
or required for the setting as per local ethical guidelines should be used, but these 
samples can also be adapted for use in the setting.
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What the Value TB Costing Tool Suite can do
The Value TB Costing Tool Suite has been organized to allow the collection of data 
and calculation of unit costs of TB service delivery at the facility level. It supports 
obtaining unit costs for both top-down and bottom-up costing, economic and financial 
cost approaches, different methodologies for measuring staff time (interviews, 
observations and timesheets) and disaggregated by key input categories. 
The Value TB Costing Tool Suite allows costing in different platforms (such as outpatient 
and inpatient care and facility outreach services), but is currently limited to facility 
level (i.e. it does not allow for community-based costing). Above-facility cost data 
collection will need to be done using an additional data collection instrument which 
is currently under development.
What the Value TB Costing Tool Suite cannot do
Due to the comprehensive nature of the tools, certain components within TB 
interventions have been omitted so that the costing process remains feasible within a 
reasonable time frame. No unit costs have been derived for individual adverse events 
related to TB treatment or prevention nor are the list of monitoring tests required to 
identify these events entirely comprehensive. However, the current tool allows for the 
cost of inpatient care to capture some time spent treating the adverse drug reactions 
associated with anti-TB drugs.  The most frequent adverse event monitoring tests 
have been included in the Tool Suite and can therefore be costed.
Adapting the Value TB Costing Tool Suite and mapping data sources
In drafting these guidelines and associated data collection instruments, efforts were 
made to ensure the specific costing’s country context, scope and objectives can be 
Box 5. The accompanying data collection instructions include the following documents
n An observation guide assists the data collector in observation of a TB service. 
n This guide will be used to estimate the bottom-up costing of an intervention and to populate the data collection 
and data entry bottom-up sheets for staff time, equipment utilization and supply consumption. 
n Observation is considered as the gold-standard method to measure staff time.
n An interview guide will be used by data collectors to carry out interviews to staff providing TB, MDR or TB/HIV 
services in the health facility and staff working in the laboratory or radiology departments. 
n The interviews, like observation, will provide the data collector with information on staff time, equipment 
utilization and supply consumption.
n Timesheets are another instrument to collect staff time. 
n Timesheets are distributed to facility staff providing TB services at the beginning of the week of data collection 
at the facility and collected on the last day of data collection. 
n The timesheets will capture the time spent on the 25 predefined TB related service outputs, non-TB services, 
administration and down time (lunch, break) over a few typical work days by various cadres of health 
professionals.
n The facility contact list collects participant names and contact information but is stored separately and securely 
at all times, ensuring no identifiable information can be linked to any data in the tools.
n Facility information sheets summarize the key features of the study and will be made available to staff 
interviewed. 
Section D. Designing data collection
Costing guidelines for Tuberculosis interventions30
incorporated. The generic tool provided alongside this guide can be modified to the 
country context and there are four main steps in this adaptation process. 
1. Defining the TB interventions that will be costed: this is done by the study team at 
the protocol development phase.
2. Defining the production process and potential data sources: this is done by the 
study team at the protocol development phase, but data collectors re-evaluate for 
each of the facilities during site visits.
3. Piloting: if a comprehensive range of TB interventions have been selected, then the 
piloting at a couple of facilities can take up to two weeks to complete. Once piloting 
has been undertaken, one must then adapt the tool to the country context.
4. Adaptation of the tools
Adapting the tools during the study pilot
During the piloting process, the research assistant(s) and team should endeavour to 
add as many of the context-specific and country appropriate service outputs, drug 
names, test procedures, service utilization labels, consumables supplies, staff titles, 
department or clinic names and other important labelling as possible.
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Section E. Data analysis, presenting results and dissemination of cost data
Data analysis
The data analysis stage is an important stage in the costing process and resources 
(research staff and money) should be allocated for this. The main purpose is to take 
the prices and quantities collected at each of the facilities and at the level above 
facilities and produce both total costs and unit costs that meet the objectives of the 
study (see Section C). However, total and unit costs on their own have little value: it 
is important to think about the unique setting from which these costs are produced 
and situate them, providing information on the elements that appear to drive cost. 
In addition, differences can be compared by subgroup, such as DS-TB, MDR-TB and 
XDR-TB. If the sample size is large enough, statistical differences between population/
facility groups can be examined. Descriptive analyses can include assessing the 
average number of visits per patient for different patient groups/subgroup (such as 
pulmonary, EPTB, new and retreatment) and the breakdown for the different types 
of visit (diagnostic visit, treatment visit, treatment support, community treatment 
visits, inpatient bed-days etc). The cost per input (as well as mean, standard deviation, 
median and interquartile range) for different interventions can also be assessed 
and looked at by patient group/subgroup. For instance, assessing the cost for first-
line treatment for different facilities broken up by input (diagnostic tests – Xpert® 
MTB/RIF, microscopy; treatment visits; inpatient bed-days etc). One can look at the 
variation within a country for the number of visits per patient for different visit type 
by health facility (the levels of care). The proportion for the inputs in a visit cost can 
also be evaluated through, for example, looking at the proportion spent on personnel; 
building space; furniture and equipment; or consumables/supplies. This can help 
in assessing the variability in efficiency. For instance, looking at the cost of smear 
micro scopy in different levels of care broken down into inputs can illustrate where the 
highest amounts are being spent from both top-down and bottom-up points of view. 
Again, the unit cost per intervention can be assessed by platform and from both top-
down and bottom-up approaches.
Econometric analysis can also be conducted on larger data sets to explore technical 
efficiency, extrapolate costs to other settings and understand the determinants of 
costs. These analyses are not outlined here, but please see Arinaminpathy et al., Silva 
et al. and Denysiuk et al. [14–16] for further reading on cost functions and other 
aspects.
Fig. 8. Post data collection activities
7. Post-data 
collection 
activities
n Commencement of data analysis and data analysis workshop (cross-country meeting)
n Preparation of reports, papers and a publicly accessible database
n Cross-country data analysis and write up
n Dissemination of findings at a country and international level
n Publicly share datasets
n Wrapping up the study and discussion about updating cost estimates managed by the NTPs going forward
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Sensitivity analyses
Whenever doing a cost analysis, it is important to assess possible areas of bias. 
Sensitivity analyses are also crucial for looking at factors that may contribute to 
uncertainty in the unit cost estimates. Examples are altering the cost of medication 
(one can often use this information to inform at what threshold the cost could become 
affordable); the utilization rate (especially if the cost analysis was done during a start-
up phase only); one could also alter the salary costs if task shifting could be likely 
in the future. This can be in the form of a one-way sensitivity analysis (univariate 
sensitivity analysis), where one alters one variable at a time, or a multi-way sensitivity 
analysis (multivariate sensitivity analysis) where one alters several factors at one time 
to see their combined effect on the cost estimates. Scenario analyses are helpful in 
looking at different approaches or options for the future. Techniques such probabilistic 
sensitivity analysis (PSA) can be used to look at uncertainty ranges in a cost analysis, 
where one initially assigns a probability range to the input data [17–20].
Presenting results and dissemination of cost data
While it is important to tailor presentations to a specific audience, in general simple 
graphical presentation of data is best. Bar graphs can effectively compare costs 
across sites, with percentage breakdowns to visually indicate which components 
are the highest/lowest contributors. For policymakers, data should be presented in 
transparent and easy to digest format, so that they can make decisions about resource 
allocation to better combat TB. Audiences of health care workers will need the 
knowledge to be translated so that it can be practically applied in a work setting, for 
instance the expense of certain tests may mean that rationing is appropriate.
The limitations of the study should be identified and described. This includes inter 
alia interventions that have not been costed, where sample size was not sufficient, 
when above-facility costs were not assessed and adaptation of methods. The ability to 
generalize and its application should be explained. For example, is it only appropriate 
to generalize to other low- and middle-income settings, or, if the sample is not 
representative of the country, only to similarly sized facilities within other districts 
or within the country. Any conflicts of interest (i.e. involvement with developers or 
pharmaceutical companies) should be declared. This allows the reader and consumers 
of costs to be able to judge whether the research is independently undertaken or may 
suffer from bias. If a conflict of interest is not declared but exposed later, the reader 
may feel misled and the credibility of the work may be reduced. 
An important part of the dissemination process is to translate the information into 
easily digestible knowledge which is appropriate for the audience. One example 
might be presentation applicable for National Strategic Plan costing. In addition, it is 
important to share feedback with those that were involved in the cost analysis, such 
as stakeholders, clinic and laboratory managers, members of the NTP and Ministry of 
Health/Departments of Health, funders, and other interested parties. 
Wherever possible data should be openly accessible to the public such as on the GHCC. 
If work is published in journal articles, open access should be granted so that the 
information becomes a public good. 
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Section F. Appendices 
Appendix 1. Basic concepts and terms  
in costing 
Cost is a general term that refers to the value of resources or inputs used to produce a 
good or service. This can refer to financial, economic, unit (or average) or other types of 
costs depending on the ingredients included. TB costing is the process of estimating 
the value of resources used for a TB service/intervention through identification, 
measurement and valuing of resources consumed by an intervention. 
Costs generally relate to four areas where costs are incurred: the health sector 
(health care providers), other sectors (e.g. education or housing sector), patients and 
households costs of seeking care, and productivity losses [21]. This manual focuses 
on costing the resources used in the health sector. In this methodology, common 
costs to different interventions (shared costs) are identified so that double counting 
(where the costs are accounted for more than once making the cost seem higher than 
it actually is) does not take place. This highlights the importance of understanding 
what one is costing, how the health system (or part of the health system) works and 
the processes that are involved. 
Costs are comprised of quantities of resource used and the unit costs or prices 
(referred to as the prices and quantities – P’s and Q’s). To estimate quantities, several 
techniques might have to be employed: this could include interviewing staff about 
the time that tasks take them, using timesheets, observing consultation time, or 
following patients through a facility. For prices, market price can be used. This could 
be estimated through the current replacement value for a piece of equipment, or the 
price paid for an item (adjusted to the relevant year). Where price data is unavailable 
(for example to value the cost of volunteer time), a shadow price can be estimated to 
reflect the value of these resources.
Economic costs reflect the full value of all resources utilized in producing a good or 
service, for example the value of all resources used in a TB intervention. Economic 
costs include all resources, whether paid for or not; volunteers or donated goods 
should be included.
An opportunity cost is the value of the benefits that are sacrificed due to making 
an alternate choice to provide a service (hence the resources are not available) [21]. 
Resources refer to monetary resources as well as staff time, building space and 
equipment etc. Another way of looking at this opportunity cost is the value or benefit 
that one could have had if one had made a different choice. Economic costs are 
sometimes referred to as opportunity costs since they represent resources actually 
consumed, preventing the opportunity to devote those resources to another purpose. 
For example, if resources are used for expanding an MDR-TB programme, those same 
resources cannot be used for additional infection control measures. The opportunity 
cost is the benefits of the additional infection control measures.
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When it comes to donated goods and services (such as volunteered time or donated 
clinic space), assessing economic costs should include and value these costs so that if 
a programme was reproduced elsewhere, all the costs would be accounted for. This is 
one area where economic and financial costs differ. 
Financial costs are the actual expenditures, or monetary amount paid (the price 
tag), which are distinctly different from economic costs which include opportunity 
cost [22]. These costs are not generalizable across settings, unless there is a similar 
payment structure.
Cost of health service provision is the cost of providing health care, for instance 
through TB interventions, but this cost does not cover the payments made by patients 
nor economic costs borne by households.
A costing can be done from the point of view of the provider (health services) or 
a societal perspective. In addition, a patient perspective assesses the costs from 
the point of view of the patients themselves and considers both the direct patient 
costs such as medical out-of-pocket payments or non-medical expenses (transport, 
relocation costs) as well as indirect costs which relate to productivity losses such 
as time off work. The provider perspective takes the point of view of the provision 
of services, so here the costs are those incurred by a hospital, clinic or TB facility 
providing the services. With a societal perspective, provider and patient costs (and 
any broader societal costs) are combined in a meaningful way to assess the overall cost 
of an intervention to both the patient and provider. 
Health care costs from the provider perspective can be divided into capital and 
recurrent costs. Capital costs are one-time costs for items that have a useful life 
of over one year – such as buildings, vehicles, laboratory or medical equipment. 
Usually capital costs are outlaid at the beginning of a programme (see Table 2 for 
a comprehensive list of TB capital and recurrent items), and do not vary per patient 
treated. These costs are defined according to useful life of potential use rather than 
purchase price alone. Capital costs should be amortized (annuitized) or depreciated 
to reflect the expected life years of capital inputs (for example a building could be 
expected to have a useful lifetime of 30 years). This means that the initial capital item 
investment (the amount paid for the capital item, or the current replacement value), 
which is usually fairly substantial once off cost, is shared over the expected lifetime of 
the item so that it can be realistically reflected in an annual cost [22]. 
Economic and financial costs also differ in the valuation of capital items. When 
performing an economic costing, one would amortize capital costs (as described 
in Appendix 8) so that both capital and recurrent costs are presented in the same 
year and can be meaningfully combined. In a sense, one is taking the large capital 
outlay and representing how much it would cost to have that item for a single year, 
by spreading the cost over the useful lifetime of that item. An amortization table is 
included in Appendix 5 and an explanation of how to calculate the amortized cost in 
Box A below and in Appendix 8 using Microsoft Excel (under subheading Amortizing 
capital costs).
Recurrent or operating costs are the value of resources or inputs with useful lives 
of less than one year. These inputs can be purchased irregularly and include chemicals 
and reagents within a laboratory. Their costs can be recovered at any time for instance 
by buying fewer supplies the next month to lower costs or by task shifting between lay 
workers and professional nurses for TB screening.
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Overhead costs are costs that are necessary to support services but are not directly 
part of providing patient care (further examples are given in Appendix 8). Integral 
overhead costs for a facility could consist of items such as administration, cleaning, 
kitchen, utilities, security, laundry, monitoring and evaluation, pharmacovigilance, 
maintenance and training (if the effects last for less than a year).
Above site level costs are items that are necessary for the functioning the health 
system as whole, such as the management of human resources, financial services, 
information technology, procurement and others. Steps should be taken to disentangle 
whether an above service item is better placed under overhead costs (at the site level) 
or above site level costs and ensure that the cost has only been costed under one of 
the two. Above site level structures are essential to the smooth functioning of TB (and 
other) services but may be challenging to allocate to the facility or service level as they 
generally aid many different facilities of various sizes and types of service provision. 
Total cost is the entire cost of producing the service, which is made up of fixed and 
variable costs. Fixed costs do not vary with the level of output [22], whereas variable 
costs vary directly with the level of output. Total costs can also be calculated 
through the addition of recurrent and capital costs, i.e. the sum of all the costs of an 
intervention. 
Box A. Amortizing capital costs
To combine capital and recurrent costs in a substantial way, capital cost should be amortized (annuitized) or 
depreciated to reflect the expected useful life years of capital inputs (for example, 30 years for buildings). 
The amortization process to estimate the annual value of the capital assets, including buildings, equipment, 
furniture, vehicles and training, is described below:
Step 1: Estimate the life expectancy (estimated life years) of the capital item; this may be 30 years for a building, 10 
years for laboratory equipment, two years for training, etc. 
Step 2: Establish the current replacement value or ‘price’ of the capital item (see source of costs above).
Step 3: Use the amortization table in Appendix 5 to identify the amortization factor based on the number of 
expected life years (or ‘number of remaining years or useful life’ in the first column) and the desired discount rate 
(1–19%), or use the payment (PMT) function (as is done in the tool).
Step 4: Divide the current replacement value by the amortization factor to arrive at the amortized cost. If a discount 
rate of 0% is selected, the current replacement value can be divided by the expected life years to provide the 
amortized cost (also called the annualized financial cost). 
Worked example 1: amortizing a building price
Step 1 Building, estimated life expectancy of 30 years
Step 2 Current replacement value $300 000
Step 3 30 years at 3% discount rate = 19.60
Step 4 $300 000/19.60 = $15 306
Step 4 if discount rate of 0% is used, then divide by the 
number of years – i.e. 30 years in this case
$300 000/30 = $10 000
This annual equivalent cost of $15306 can then be used when calculating the cost of space. For instance, if 30% of 
the building is used exclusively for TB outpatient visits, then the estimated annual cost of space allocated for TB 
outpatient visits is $4592. If 100 outpatient TB visits are made in the year, then the cost per TB outpatient visit for 
space only is $45.92.
The economic (using standard and local discount rates) and financial costs then need to be allocated to the 
departments providing direct (outpatient, inpatient and community), support (laboratory and radiology) and indirect 
services (pharmacy, administration & management, and other overhead services). The proportion allocated to each 
department has already been completed based on the building space being costed.
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Marginal cost is the additional cost to produce one extra unit (change in total cost 
when one extra unit is produced) [22]. 
Unit costs or average costs (mean costs) are the total costs divided by the quantity 
(service/output), with output being measured in different ways (i.e. the cost per 
patient treated, the cost per test or the cost per patient retained).
Full costing assesses all the resources used in the intervention, including basic 
infrastructure, overhead inputs, etc., as opposed to incremental costing.
Incremental costing estimates the costs of adding or implementing an additional 
study or programme to existing services. It is useful when sound data of existing 
service cost is available, but difficult to generalize to other settings. It does not include 
the cost of existing services and is appropriate when the intervention being costed 
is not a major component of an organization’s activities. Incremental costing will 
underestimate costs that are of a general administrative nature (such as overhead 
inputs). It is more difficult to generalize from incremental cost analyses, unless the 
prior level of existing services and infrastructure is clearly specified and understood. 
Defining incremental costs may be challenging unless the analyst has sound data on 
current health service delivery capacity.
A cost function reflects the underlying production function of a service and how 
inputs/factors of production are combined to produce a health service – in this case, 
TB service. It describes how cost varies with input prices, volume of service provision 
(scale), quality or other factors.
Real world costing is done as per actual implementation, as seen in health facilities. 
This contrasts with guideline costing/normative best practice costing which is 
done per national (or WHO) guidelines. In an ideal world, guideline costing and real-
world costing would produce similar results, however in most cases it is likely that 
there will be deviations in the real-world costing (for instance practical changes to the 
guidelines). 
Two methods that are used in costing are bottom-up and top-down costing, 
although generally mixed methodology is used (a combination of both bottom-up and 
top-down costing). In essence, this refers to whether there are the time and resources 
needed to enter a facility and cost all the processes that are being undertaken within 
a facility or laboratory providing TB services (bottom-up costing), or whether if one 
has the appropriate information available that allows one to cost the services using a 
top-down approach (also known as gross costing or step-down accounting/costing). 
Both approaches have their limitations; however, Cunnama et al. 2016 recommend 
doing both as a gold standard, so that a range of costs can be produced, the lower 
limit representing the most efficient practice without regard for breaks, leave or 
suboptimal processing (bottom-up cost value). The upper limit represents a more 
inefficient and, in some ways, more realistic cost in terms of inclusion of leave, breaks, 
sub optimal processing speed and down time (top-down cost value). If the researcher 
has the resources (time and money) to perform both methodologies, then this is the 
recommended practice. Examples of these methodologies are given in Appendix 8.
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Appendix 2. Specific TB interventions 
Understanding the process of the intervention will help to establish which inputs are 
needed and what units will be costed. For example, inputs for costing an intervention 
in a clinic would differ from those used for costing in a laboratory setting. For this, 
it is necessary to describe the interventions (through national guideline review and 
consultation with experts) and how they are undertaken in the facility, laboratory, 
community or other setting (through time-motion studies, observation, work 
sampling or interviews).
To describe the TB intervention, one needs to have a clear understanding of the 
coverage in terms of what the intervention aims to achieve, whether that is defined 
by intervention specific targets or recent epidemiological data pertaining to the 
intervention (see Figure 9).
Fig. 9. Intervention flow chart
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interven-
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are being 
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service
Where the 
intervention 
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such as 
public or 
private 
facilities, a 
general hos-
pital or health 
centre, within 
a community 
or household 
setting
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adults or 
children, PTB 
or EPTB, HIV+ 
or HIV-, latent 
TB
Such as an 
episode or 
for a patient, 
treatment 
phase, during 
implemen-
tation or 
scale-up
E.g. for 
passive case 
finding this 
would include 
diagnostic 
visits, 
diagnostic 
tests and 
any patient 
support 
This can 
include tests, 
treatment 
protocols or 
drug regi-
men, contact 
tracing or 
follow-up, 
M-health 
or infection 
control equip-
ment and 
supplies
Vaccination
Vaccination for TB is used to prevent TB and currently includes the BCG vaccine for 
infants, children and young adults (between eight and eighteen years old). Treatment 
for adverse reactions has been included as part of the vaccination intervention.
TB case detection and diagnosis: Passive case finding
PCF is defined as detection of TB cases (screening and diagnosing of active and latent 
TB) reporting to public or private TB services in health facilities. The standard method 
of identifying people with TB is PCF, where individuals with TB symptoms present 
themselves at a health facility. A health worker assesses the person and orders a 
diagnostic test. Several technologies are available for PCF depending on the setting 
and patient attributes, including a verbal symptom screen, cough triage, sputum 
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induction, Xpert® MTB/RIF, (LED or Ziehl-Neelsen (ZN)) microscopy, culture (solid 
or liquid), film and digital x-ray, rapid HIV test, line probe assay for first (LPA-FLD) 
and second-line drugs (LPA-SLD), drug sensitivity testing (DST), LAMP, lateral flow 
urine lipoarabinomannan assay (LF-LAM), interferon-gamma release assay (IGRA) 
(where used for detection of latent TB infection (LTBI)), tuberculin skin test (TST, 
also known as Mantoux test or purified protein derivative (PPD) skin test), fine 
needle biopsy, bronchial and gastric lavage, and tests for extra-pulmonary TB (EPTB) 
(aspirates, computed tomography (CT) scan and ultrasound). Other tests include: HIV 
confirmatory test, cluster of differentiation 4 (CD4) count, erythrocyte sedimentation 
rate, total white blood cell count, full heamogram, aspartate aminotransferase 
(AST also known as serum glutamic-oxaloacetic transaminase (SGOT)), creatinine, 
creatinine clearance, glucose random blood sugar (RBS), lactic acid, lipase, thyroid 
stimulating hormone, body fluid analysis polymerase chain reaction – deoxyribonucleic 
acid (PCR-DNA) and electrocardiography (ECG). The population of concern includes 
both children and adults, irrespective of HIV status or TB strain. Costing should be 
conducted for the entire duration of the diagnostic visit, diagnostic test and patient 
support activity. PCF occurs in both public and private health facilities, but rarely 
occurs outside of the health facility or laboratory. 
TB case detection and diagnosis: Intensified case finding
ICF detects potential active and latent TB cases among people living with HIV 
or diabetes or attending maternal and child health clinics or in other high-risk 
populations, receiving non-TB health care. Symptom screening, film or digital x-ray 
and Xpert® MTB/RIF are the main ICF technologies, but technologies used in PCF 
may also become part of the diagnostic algorithm for HIV positive adults, persons 
within high-risk groups (including people exposed to drug-resistant TB) attending 
health facilities, and children. Screening and diagnostic visits, diagnostic tests and 
patient support activities should be costed to obtain the unit cost of ICF.
TB case detection and diagnosis: Active case finding
ACF is defined as screening and diagnosing active and latent TB in those who are not in 
public health care (i.e. who are not detected passively). Generally, fewer technologies 
are used to detect cases actively, which include a verbal symptom screen, Xpert® MTB/
RIF, microscopy (LED), film or digital X-ray, rapid HIV test, contract tracing, fine 
needle biopsy aspirates, CT scan or ultrasound. Other tests can include culture (solid 
or liquid), LPA, DST, IGRA, TST, and bronchial or gastric lavage. It can be conducted in 
private or public facilities, in mobile clinics, through outreach programmes such as to 
schools, prisons, or within the household. Target populations are household contacts 
(adults and children less than five and between five and eighteen years old), poor urban 
populations, prisoners, mobile populations, migrant populations, healthcare and 
other workers with an occupational risk of contracting TB. Any new ACF technologies 
should be costed during the start-up as well as the continued implementation for a 
patient or an episode. The activities included in ACF are the screening visits, diagnostic 
visits, diagnostic tests and all patient support services.
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TB treatment 
TB treatment includes all activities involved in treating patients with active TB, 
observation of treatment, patient support, restoring quality of life and productivity, 
preventing relapse or death, reducing transmission and preventing development 
and transmission of drug resistance. During the intensive and continuation phases 
of treatment, persons of all ages being treated for either DS-TB or DR-TB (mono-
resistant, poly-drug resistant, Rifampicin resistant, MDR-TB, pre-XDR-TB or XDR-TB) 
can be treated within the household, the community, through outreach programmes, 
in public or private facilities, or at general or specialized TB hospitals. HIV-positive or 
negative patients with either pulmonary TB (PTB) or EPTB are included. In addition 
to the drugs for first-, second- and third-line treatment; retreatment, palliative care, 
monitoring tests for treatment response, adverse events, nutritional assessment, lost 
to follow-up tracing, ART regiment if HIV-positive and M-health are included in TB 
treatment.
TB prevention
TB prevention refers to screening and treatment to prevent latent and active TB (PTB 
and EPTB) amongst children and HIV-positive adults. Screening visits, treatment 
monitoring (including for breakthrough disease, adverse events, acquired drug 
resistance), visits occur in public or private facilities. The technologies for prevention 
of TB include symptom screening to rule out active TB, IGRA test or TST, as well as 
treatment protocols of isoniazid for six months (6H), lifelong isoniazid (H), three 
months of once-weekly isoniazid and rifapentine (3HP), or rifapentine only, ART 
regimen for HIV positive patients and cotrimoxazole prophylaxis.
TB infection control
Infection control for TB in environments such as health facilities, laboratories, 
congregate settings and households involves a combination of activities to minimise 
the risk of transmitting TB within these settings. Successful TB infection control 
includes early and fast diagnosis of TB, coupled with appropriate management of 
people with TB. 
Within health facilities, in addition to the administrative controls to reduce diagnostic 
delays and prompt treatment initiation, infection control for patients, laboratory staff 
and health care workers includes the use of ventilation systems, laboratory biosafety 
systems, UV fixtures and personal protective equipment. 
Congregate settings include hospital premises, prisons, refugee camps and schools. 
TB infection control in these settings must be coordinated with other sectors. Within 
households, TB infection prevention includes campaigns educating on behaviour and 
social change to minimize exposure. The delivery platforms include private and public 
health facilities, as well as facilities managed by international and national NGOs. 
Infection control can also occur in community-based activities and during outreach 
activities.
TB programme above site services: Above service costs
At the national level activities and technologies that contribute to the successful deliv-
ery of TB services include development of strategic plans, TB care guidance develop-
ment or adaptation, programme reviews, national and regional meetings, surveys, 
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management and information systems, supervision, procurement and supply chain 
management, transportation of specimens, advocacy, technical assistance, training, 
accreditation and quality assurance of labs, community media or information, educa-
tion and communication (IEC) campaigns or any partnership activities.
The delivery platforms for these activities and technologies are ministries of health, 
NTPs, reference laboratories, government and non-government research institutes, 
public health facilities, private health facilities and laboratories, regulatory bodies for 
food, drugs and health, NGOs, and bi- and multi-lateral partners, including WHO. 
Populations involved in these activities include health care workers, laboratory staff 
and management involved in TB or any support services.
Defining standard costs for each intervention
Table 3 was devised as part of the GHCC and Reference Case development. The table 
lists the interventions and a default and optional unit cost per recipient. The default 
unit cost per recipient is the one that makes the most sense in terms of standardising 
and using these costs for budgeting and modelling purposes. Table 3 also lists the 
possible outputs as well as the direct and ancillary (supportive) unit costs per output. 
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Appendix 6. Protocol outline 
Title of the study
Investigators and institutional affiliations
Abstract
Introduction/Background
Justification for the study/Purpose and study question
Null hypothesis
Objectives:
1. General objectives
2. Specific objectives
Study design and methodology:
1. Study site 
2. Study populations
3. Sampling 
4. Procedures
a. Costing methods 
b. Interventions and unit costs 
c. Piloting and data collection 
Perspective of the evaluation 
Selecting a study team
Data management:
1. Data storage 
2. Data analysis
Intellectual property
Time frame/Duration of the study:
Ethical consideration:
1. Human subjects
2. Informed consent
3. Confidentiality
4. Benefits and risks
5. Data sharing
6. Community engagement
Expected application of the results
References
Appendices:
Appendix 1: Summary budget 
Appendix 2: Justification of budget 
Appendix 3: Role of investigators 
Appendix 4: Description of interventions
1. Vaccination intensified case finding 
2. Active case finding
3. Passive case finding
4. Treatment of TB
5. Prevention (latent TB infection treatment) 
6. Infection prevention control 
7. TB policy, planning, coordination and management 
Appendix 5: Facility information sheet 
Appendix 6: Informed consent 
Appendix 7: Curriculum vitae of each investigator 
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Appendix 7. Examples of queries and 
comments from ethics committees 
1. What will happen if facilities do not agree to take part? Will you need to rerun 
your sample?
2. Could you add more information on the observations?
3. Special care needs to be given to ensure the anonymity of participants and to 
mitigate the risk that they are identifiable by their location/institution. Be careful 
about how you describe respondents to ensure that they cannot be identified 
by location/role. The sentence “Your questionnaire will not bear your names; 
this way your responses will be anonymous” is not always true if you reveal the 
respondents job title and hint at their location – colleagues/managers will know 
who has been interviewed and may be able to identify who said what.
4. In both the information sheet and consent form, it should be specified how the 
observation will be done, who and number of observers involved. Similarly, with 
the timesheet it should state in the consent form the actual period rather than 
saying ‘over the period specified’.
5. In the information sheet, it states that participation is voluntary and that 
choosing to withdraw can be at any time without consequence. The committee 
suggest adding the commonly used ‘without the need to give a reason’.
6. The committee thinks you should consider asking participants to initial the 
sentences indicating permission granted for different aspects of your research 
rather than ticking a box.
7. How will the data be aggregated? Since only 3–5 staff per facility will be inter-
viewed, will there not be a risk of breach of confidentiality?
8. The approach and justification for the proposed sampling of health facilities is 
unclear. Please explain how the reference list of 25 was derived?
9. The information sheet/consent form states that they may be asked to complete a 
diary over the course of one week or allow researchers to observe them as they go 
about daily tasks. Is the observation for 1-day or 1-week? Please make that clear 
to the participant.
10. Kindly consider adding the study population in the title.
11. Please clarify whether both direct and indirect costs will be collected.
12. Indirect cost is an important cost driver for TB services, why was this not neces-
sary in this study?
13. Three (3) regions Nairobi, Eastern and Western Kenya were selected due to high 
number of TB cases, but sampling table does not show the five other regions of 
Kenya to justify site selections. Please clarify.
14. Sampling of health facilities has been provided but the sample size determination 
has not been provided. Of the total 3690, you will randomly select 24 facilities, 
which translates to 20% margin of error which is quite low compared to traditional 
5% margin of error which would need 350 health facilities with adequate power 
to generalize to the entire country: please provide a section for sample size 
determination and procedures and level of power needed for analysis.
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15. Please clarify the exclusion of prisoners as study subjects; the other facilities 
listed where the study may be conducted will also possibly have a mix of funding 
resource? Given also their close living conditions, the likelihood of TB infection 
is high.
16. Per protocol costs tend to over-estimate costs if the intervention is funded by 
donors and often deviate from real world costs, how will the study handle these 
variances? Please clarify.
17. Which econometric models/methods will be used in the analysis?
18. Given that you intend to observe health providers in the course of delivering 
service, please also [ensure] direct sensitization of the study activities to patients 
who will be present during that observation, through fliers, posters etc.
19. In the informed consent document, under “who has allowed…”, please indicate 
the institution names rather than several national and international committees 
for added confidence.
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Appendix 8. Value TB Costing Tool Suite  
This appendix details all the aspects included in the Value TB Data Collection Tool and 
the Data Entry Tool, providing instruction and  some methodology. For ease of use, an 
image of each of the sheets is displayed for the different sections. The layout follows a 
thought process of how one might collect and enter data, however given the nature of 
costing the sequence of quantities and prices collected may vary. 
data collection tool
The Data Collection Tool, used by data collectors, is described here (see Figure 
10a). First, general instructions are given for the tool sheets. This is followed 
by an overview of how to use the generic unadapted tool to collect facility 
data for bottom-up and top-down unit costs calculation. 
Types of sheets
■n In the Data Collection Tool, there are five types of color-coded sheets. 
■n Black sheets are meant to help with the planning of the data collection and to 
acquire an understanding of the structure and processes within the facility. 
Fig. 10a. The Value TB Costing Tool Suite (Data Collection Tool highlighted in orange)
Value TB generic facility 
provider cost 
Data Collection Tool 
Facility provider cost Data Collection Tool 
(Country-specific assumptions & parameters,
facility-selection of relevant TB service delivery outputs)
Costing Guidelines 
for Tuberculosis 
Interventions (for facility 
provider costing)
Facility provider cost Data Entry Tool 
for one facility used for initial analysis 
tool (generic/no adaptation required)
Number 
of 
facilities 
in sample
Extraction of 
P’s and Q’s for 
analysis in a 
statistical package
Value TB cost 
model – analysis
Unit costs for all TB 
interventions/services for 
one country
• Per visit/test BU and TD
• Per patient BU and TD
X
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■n These sheets, in particular Data collection planning 1 and Data collection 
planning 2, can be used during an introductory visit while one becomes familiar 
with the facility. 
■n Data should be entered into the yellow cells and nowhere else. 
■n The blue sheets are for data related to the facility, including identifying facility-
specific service outputs, inventory of capital assets, building dimensions, overhead 
(recurrent and capital) costs and availability of above service level data. 
■n Green sheets are for prices for drugs, supplies, and equipment.
■n The grey sheets relate to TB service utilization for the 20 standardized service 
outputs and at least 39 diagnostic and monitoring tests being costed, as well as the 
drug regimens and supplies used.
■n The red sheets are for capturing quantities related to time for staff (assessed by 
observations, interviews and timesheets) and usage for equipment, supplies and 
vehicles (observation and interviews), which are inputs for both top-down and 
bottom-up costing.
■n In the red sheets one would collect and enter the information on utilization within 
the health facility, such as the annual number of outpatient and community visits 
for TB-related services and for the entire facility. 
■n A breakdown is also provided for top-down and bottom-up relevant quantities. 
For example, for drugs, the top-down quantities refer to the total amount of each 
TB medication disbursed within the facility, while for the bottom-up quantities 
sampled usage by patients is collected. 
■n The template for staff-time interviews is used as one method to capture the 
quantity and allocation of staff time. 
■n The second method is that of weekly timesheet templates, also printable. 
■n During the detailed costing, these would be printed out or provided on electronic 
tablets to staff members at the beginning of the data collection week and collected 
at the end of the week.
■n Total drug expenditure, which will enable top-down cost calculations later on, will 
be estimated based on the product of the total annual quantity of drugs disbursed 
at the facility by the unit price of the drugs. 
■n Similarly, bottom-up calculations will be performed based on the product of the 
drug prices and the average quantity per average patient for each TB treatment and 
prevention regimen by phase.
■n The instructions for Data Collection Tool often apply to the Data Entry Tool 
too. This is because one collects the quantities (such as minutes observed, etc.) and 
prices in the Data Collection Tool and then transfers the pertinent information 
to the Data Entry Tool, where costs are allocated to departments and services 
and the unit costs are calculated.
■n Throughout the data collection and Data Entry Tools, if an input cell is not 
applicable, it can be left blank or the cell can be changed to green (MS Excel ‘Good’ 
style). 
■n Do not enter NA or 0 in cells that are not applicable, as this may affect the 
calculations in the Data Entry Tool.
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Adaptation of the tool to the context
In addition to default listings, there ispace to add as many of the context-specific 
and country appropriate service outputs, drug names, test procedures, service 
utilization labels, consumables supplies, staff titles, department or clinic names 
and other important labelling as possible, is provided in blue font in the non-yellow 
(un-highlighted) cells, such as in the column labelled ‘Health care worker type’ in the 
Staff Salaries sheet (9) or by including yellow highlighted cells where information 
can be typed in, such as the ‘Name or description of supply’ column in the Price list-
Supplies sheet (22) of the Data Collection Tool. 
Without adaptation, the generic Data Collection Tool allows the  
data collector to:
A. Plan for data collection
■n As a guide for planning the data collection, it is estimated that a health centre 
would require two days, a large health centre or small hospital would require four 
days and a regional or tertiary hospital or reference laboratory would require two 
weeks.
■n Sheets Data collection planning 1 (4) and Data collection planning 2 (5) can 
be used during an introductory visit while one becomes familiar with the facility. 
Data collection planning 1
■n This is an optional sheet that has been developed to help with planning for data 
collection by noting the location and title of the contact person who can provide 
further information about each TB intervention type.
■n Please be sure to only record the title of the contact person and not their name in 
this tool so that data protection and participant anonymity are ensured.
■n If one would like to capture the name of the contact, please use the separate 
facility contact workbook, which should always be saved separately from the 
data, in a locked cabinet or with password protection.
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 4.Data	  collection	  planning	  1
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Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection HH:MM
Name	  of	  data	  collector
Sheet	  complete	  (dropdown)
Class Type
Intervention	  
provided	  at	  or	  
through	  facility?
[use	  dropdown]
Location	  1	  of	  
intervention	  (facility	  
or	  offsite)
[use	  dropdown]
Title	  of	  person(s)	  
responsible	  for	  
intervention
Location	  2	  of	  
intervention	  (facility	  
or	  offsite)
[use	  dropdown]
Title	  of	  person(s)	  
responsible	  for	  
intervention
Location	  3	  of	  
intervention	  (facility	  
or	  offsite)
[use	  dropdown]
Title	  of	  person(s)	  
responsible	  for	  
intervention
Location	  4	  of	  
intervention	  (facility	  
or	  offsite)
[use	  dropdown]
Title	  of	  person(s)	  
responsible	  for	  
intervention
VACCINATION BCG	  vaccination
Passive	  case	  finding
Intensified	  case	  
finding	  -­‐	  cough	  
triage
Intensified	  case	  
finding	  -­‐	  screening
Active	  case	  finding
If	  no,	  list	  missing	  data?
	  INSTRUCTIONS:	  THIS	  SHEET	  IS	  OPTIONAL.	  It	  is	  intended	  to	  help	  you	  understand	  and	  plan	  your	  interviews	  and	  other	  data	  collection.
There	  is	  space	  to	  identify	  up	  to	  4	  locations	  (within	  the	  facility	  or	  community	  spaces)	  where	  each	  TB	  intervention	  type	  occurs,	  with	  the	  title	  of	  the	  corresponding	  contact	  person.	  The	  information	  in	  this	  sheet	  can	  be	  obtained	  from	  the	  head	  TB	  nurse	  or	  another	  staff	  member	  with	  
knowledge	  of	  TB	  service	  delivery.
Interview	  Planning
TB	  CASE	  
DETECTION	  AND	  
DIAGNOSIS
Notes
[include	  any	  additional	  details	  on	  the	  nature	  
and	  extent	  of	  the	  intervention,	  where	  
appropriate]
INTERVENTIONS
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■n For each intervention, the user includes services/interventions that are happening 
both within the facility and in the community. 
■n Community visits (BCG vaccination, ACF and TB Treatment) can occur in various 
platforms.
■n The user specifies the platforms where these TB services are offered through this 
health facility. 
■n These platforms should be specified and could include health clinics, health posts, 
community buildings, households, mobile clinics, schools, places of work, prisons 
or camps. 
■n The ‘TB Screening, Diagnostic & Monitoring Tests’ are for diagnosis of latent and 
active TB, and HIV, as well as monitoring of treatment for active TB. 
Data collection planning 2
■n In addition, the user can also fill in a complementary sheet (Data collection 
planning 2) to organize the data collection by the data collection methodology 
(timesheets, interviews, observation, and extraction of service statistics, resource 
quantities, prices and overhead data). 
■n Each staff member or input can then be selected from a dropdown or is listed under 
the methodology type. 
■n The potential locations for the data and the corresponding data collection sheet are 
either listed or can be selected from a dropdown.
■n In order to track the data collection progress, the start and end date, person 
responsible for obtaining the data and the status of the data can be completed as 
one proceeds.
■n The dropdown options for the status column are: not started, in progress, completed 
and not applicable and each is colour-coded, so the status can be visually assessed 
at a glance. 
■n This checklist sheet is optional and intended to assist with the organization of the 
costing process.
■n For various types of data needed for completing the tool, Appendix 8 provides 
potential sources (see page 31, Table 4.1 of WHO Guidelines for cost and cost-
effectiveness analysis of tuberculosis control (2002))
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 5.Data	  collection	  planning	  2
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Data	  collection	  activity/category
[use	  dropdown]
Location	  in	  facility
[use	  dropdown] Sheet	  name
Start	  date	  of	  interview,	  
observation	  or	  extraction
End	  date	  of	  interview,	  
observation	  or	  extraction
Status
[use	  dropdown]
Data	  collector	  
responsible Notes
A. Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
20.Staff	  time	  sheets
INSTRUCTIONS:	  This	  checklist	  can	  be	  used	  to	  keep	  track	  of	  the	  various	  data	  needed	  and	  obtained	  from	  the	  different	  cadres	  of	  health	  staff	  in	  the	  departments	  of	  the	  health	  facility.	  The	  'Status'	  column	  allows	  you	  to	  indicate	  whether	  the	  data	  is	  not	  
applicable	  to	  this	  facility,	  not	  started,	  in	  progress	  or	  complete	  and	  is	  colour	  coded	  to	  reflect	  the	  status.	  
Please	  note,	  the	  list	  included	  is	  not	  exhaustive	  and	  additional	  rows	  can	  be	  added	  to	  the	  checklist	  to	  include	  more	  staff.	  Potential	  locations	  for	  data	  collection	  have	  been	  included	  but	  these	  can	  be	  edited	  based	  on	  the	  structure	  of	  the	  facility	  and	  the	  TB	  
services	  provided	  there.
Checklist
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Title page
■n This provides an overview of the study, outlining the aims of the study and the 
tool, as well as how the data can be used. 
■n The example of the Value TB study is used throughout this section.
Glossary 
■n Defines the acronyms and abbreviations used within the tool. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services
27/11/19 Page	  1
AE adverse	  events
ACF active	  case	  finding
AFB acid-­‐fast	  bacilli
ALT alanine	  aminotransferase	  (also	  known	  as	  SGPT)
AST asparate	  aminotransferase	  (also	  known	  as	  SGOT)
BCG bacille	  Calmette-­‐Guérin
BSC biosafety	  cabinet
BU bottom-­‐up	  cost	  estimation/allocation
BUN blood	  urea	  nitrogen
CBC complete	  blood	  count
CCC comprehensive	  care	  clinic
CT computed	  tomography
CXR chest	  x-­‐ray
DOTS directly	  observed	  therapy,	  shortcourse
DR drug-­‐resistant
DS drug-­‐susceptible
DST drug	  susceptibility	  testing
E Ethambutol
ECG electrocargiogram
Glossary
VALUE-­‐TB
Data	  collection	  tool	  for	  estimating	  unit	  costs	  of	  TB	  services
VALUE-­‐TB	  is	  a	  three-­‐year	  project,	  funded	  by	  the	  Bill	  and	  Melinda	  Gates	  Foundation,	  established	  to	  work	  with	  National	  
Tuberculosis	  Programmes	  (NTPs)	  from	  high	  TB	  burden	  countries	  to	  collect	  unit	  cost	  data,	  using	  new	  standardised	  methods.	  
Project	  overview:
The	  included	  TB	  interventions	  are	  those	  that	  are	  most	  relevant	  for	  future	  local	  planning	  and	  resource	  requirement	  projections	  and	  have	  been	  jointly	  defined	  by	  
the	  NTP	  and	  the	  VALUE-­‐TB	  team.
This	  cost	  data	  collection	  tool	  has	  been	  developed	  to	  estimate	  the	  unit	  costs	  of	  a	  comprehensive	  set	  of	  TB	  services	  from	  the	  providers'	  perspective.	  It	  is	  a	  facility-­‐
based	  tool	  that	  collects	  data	  needed	  to	  calculate	  the	  bottom-­‐up	  and	  top-­‐down,	  economic	  and	  financial	  costs	  of	  TB	  services	  offered	  at	  this	  facility.	  
for	  programme	  management,	  funding	  and	  planning
to	  inform	  the	  estimates	  of	  the	  costs	  of	  TB	  services	  globally
Using	  this	  instument,	  financial	  and	  TB	  service	  records	  will	  be	  examined;	  all	  rooms	  and	  equipment	  used	  for	  TB	  will	  be	  listed;	  staff	  will	  be	  interviewed	  about	  their	  
time	  spent	  on	  different	  activities;	  some	  activities	  will	  be	  observed;	  and	  price	  data	  will	  be	  collected,	  including	  supplies,	  equipment	  and	  salaries.
The	  estimated	  time	  for	  data	  collection	  is	  approximately	  1	  week	  per	  facility,	  with	  data	  being	  collected	  from	  20	  to	  30	  public	  and	  private	  providers	  of	  TB	  services	  
and	  interventions	  nationally.	  
There	  are	  two	  tools	  required	  to	  estimate	  the	  unit	  costs	  of	  TB	  services	  at	  the	  facility	  level:	  this	  Data	  Collection	  Tool	  and	  an	  accompanying	  Data	  Entry	  Tool.	  The	  
data	  collection	  tool	  will	  be	  used	  by	  data	  collectors	  while	  at	  the	  facility	  to	  gather	  the	  required	  data.	  The	  data	  entry	  tool	  will	  be	  compiled	  by	  the	  study	  principal	  
investigator	  or	  study	  coordinator	  to	  produce	  the	  calculated	  unit	  costs.
Outpatient	  and	  community	  services	  linked	  to	  this	  facility	  will	  be	  costed.	  While	  the	  unit	  costs	  of	  TB	  related	  inpatient	  care	  are	  also	  calculated,	  this	  has	  not	  been	  
done	  at	  the	  patient	  level.	  The	  estimated	  values	  may	  include	  time	  spent	  in	  hospital	  receiving	  treatment	  for	  adverse	  events	  but	  the	  additional	  costS	  of	  tests	  and	  
drugs	  for	  TREATING	  adverse	  events	  has	  not	  been	  included	  so	  that	  the	  tool	  remains	  feasible	  within	  a	  reasonable	  amount	  of	  time.
The	  cost	  data	  collected	  in	  this	  tool	  can	  further	  be	  used:
March	  8,	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Instructions 
■n Describes the colour-coding of the sheets and the cells in the tool and how they 
should be used. 
■n Instructions throughout the tool are in blue font, including in cells where data 
type or name is stated, and the blue font tells one how to input the data needed 
(e.g. [see dropdown]) or provides an example of the options (e.g. Culture – liquid 
media [e.g.: MB/Bact Alert, Bactec Mycobacteria Indicator Tube (MGIT) 960]).
■n The data collection sheets have been formatted so they can be printed on A4 paper 
in either portrait or landscape orientation. 
■n If one finds that the printed documents are too small, the size of paper can be 
changed in the Page Layout tab of Excel and the scaling increased to allow the 
content to fill up the entire space.
B. Record data related to the facility including identifying facility-specific service 
outputs, inventory of capital assets, building dimensions, overhead (recurrent 
and capital) costs and availability of above service level data 
Facility characteristics
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1.
2.
3.
4.
5.
6.
Instructions
Black	  sheets	  are	  designed	  to	  help	  plan	  the	  study	  but	  no	  data	  is	  collected	  here	  so	  the	  degree	  of	  utilisation	  of	  these	  sheets	  is	  up	  to	  you.
Blue	  sheets	  capture	  captial	  and	  recurrent	  data	  for	  the	  facility.	  
Grey	  sheets	  describe	  where	  and	  how	  TB	  services	  are	  delivered	  and	  how	  much.	  
Green	  sheets	  are	  prices	  and	  expenditure.
All	  sheets	  in	  this	  tool	  have	  been	  formated	  so	  that	  they	  can	  be	  printed	  and	  data	  collected	  on	  hard	  copies	  or	  
entered	  electronically	  into	  the	  sheets.
This	  data	  collection	  tool	  is	  comprised	  of	  black,	  blue,	  grey,	  red	  and	  green	  sheets.	  
Red	  sheets	  relate	  to	  staff	  time.
	  Optional	  sheets:
Additional	  instructions	  for	  data	  collection	  is	  given	  in	  blue	  text	  throughout	  the	  tool.
Please	  use	  the	  "Notes"	  column	  to	  explain	  any	  values	  that	  are	  not	  in	  the	  spreadsheet,	  provide	  more	  detail	  on	  the	  source	  or	  method	  of
	  	  calculation	  of	  the	  data,	  or	  anything	  else	  that	  you	  think	  would	  be	  of	  interest.	  
Do	  not	  enter	  data	  anywhere	  else.
The	  yellow	  cells	  are	  input	  cells	  where	  you	  need	  to	  enter	  data.	  
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 6.Facility	  Characteristics
27/11/19 Page	  1
Start	  date	  of	  data	  collection dd/mm/yyyy HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy HH:MM
Name	  of	  data	  collector
Country
District	  name
Town/city	  name
Sheet	  completed	  [use	  dropdown]
Source Year	  of	  data
Facility	  name
Facility	  location/address	  1
Facility	  location/address	  2
Geography	  1	  -­‐	  urbanicity	  [use	  dropdown]
Geography	  2
Geography	  3
Facility	  level	  [use	  dropdown]
Ownership	  [use	  dropdown]
Size	  (approximate)	  of	  facility	  buildings	  (m2)
Size	  (approximate)	  of	  land	  (m2)
Operating	  hours	  of	  facility (total	  opening	  hours	  per	  week)
Operating	  hours	  of	  TB	  services (total	  opening	  hours	  per	  week)
Total	  hospital	  beds	  (inpatient) (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Total	  day	  beds	  (outpatient) (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Total	  outpatient	  visits (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Size	  of	  catchment	  population
Total	  clinical,	  allied,	  and	  auxiliary	  staff	  FTE
Total	  support	  and	  administrative	  staff	  FTE
Total	  staff	  FTE
INSTRUCTIONS:	  on	  day	  1	  of	  data	  collection,	  meet	  with	  facility	  manager,	  briefly	  outline	  VALUE-­‐TB	  background	  and	  objectives,	  obtain	  written	  informed	  consent.	  Then	  obtain	  an	  overview	  of	  the	  facility	  
characteristics	  and	  the	  population	  it	  serves.	  This	  sheet	  will	  be	  used	  to	  provide	  a	  description	  of	  the	  health	  facility	  and	  provide	  context	  when	  reporting	  results.
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Start	  time	  of	  data	  collection
End	  time	  of	  data	  collection
(days	  of	  the	  week)
(days	  of	  the	  week)
0
NotesValue
Facility	  Characteristics
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■n Information about the geography where the facility is located includes whether 
that area is urban, rural or a mixture of the two. 
■n Local knowledge of potential drivers of costs is additional contextual information 
(e.g. socio-economic status of community) that can be included in the Geography 
2 and Geography 3 cells.
■n The size of all the buildings at the facility should be reported in square metres (m2). 
■n The best-case scenario is if the facility has a record of the size in square metres or, 
better still. a map with the dimensions and floor plan.
■n  If this is unavailable see options for estimating the facility size in Building space. 
■n Operating hours for the entire facility and of TB services (regular hours of TB 
clinic) should be recorded by first indicating the days of the week that the facility 
is open and the services are provided, and then by inserting the total hours of 
operation of the facility and TB services during a seven day week. 
■n Please be sure to enter values for both the facility and TB services, even if they are 
the same.
■n Total hospital beds (inpatient) should be reported for the entire hospital (all) as 
well as for DS-TB, MDR-TB and TB-HIV patients. Values should be reported for the 
same categories for day beds (outpatient), which may also be referred to as cots, 
gurneys or other name in different settings. 
■n Information about the TB services offered at that facility is being captured for 
treatment services, patient support during diagnosis or treatment, and community 
services provided through or to the facility. 
■n Additional service outputs relevant to the facility can be selected from dropdowns 
in the categories of visit and bed-day types; additional laboratory tests; additional 
radiology tests; and other TB services. 
■n Other TB services could include, but are not limited to, lost to follow-up tracing 
by a home visit, contact tracing, education or health talks, adherence or infection 
control.
Adaptation
If one requires an additional service output for any of these categories that is not already an option, please go to 
the Lists sheet at the end of the tool and enter the name of the service output in the yellow cells of the relevant 
category.
Building space
■n The value of the building could be obtained by sourcing the current replacement 
value for a similar type of building and situation. This could be the value of 
rebuilding a clinic in an urban, peri-urban or rural area. 
■n An architect, structural engineer, centre for scientific and industrial research or 
construction company could be contacted to give a valuation of the facility. 
■n Alternatively, original facility records from when it was built, sourced from the 
facility administrative department or government records offices, could be used 
and inflated to arrive at the current value. 
Costing guidelines for Tuberculosis interventions64
■n If these options are not available then one could look at the insurance valuation of 
the building, the cost per square metre (m2) in that area (from commercial realtors, 
construction companies or the internet), tax forms for the building or government 
rate for stamp duty. 
■n If buildings have been recently renovated, then the cost can be inflated using the 
consumer price index (CPI) for the country.
■n The rental value, if the facility or certain buildings within the facility have been 
rented, can be found in the lease agreement, sourced from the finance department 
within the facility or from the leasing agency.
■n The size measurements should be in square metres (m2). 
■n If perimeters are measured in feet, please convert to metres by multiplying by 
0.305, then calculate the area, or convert square feet to m2 by multiplying by 
0.093. 
■n Data for the MDR-TB clinic in the Outpatient Department (OPD) should be 
included only if there is a separate space for MDR-TB services within the facility. 
■n If the total land space is known but not the building size, then one option is to 
estimate the proportion land that the building resides on which can then be 
multiplied by the total size of the land (m2) and the number of floors (if a multi-
storey building is being costed).
■n It is a good idea to ask if there is a map of the facility or draw a map. On this map 
note which rooms are dedicated to TB consultation, sputum collection, waiting, 
diagnostics, dispensing medication, other services, shared spaces (e.g. space that 
is used for both TB and HIV care). 
■n If space is shared, note if specific days are assigned to the room or how the time is 
divided. 
■n One can then physically measure the space with a laser distance measurer or a tape 
measure. 
■n The dimensions of the various areas may also be obtained from building plans or 
by estimating based on length of steps (if a step is on average one metre). 
■n Street mapping software (e.g. Google Earth) can also be used for land or external 
buildings; again, multiplying the measured size by the number of floors.
Value	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Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection HH:MM
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
Owned,	  rented	  or	  donated
[use	  dropdown]
Value	  if	  sold	  today	  
(local	  currency)
OR	  Annual	  Rent	  
(local	  currency)
Building	  -­‐	  general	  information
Name	  of	  department	  or	  clinic	  or	  room	  or	  area	  or	  
building
Name	  of	  department/	  clinic/	  room/	  
area/	  building	  in	  language	  of	  site
Size	  of	  department/	  
clinic/	  room/	  area/	  
building	  
(m2)
Percent	  of	  space	  used	  
for	  TB
(%) Notes
Outpatient	  Department	  (OPD)
OPD:	  General
OPD:	  Registration	  office/reception	  area
OPD:	  TB	  clinic
TB:	  Common/waiting	  area
TB:	  Sputum	  collection	  room	  or	  space
TB:	  Consultation	  area	  (with	  doctor)
TB:	  Convalesing	  area	  (with	  nurse)
TB:	  Dispensary	  for	  medication
TB:	  Laboratory
TB:	  Management	  of	  TB	  services	  (eg:	  office(s)	  of	  
nurse	  in	  charge	  for	  TB	  clinics)
TB:	  Other	  space
INSTRUCTIONS:	  Obtain	  or	  create	  map	  of	  each	  area	  with	  dimensions.	  Please	  ensure	  that	  there	  is	  no	  overlap	  of	  the	  dimensions	  of	  the	  spaces	  within	  each	  department	  or	  building;	  that	  is	  if	  the	  values	  for	  clinics,	  rooms	  or	  
areas	  are	  not	  available,	  put	  values	  for	  the	  entire	  department.
If	  there	  are	  additional	  spaces	  within	  a	  department	  that	  are	  not	  included	  in	  the	  list,	  use	  the	  rows	  with	  'other	  space'	  and	  change	  the	  name	  to	  match	  that	  space	  as	  used	  within	  the	  facility.
If	  a	  space	  is	  used	  for	  more	  than	  one	  output	  (e.g.	  LPA	  preparation	  and	  culture)	  then	  please	  list	  all	  outputs	  relevant	  to	  that	  space	  in	  the	  'Notes'	  section.
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If	  no,	  list	  missing	  data?
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■n One can then add these measurements to the map. This allows for repeatability 
in the future as the ‘quantities’ of the building will be known and mapped with 
measurements so one can then work out the space used if the room allocation 
changes i.e. the square meterage of the building.
■n The size of the space is then calculated by multiplying the length by the breadth of 
the room resulting in the number of square metres. 
■n The total space of the facility can then be calculated by adding together all the 
rooms (or if it is a perfect square or rectangle one could calculate the total square 
meterage of the building by multiplying the length by the breadth). 
■n If TB services are provided in a designated space then the total space for TB would 
be calculated by adding space that the TB services utilize in metres squared (for 
example using a bottom-up approach, 3 rooms which are each 5m2=a total of 15m2 
for TB services in a 100m2 facility). 
■n Do not include spaces that are no longer in use for instance if they are abandoned 
or derelict. However, ‘empty space’ should be included.
■n In order to not double count, either fill in the total m2 value for a department or 
the subsets, but not both. 
■n If the TB services do not occupy a designated area one could calculate the space 
used in top-down manner (described under the data entry sheet). 
■n If there are spaces at the facility where TB services are performed that have not 
been listed in the sheet, try to include the space (including m2 and proportion 
used for TB) in the most overarching department or room and make a note of the 
additional space that has been captured there (rather than adding a room). 
■n For example, to incorporate the size and percentage of space allocated TB for a 
consulting room for the laboratory doctor, that space can be included under 
‘Laboratory – main’. 
Recurrent expenditure
■n This usually relates to the running costs of the facility (i.e. clinic, hospital or lab-
oratory) such as administration, kitchen, utilities (water, gas, heating, cooling, 
electricity), security, laundry, maintenance (of buildings, vehicles, furniture and 
equipment), cleaning, monitoring and evaluation/pharmacovigilance, mainte-
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Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
Recurrent	  overhead	  costs	  (ENTIRE	  FACILITY)
Annual	  expenditure
(Local	  currency)
Water
Sewerage	  and	  sanitation
Electricity	  (light	  and	  heat)
Gas
Bio-­‐safety	  disposal
Other
TOTAL	  UTILITIES
Internet
Telephone
Post
TV	  and	  radio
Other
TOTAL	  COMMUNICATIONS
Stationery	  and	  general	  office	  supplies
Printing
Subscriptions
Packaging
Photocopying
Other	  admin	  costs
TOTAL	  ADMINISTRATIVE
Notes
[Include	  HMIS	  code	  for	  easy	  verification,	  if	  relevant]
Recurrent	  expenditure
INSTRUCTIONS:	  Data	  collected	  in	  this	  sheet	  should	  be	  for	  the	  ENTIRE	  FACILITY	  and	  downloaded/extracted	  from	  the	  facility	  expenditure	  records.
If	  disaggregated	  expenditure	  for	  a	  category	  (e.g.	  administrative,	  food,	  etc.)	  is	  not	  available,	  please	  enter	  the	  total	  value	  for	  that	  category	  in	  the	  row	  provided.	  Proportion	  of	  total	  expenditure	  (column	  
D)	  can	  be	  used	  if	  the	  information	  is	  available.
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nance, training (such as in service training the effects of which potentially last less 
than one year) and quality assurance, etc.
■n Supplies in the facility, such as gloves, masks, etc., can also be costed under 
recurrent overhead costs (for laboratories this has been described under diagnostic 
tests below). Other recurrent costs could include calibration of instruments, 
administration of cash transfers or similar expenditures.
■n Infrastructure/resources jointly used or shared between different departments 
within a health system/programme or facility (such as administration, mainte-
nance, transport, electricity, etc.) are known as overhead inputs. 
■n In a cost analysis, overhead inputs are allocated accordingly to various departments 
or activities. For example, inputs could be allocated to ‘cost centres’ (depends on 
how cost data are organized, and cost centres are defined). 
■n An allocation basis needs to be defined for allocating each input to various cost 
centres. For instance, some costs can be assigned directly to certain cost centres. 
■n If ‘inpatient care’ is a cost centre, then the line item ‘laundry’ could be allocated to 
that centre, using ‘a patient day equivalent’ as an allocation method. 
■n If ‘maintenance’ is a cost centre, then ‘floor space utilized by department’ could 
be a useful allocation method. Allocation of overhead inputs usually requires step 
down costing.
■n It is important to note which costs have been considered overhead costs at the 
facility level (service level) and which costs are included in above service level 
costs, so that double counting does not take place. 
■n The easiest way to distinguish between overhead costs at the facility level and 
above service level costs, is to ascribe any operating costs to the facility level under 
overhead costs if they occur and are paid for by the facility. 
■n Overhead costs are often obtained through the finance office at a larger facility, 
facility records or through interviews with staff.
TransportationValue	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A Health	  Facility	  or	  Laboratory	  Owned	  Transport	  Service
Vehicles Number	  of	  vehicles Life	  expectancy	  (years)
Own,	  rent	  or	  donated
If	  own	  or	  donated,	  
current	  market	  value	  
of	  all	  vehicles
(local	  currency)
If	  rent,	  total	  annual	  
rental	  value
(local	  currency)
Total	  annual	  maintenance	  
costs	  (insurance,	  repairs	  
etc.)
(local	  currency)
Total	  annual	  fuel	  costs
(local	  currency)
Ambulance
Bicycle
Motorcycle  
Small  car
Large  car
SUV
Mini-­van
Van
Mobile  clinic
Bus
Other
Transportation
INSTRUCTIONS:	  Data	  is	  for	  transportation	  of	  TB	  specimens,	  supplies,	  drugs	  or	  results	  or	  transporting	  TB	  patients	  for	  diagnostics	  or	  treatment	  or	  TB	  staff	  for	  provision	  of	  TB	  services.
The	  sheet	  contains	  data	  to	  be	  sourced	  from	  the	  Finance	  and	  Human	  Resources	  Departments,	  as	  well	  as	  utilisation	  data.
Ensure	  both	  sections	  A	  (health	  facility	  or	  laboratory	  owned	  services)	  and	  B	  (courier	  services)	  are	  completed	  where	  relevant.
Ask	  FINANCE	  DEPARTMENT
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■n Vehicles used by a facility, for instance vans used for transporting TB patients or 
mobile clinics, should be included as capital items. 
■n For vehicle current market (i.e. replacement) value, a vehicle with equivalent 
specifications can be used and derived by contacting local automotive dealers or 
visiting their websites
■n Allocation to TB for each vehicle should be derived by asking the transportation 
manager or driver to estimate based on the time and/or mileage for TB services 
divided by total time and/or mileage.
■n The percent of time spent on TB for Department 1 (column O) and Department 2 
(column Q) should add up to 100%.
■n Note: if any services, such as transportation or training, are paid for by the NTP 
or NGOs but the benefit of the service is at the facility level, the costs still need to be 
included in this facility costing tool. For example, courier services paid for by the NTP 
are for samples for patients seen at the facility, so these costs need to be included in the 
facility tool.
Training
■n Costs of training are usually established through facility records or by estimating 
the cost of replicating a similar training (for example by looking at a venue cost, 
catering costs, facilitator hourly rates etc.).
■n For training (which is considered a capital asset if the effects will last longer than 
a year), bottom-up costing requires obtaining the duration of training, number 
of staff trained, transportation and/or per diem costs, training materials used, 
number of facilitators/trainers and their qualifications. 
■n The top-down approach to training is to look at the expenditure on training for TB 
services and divide this by the staff that received the training. 
V lue	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 12.Training
27/11/19 Page	  1
Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection HH:MM
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
Name	  of	  training
Facility,	  or	  if	  offsite	  
provide	  location
Training	  provider	  
(institution	  or	  
programme	  name) Date	  of	  training
Duration
(days)
Number	  of	  
partipants	  from	  
this	  facility
Training	  fees	  per	  
participant
(local	  currency)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
If	  no,	  list	  missing	  data?
Training
INSTRUCTIONS:	  Training	  data	  should	  be	  TB	  related,	  for	  staff	  of	  this	  facility.
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■n Data needs to be for all TB-related training for staff attached to this facility. 
■n Training fees are the amount paid for the training to occur, including costs for 
facilitators and any training material.
■n Allocation of training costs to TB can be obtained by asking the person receiving 
the training (or another member of staff with this knowledge, e.g. their manager 
or TB focal person) about the total time (hours or days) spent on TB compared to 
the time for any other training topic. 
■n This information may also be obtained from training letters held in the Human 
Resources department or within the TB department.
■n If training covers more than one service output, the training can be entered on 
multiple rows and allocated to the respective outputs based on the proportion for 
each. 
■n If the proportion is not known, these could be split. For example, a four-day 
training on TB outpatient and inpatient treatment can be entered as:
1. TB treatment training | 4 | 10 | 200 | 25 | 100 | 0 | 100% | Outpatient diagnostic 
visit | 50%
2. TB treatment training | 4 | 10 | 200 | 25 | 100 | 0 | 100% | Outpatient treatment 
visit | 50%
Above service level
■n The above service level costs are for activities that support the facility but are paid 
for by external sources such as the NTP (for instance, management of human 
resources, financial services, information technology, procurement and others). 
■n These above service level costs can be TB-specific (i.e. not shared such as training 
for health care workers on TB reporting standards) or shared between TB and other 
services (such as training for health care workers on general reporting standards). 
■n This would mean that training provided by the NTP for employees nationally 
would fall into above service level costs, whereas in service training (facility level 
training) would be considered an overhead or service level cost. 
Valu 	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 13.Above	  Service	  Level
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Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection HH:MM
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
TB	  processes	  -­‐	  above	  service	  level	  costs Type	  of	  support Whom? How	  often?
If	  yes,	  please	  describe	  the	  type	  of	  TB	  support	  and	  the	  frequency.
D
ru
gs
How	  often	  are	  TB	  drugs	  delivered	  to	  the	  facility?
Have	  there	  been	  any	  stock-­‐outs	  of	  TB	  drugs	  in	  the	  last	  year?
If	  yes,	  describe	  frequency	  and	  circumstances	  of	  TB	  drugs	  stock-­‐out.
Su
pp
or
t
Do	  you	  receive	  TB	  support	  from	  other	  entities?
Above	  Service	  Level	  Costs
INSTRUCTIONS:	  This	  sheet	  assesses	  the	  ease	  of	  access	  of	  above	  facility	  level	  cost	  data	  and	  is	  optional.	  If	  you	  do	  wish	  to	  collect	  this	  information,	  speak	  with	  the	  facility	  manager	  or	  TB	  focal	  person	  at	  the	  facility.
Notes	  (including	  any	  additional	  support	  activities)
What	  type	  of	  TB	  supervisory	  support	  do	  you	  receive	  from	  the	  district	  health	  bureau/authority ?	  
How	  often?
What	  type	  of	  TB	  support	  do	  you	  receive	  from	  the	  National	  TB	  Programme?	  How	  often?
If	  no,	  list	  missing	  data?
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■n Allocations of above service level are implemented in the Data Entry Tool. 
■n The data collection for above service level costs is done separately from the facility 
data collection. 
■n It involves approximately an additional week of data collection at the national, 
district or regional level. 
■n However, to guide the allocation of above service level costs to each facility, the 
data collector will complete the Above service level sheet which covers visits 
related to monitoring and supervision and drug procurement from national, 
regional or district levels.
■n There are different ways to allocate above service level costs. The recommended 
approach is weighting based on the number of staff at each facility (Figure 12); 
equal weighting is not recommended. 
■n The shared above service level costs would need to be further allocated to TB services 
based on the utilization figures for the facility. In this tool, the above service level 
costs cover support from the NTP, other entities and delivery of medication
C. Record prices for drugs, supplies, and equipment 
Equipment inventory
■n The Data Collection Tool includes a default list (alphabetically ordered) of 
equipment used for TB care. Default categories are to be used in preference to 
adding new elements to the list given that there are automatized links within the 
tool. 
■n The equipment price list should be collected centrally and used for each facility. If 
the prices paid for the equipment are known, then (inflate using CPI if necessary 
and) convert to United States dollars (USD) using the exchange rate of that year. 
■n The standard and most appropriate value for the unit price is the replacement cost.
■n Equipment and furniture that are used at the facility for TB services, for instance 
beds, tables, chairs, x-rays, biosafety cabinets etc., should be included as capital 
items. 
■n As the interest lies in the TB services only, any equipment that is not used for TB 
services should not be captured. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 8.Equipment	  Inventory
27/11/19 Page	  1
Equipment	  name Department Clinic	  or	  room
Manufacturer
[if	  applicable]
Model
[if	  applicable]
%	  use	  for	  TB
[eg.	  Based	  on	  TB	  tests/all	  
tests	  performed	  by	  total	  
numbers	  of	  machines]
Analytical	  balance
Analytical	  balance	  (electronic)	  for	  DST
Autoclave	  -­‐	  horizontal
Autoclave	  -­‐	  vertical
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  1
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  2
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  3
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  4
Automatic	  filling	  station
AVR	  (for	  autoclave)
BACTEC	  -­‐	  starter	  kit
BACTEC	  MGIT	  320	  System
BACTEC	  MGIT	  960	  system
BACTEC	  printer
Balance	  (analytical)
Balance	  (precision)
Balance	  (precision)	  -­‐	  electronic
Biosafety	  cabinet	  -­‐	  2	  filters
Biosafety	  cabinet	  -­‐	  3	  filters
Biosafety	  cabinet	  -­‐	  BSC	  Type	  II	  A
Biosafety	  cabinet,	  with	  horizontal	  laminar	  airfl w	  
hood	  and	  UV	  light
Biosafety	  cabinet,	  with	  vertical	  laminar	  flow	  hood	  
and	  UV	  light
Blender	  with	  glass	  jar
Bottle	  washer
Inventory	  -­‐	  equipment	  and	  furniture
INSTRUCTIONS:	  This	  should	  be	  a	  complete	  list	  of	  all	  equipment	  and	  furniture	  used	  in	  any	  of	  the	  TB	  service	  outputs.	  If	  there	  is	  more	  than	  one	  of	  a	  particular	  type	  of	  equipment	  but	  with	  different	  manufacturers	  and/or	  models,	  please	  list	  them	  separately.	  For	  several	  pieces	  of	  equipment	  with	  the	  same	  make	  and	  model,	  indicated	  
the	  quantity	  in	  use	  at	  the	  facility	  for	  TB	  services.
Any	  additional	  equipment	  or	  furniture	  that	  is	  not	  already	  included	  in	  this	  sheet	  should	  be	  added	  to	  the	  bottom	  of	  the	  appropriate	  section.
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■n The bottom-up approach to costing these items is by auditing/counting how many 
there are within the facility. 
■n The facility may keep a record of all the equipment and furniture; however, one will 
need to establish if these are used for TB services or not. 
■n It is often useful to note which rooms these items can be found in, on the map of 
the facility. 
■n A new line should be used for each piece of equipment or furniture, for instance if 
there are 10 chairs then 10 lines are used to enter information for these 10 chairs. 
The top-down approach would be to take lists of all the equipment and furniture 
(or expenditure of all the equipment and furniture) 
■n When estimating usage of equipment, the bottom-up approach is either through 
observation or interview, while timesheets are used for the top-down approach. 
■n Observation should be the default; if not possible, then collect equipment infor-
mation via an interview. Keep good notes on things such as stockouts, broken 
equipment and overused equipment (i.e. estimated life years (ELY)=5 but used for 
30 years) so that one can try to understand and explain cost variation. 
■n If equipment is broken but was used in the last year and will be fixed or replaced, 
then this should be costed. The same is true for equipment that has been purchased 
and has not yet been used but is planned to be used (for instance if training is 
pending). 
■n Derelict equipment that has broken down and will not be fixed should not be 
costed – if this has not been used in a year and is not expected to be used again, the 
item should not be costed.
Price list-drugs
■n Drug prices per drug delivered at the health facility are collected. ‘Wastage of 
supplies’ is also documented; this is an estimate of the percent of drugs thrown 
out, i.e. drugs expired or damaged, within the year.
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 21.Price	  list-­‐Drugs
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Drug	  wastage	  factor
Transportation	  mark-­‐up	  (within	  country),	  % (1st-­‐line	  drugs) (2nd-­‐line	  drugs)
Drug	  name Product	  code	  (e.g.	  GDF) Strength Unit	  of	  measure
Items	  per	  
unit
Order	  size
(#	  units)
Order	  price
(local	  currency)
Unit	  price
(local	  currency)
Unit	  price
(USD) Source/vendor TB	  intervention
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) FDC-­‐child Per	  pack/blister 84 FDC-­‐child
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 FDC-­‐adult Per	  pack/blister 672 FDC-­‐adult
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 FDC-­‐adult Per	  pack/blister 336 FDC-­‐adult
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  
tablet(s),	  Blister(s)
3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐672 FDC-­‐adult Per	  pack/blister 672 FDC-­‐adult
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  
tablet(s),	  Blister(s)
3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  
(28x3)
FDC-­‐child Per	  pack/blister 84 FDC-­‐child
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐
(B)-­‐672
FDC-­‐adult Per	  pack/blister 672 FDC-­‐adult
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐
(B)-­‐336
FDC-­‐adult Per	  pack/blister 336 FDC-­‐adult
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister
Price	  List	  for	  Drugs
INSTRUCTIONS:	  Please	  provide	  data	  for	  the	  yellow	  cells.	  The	  unit	  price	  in	  local	  currency	  is	  for	  drugs	  that	  are	  procured	  locally	  and	  the	  unit	  price	  in	  USD	  is	  for	  drugs	  and	  supplies	  that	  are	  sourced	  outside	  of	  the	  country.	  
Standard	  drugs	  for	  TB	  treatment,	  prevention	  and	  palliative	  care	  have	  already	  been	  listed.	  Any	  additional	  drugs	  that	  are	  not	  already	  included	  should	  be	  added	  at	  the	  bottom	  of	  the	  appropriate	  section.
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This	  sheet	  can	  be	  used	  to	  get	  prices	  on	  drugs	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	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■n The unit price of many of the drugs on this list can be centrally sourced through 
the Ministry of Health, Central Stores, some government procurement agency or 
from the Stop TB Partnership’s Global Drug Facility.
■n If locally obtained prices are not available one can use international prices 
available through http://www.stoptb.org/assets/documents/gdf/drugsupply/
GDFMedicinesCatalog.pdf as recommended by the Reference Case [5]. 
■n These values need only be obtained once and can be used for all facilities. 
■n For drugs that are not sourced internationally or are unique to a particular 
facility, e.g. if XDR treatment is only offered in one specialized facility, invoices or 
procurement records may need to be sourced at the facility level.
■n The order size and price for the year should be collated and entered into columns 
G and H. The source of the quantity or price data or the vendor should be included 
in column K.
Price list-supplies
■n The Data Collection Tool includes a default list (alphabetically ordered) of 
supplies used for TB care. Default categories are to be used in preference to adding 
new elements to the list. 
■n A price list for the supplies used at the facility may be centrally sourced, but it is 
likely that some supplies would have been obtained from a vendor directly through 
the facility. 
■n Multiple sources of data are acceptable.
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 22.Price	  list-­‐Supplies
27/11/19 Page	  1
Name	  or	  description	  of	  supply Unit	  of	  measure
Package	  amount	  
or	  volume
Price	  per	  package
(local	  currency)
Price	  per	  package
(USD) Brand Source/vendor
0.5-­‐10	  μl	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  (Long	  tip)	  
10-­‐100	  μl	  tips	  
1-­‐20	  μl	  tips	  
1-­‐200	  μl	  pipette	  tips	  
1-­‐200	  μl	  tips	  
20-­‐200	  μl	  pipette	  tips	  
20-­‐200	  μl	  pipette	  tips	  
2ml	  standard	  reaction	  tube	  
Applicator	  stick	  (disposable) box 20
BACTEC	  MGIT	  960	  AST	  transport	  rack	  –	  
445942.	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  (100	  tests,	  
PANTA	  and	  OADC	  combined)	  Catalogue	  No:	  
245124	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  (PANTA	  
and	  OADC	  combined) kit 100
BACTEC	  MGIT	  OADC	  Kit	  for	  Manual	  MGIT	  
Catalogue	  No:	  245116	  
BACTEC	  MGIT	  PANTATM	  Kit	  for	  Manual	  MGIT	  
Catalogue	  No:	  245114	  
BACTEC	  MGIT	  PZA	  kit kit 50
BACTEC	  MGIT	  PZA	  tubes pack 25
BACTEC	  MGIT	  S.I.R.E.	  Kit	  for	  Manual	  MGIT	  
Catalogue	  No:	  245119	  
Price	  List	  for	  Supplies
This	  sheet	  can	  be	  used	  to	  get	  prices	  on	  supplies	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	  
INSTRUCTIONS:	  The	  list	  of	  supplies	  is	  not	  exhaustive	  so	  please	  insert	  any	  additional	  supplies	  that	  have	  been	  provided	  to	  health	  facilities	  to	  provide	  TB	  services	  at	  the	  end	  of	  the	  relevant	  
supplies	  section.
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Staff salaries
■n The list of staff should include any personnel involved in TB services, i.e. any staff 
who spend at least 10% of their time on TB or anyone with TB-specific tasks in 
their job description. 
■n The list is organized by direct service personnel, support personnel and volunteers. 
To provide clarity on where staff salaries should be allocated, one can append the 
location of the health care worker to their title (e.g. ‘Nurse 2’ can become ‘Nurse 
2 – ART clinic’).
■n The gross annual salary of each staff member should be provided. Staff salaries 
are often obtained through the finance office at a larger facility, facility records or 
through interviews with staff. It may necessary to approach a central finance office 
and human resources department separately to obtain the list of staff titles at a 
facility and the corresponding salaries. 
■n If gross salaries are not available, obtain the net (post deductions) value. Using an 
estimate of the proportion of income tax and other deductions relevant to the type 
of employee in the country, calculate the gross salary. For instance, if net annual 
salary for a nurse is $61,237 and the average income tax is 20%, with additional 
deductions averaging 9%, the gross salary would be ($61,237/(100-(20+9)%)) = 
$86,249.30.
■n If it is not possible to collect the actual salary data for facilities based on the staff 
mix, an average salary can be used for a cadre of staff. 
■n Gross annual benefits should include housing and travel allowances, or payments, 
hazard or other incentive pay, and any other payments made to staff for their 
service to the facility. 
■n For staff working less than the full year of assessment (i.e. retiring, resigning or 
doing periodic work), the gross annual salary should be adjusted by the proportion 
of the year worked.
■n Similarly, the working hours per week on average over the year should account for 
any time when the staff member was not working at the facility, by using the total 
hours worked for the year of assessment and finding the average hours per week 
across the entire year.
■n The method used to measure staff time for each health care worker included in the 
study should be captured in column H. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 9.Staff	  Salaries
27/11/19 Page	  1
Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection HH:MM
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection HH:MM
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
Health	  care	  worker	  category
Gross	  annual	  salary	  (local	  
currency)
Gross	  annual	  benefits
(local	  currency)
Total	  working	  hours	  per	  
week Quantity	  of	  staff
Clinical,	  allied	  and	  auxiliary	  staff
Support	  and	  administrative	  staff
Total	  Staff
Fa
ci
lit
y	  
St
af
f
If	  no,	  list	  missing	  data?
Staff	  Salaries
INSTRUCTIONS:	  'TB	  Personnel'	  should	  list	  every	  staff	  member	  (direct	  and	  support)	  providing	  TB	  services	  within	  the	  facility.
For	  staff	  salaries,	  if	  gross	  values	  are	  not	  available,	  use	  net	  values	  and	  gather	  information	  on	  government	  (central	  and	  local)	  and	  other	  deduction	  types	  and	  quantities/proportions	  (e.g.	  income	  tax,	  PAYE,	  health	  surcharge,	  etc.).
If	  relevant,	  the	  type	  of	  health	  care	  worker	  (column	  C)	  can	  be	  modified	  to	  include	  the	  clinic	  or	  specialty	  of	  the	  health	  care	  worker.
Data	  for	  columns	  I	  to	  M	  should	  only	  be	  obtained	  if	  a	  timesheet	  is	  NOT	  obtained	  for	  that	  staff	  member	  (e.g.	  for	  all	  support	  personnel,	  phlebotomists,	  pharmacists,	  etc.)
Notes
73 Section F. Appendices
■n Specialized personnel providing direct services (e.g. phlebotomists, pharmacists, 
social workers, etc.) should be interviewed to provide an estimate of the proportion 
of time spent on TB, and how that time is split between various departments (e.g. 
outpatient and inpatient departments for social workers).
■n Recommendation: For staff, bottom-up costing is performed either through observation 
or interview; for top-down costing, timesheets are used. Observations, interviews 
and timesheets should be administered to at least one staff member per cadre in a big 
facility, however for small facilities, where perhaps there are only two staff members 
working on TB, both should be interviewed and given timesheets. There should be at 
least one bottom-up and one top-down estimate of staff time per service. However, if an 
observation or interview is impossible, one can use an assumption based on interviews at 
another facility, standard operating procedures or a demonstration of a process.
D. Record TB service utilization for the 20 standardized service outputs and  
at least 39 diagnostic and monitoring tests being costed, as well as the drug 
regimens and supplies used 
Service statistics
■n Estimation of unit costs requires information on utilization which covers data on 
services received by patients in a facility, or about diagnostic tests processed in a 
laboratory. 
■n The figures needed vary depending on the unit cost to be calculated; however 
standard utilization data might be “Total number people initiating treatment for 
MDR-TB using the long regimen per year” or “Total number of inpatient bed-days 
for DS-TB treatment per year” or “Number of Xpert® MTB/RIF tests performed 
per year”. 
■n These utilization data allow one to allocate costs if a top-down methodology is 
being utilized.
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 14.Service	  Statistics
27/11/19 Page	  1
Start	  date	  of	  data	  collection dd/mm/yyyy Start	  time	  of	  data	  collection
End	  date	  of	  data	  collection dd/mm/yyyy End	  time	  of	  data	  collection
Name	  of	  data	  collector
Sheet	  completed	  [use	  dropdown]
Year	  of	  data	  (latest	  financial	  or	  calendar	  year)
Unit
Annual	  quantity	  -­‐	  entire	  
facility
Annual	  quantity	  -­‐	  
TB	  services	  only Source	  document	  or	  file	  name
Outpatient	  visits
TB	  Clinic
MCH	  Clinic
Paediatric	  Clinic
HIV	  Clinic
Chronic	  Disease	  (diabetes)	  Clinic
Comprehensive	  Care	  Clinic
Inpatient	  beddays
Inpatient	  admissions
Laboratory	  tests	  (all	  labs)
Microbiology	  Lab	  -­‐	  tests
Bacteriology	  Lab	  -­‐	  tests
Laboratory:	  main	  (clinical	  path,	  incl	  haematology)	  -­‐	  tests
Area	  for	  blood,	  serum,	  plasma	  collection	  -­‐	  samples
Area	  for	  sputum	  sample	  collection	  -­‐	  samples
Area	  for	  AFB	  and	  GeneXpert	  -­‐	  tests
Area	  for	  biopsy	  -­‐	  tests
Area	  for	  LPA	  -­‐	  tests
Laboratory:	  culture	  -­‐	  tests
Radiology	  tests
INSTRUCTIONS:	  This	  sheets	  asks	  for	  summary	  facility	  data	  (C12-­‐C31)	  as	  well	  as	  summary	  and	  disaggregated	  data	  for	  TB.
Service	  statistics	  data	  should	  be	  obtained	  from	  the	  head	  of	  the	  facility,	  head	  of	  the	  laboratory	  or	  radiology	  departments,	  head	  of	  respective	  clinics	  or	  other	  personnel	  who	  perform	  surveillance	  or	  prepare	  service	  utilisation	  
reports	  (HMIS).
TB	  treatment	  data	  can	  be	  extracted	  from	  the	  TB	  Register	  or	  annual	  or	  quarterly	  reports	  for	  TB.	  
Data	  should	  be	  collected	  only	  for	  service	  outputs	  performed	  at	  the	  facility	  or	  for	  community	  services	  performed	  by	  staff	  from	  this	  facility.
Please	  ensure	  that	  the	  metrics	  listed	  and	  period	  for	  the	  data	  collected	  matches	  that	  of	  the	  Service	  outputs 	  of	  the	  '15.Service	  Description	  '	  sheet.
Service	  Statistics
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If	  no,	  list	  missing	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■n Data will be collected for total facility and TB specific utilization data for the 
main departments (‘Section I: Health facility statistics’ – Outpatient, Inpatient, 
Laboratory and Radiology) within the facility, with some disaggregation by clinic 
or laboratory specialization. This service utilization data can be obtained from 
health management information system (HMIS or DHIS2), or other routinely 
reported TB data.
■n Data will also be collected for TB service outputs only which can be populated 
using the WHO Global TB recording and reporting forms (https://apps.who.int/
iris/bitstream/handle/10665/44840/9789241564465_eng.pdf?sequence=1) for 
the facility, except for the distinction between short and long MDR-TB treatment 
which is not always available from routine reporting. ‘Section II: TB service 
statistics’ is for TB service outputs only, within Section II, rows 29–37 can be 
populated using the WHO Global TB recording and reporting forms for the facility. 
Rows 39–55 should be obtained from disaggregated TB reports for the key facility 
departments, as well as community services provided through this facility
■n It is important that the utilization data collected in this sheet is for the year of 
assessment of the study and matches the cost data being collected for the facility. 
■n If it is unavoidable that this criterion cannot be met at this facility and any of the 
data is not for the year of assessment, be sure to indicate this in the ‘Notes’ column 
of this sheet.
■n The ideal is to collect information on the number of visits that actually occur at a 
facility based on the reporting done by the facility. 
■n However, if number of patients is known but not number of visits, it is then 
appropriate to calculate the number of visits using the average number of visits 
per patient = average #visits per patient * #patients. 
■n For test volume, if there are no records for the annual values, the head of the 
laboratory or equivalent personnel should be requested to estimate the total TB 
and all tests per week and then multiply this number by 52 to get the annual value. 
Present this figure to the person being interviewed and ask if this is a reasonable 
estimation.
■n If there is missing data, the allocations (see Data Entry Tool) cannot be calculated, 
so this should be avoided as far as possible.
Service description 
■n The average number (quantity) of each service output required for each patient type 
(population, regimen and phase) is obtained by interviewing the TB head nurse or 
focal person or another member of staff with knowledge of TB service utilization. 
This is entered into the yellow cells (grey cells indicate where the service output is 
not applicable to that intervention).
■n The gold standard here is to obtain the average per patient type by extracting the 
service utilization from patient records and calculating the average. However, 
if one does not have ethical approval to extract data from patient records or are 
unable to access them, the quantities should be obtained by interviewing the TB 
focal person or head nurse at the facility or an individual who has knowledge of the 
service utilization for the TB services at the facility. 
75 Section F. Appendices
■n For the community vaccination visits, the total number of visits per year and 
the number of infants vaccinated in that year are needed (in rows 16 and 17, 
respectively). This will be used to calculate the average number of people vaccinated 
during a community vaccination visit and subsequently the cost per person 
vaccinated during a visit. 
■n Similarly, the total visits in the year of assessment and the total people screened 
are needed (rows 20 and 21) as inputs to calculate the cost per person screened.
Drug services
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 15.Service	  Description
27/11/19 Page	  1
INTERVENTION	  CLASS VACCINATION
INTERVENTION	  TYPE BCG	  Vaccination
PTB EPTB PTB EPTB PTB EPTB PTB EPTB PTB EPTB PTB EPTB
REGIMEN
PHASE
Service	  output
Outpatient	  vaccinations
Outpatient	  cough	  triage
Outpatient	  screening	  visit
Outpatient	  diagnostic	  visit
Outpatient	  visit	  type	  1
Outpatient	  visit	  type	  2
Outpatient	  visit	  type	  3
Inpatient	  bed-­‐day	  type	  1
Inpatient	  bed-­‐day	  type	  2
Community	  vaccinations
Community	  screening	  visit
Community	  diagnostic	  visit
Community	  treatment	  visit
Community	  other	  visit
Community	  event
Lost	  to	  follow-­‐up	  tracing	  per	  person	  on	  contact	  list	  
(phone	  calls)
Patient	  support	  during	  diagnosis
Patient	  support	  during	  treatment
Other	  service	  type	  1
Other	  service	  type	  2
Active	  Case	  FindingIntensified	  Case	  Finding	  -­‐	  cough	  triage Intensified	  Case	  Finding	  -­‐	  screening
INTERVENTION	  POPULATIONS
Infant Adult Child HIV+ High-­‐risk	  population HIV+ High-­‐risk	  population Platform	  1 Platform	  2 Platform	  3 Platform	  4
TB
	  s
er
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ce
s
Passive	  Case	  Finding
Service	  Description
INSTRUCTIONS:	  Service	  description	  data	  for	  TB	  should	  be	  obtained	  from	  the	  TB	  Nurse	  in	  Charge	  within	  the	  TB	  clinic	  or	  another	  staff	  member	  with	  knowledge	  of	  TB	  service	  utilisation.	  It	  is	  fine	  to	  ask	  more	  than	  one	  person	  with	  knowledge	  of	  the	  quantities	  provided	  at	  this	  facility.
Data	  should	  be	  collected	  only	  for	  service	  outputs	  performed	  at	  the	  facility	  or	  by	  staff	  attached	  to	  the	  facility	  and	  is	  per	  patient	  per	  intervention.
QUANTITY	  PER	  PATIENT	  (visits,	  beddays	  or	  tests)	  for	  year	  of	  assessment
TB	  CASE	  DETECTION	  &	  DIAGNOSIS
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 16.Drug	  Services
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  1
Quantities	  (units)	  per	  (average)	  patient…
INTERVENTION	  CLASS	  
(TREATMENT	  ONLY)
REGIMEN
PHASE
Total	  annual	  
quantity	  
disbursed	  for	  TB	  
(in	  units) In
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Drug/pharmaceutical	  product Product	  code Unit	  of	  measure
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) Per	  pack/blister
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  
Blister(s)
2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 Per	  pack/blister
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  
Blister(s)
2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 Per	  pack/blister
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  
tablet(s),	  Blister(s)
3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐
672
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  
tablet(s),	  Blister(s)
3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  
(28x3)
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  
Film	  coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐
(B)-­‐672
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  
Film	  coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐
(B)-­‐336
Per	  pack/blister
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister
1st	  Line	  TB	  TREATMENT
DS-­‐TB
EPTB PTB
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Adult
EPTB
New	  and	  relapse Previously	  treated
Drug	  Services
INSTRUCTIONS:	  In	  column	  E,	  provide	  the	  total	  annual	  quantity	  disbured	  for	  each	  TB	  drug	  prescribed	  at	  the	  facility.	  In	  the	  remaining	  cells	  (columns	  F-­‐BQ)	  input	  the	  average	  quanity	  of	  each	  drug	  per	  average	  patient	  for	  each	  TB	  regimen	  and	  phase	  that	  is	  provided	  at	  the	  facility	  in	  the	  year	  of	  assessment.	  
Data	  on	  TB	  drugs	  can	  be	  sourced	  from	  the	  TB	  register	  in	  the	  TB	  Clinic	  and	  TB	  prevention	  drug	  data	  from	  the	  clinics	  where	  those	  activities	  are	  performed	  (e.g.	  HIV	  clinic),	  as	  well	  as	  the	  pharmacy,	  procurement	  and	  accounting	  departments.
If	  a	  drug	  used	  at	  this	  facility	  is	  not	  included	  in	  the	  list,	  please	  included	  it	  at	  the	  bottom	  of	  the	  relevant	  section	  and	  add	  to	  the	  corresponding	  section	  in	  the	  '21.Price	  list-­‐Drugs'	  sheet.
INTERVENTION	  
POPULATIONS
PTB
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■n As with diagnostic tests, for TB drugs one needs to first understand how medication 
is dispensed in terms of location (clinic, hospital, outreach or mobile clinics etc.), 
frequency (daily (directly observed therapy, short-course (DOTS)), monthly, twice 
monthly, etc.), as well as who is involved in dispensing medication (pharmacist, 
doctor, nurse, community health care worker etc.). 
■n Following the methodology of the Data Collection Tool, the quantities to be 
entered should ideally be the actual average for all patients treated (for an episode 
of care). If this information is not available, include the protocol value for an 
average patient in the respective regimens. 
■n If the actual values are known, a note can state the protocol value.
■n Only drug quantities for treatment that is happening at the facility should be 
entered. For example, if the hospital only does one week of intensive phase, then 
only include that one week’s worth of drugs for the hospital costing.
■n The drugs remaining to complete the treatment regimen should be included in 
the facility from which they are distributed, such as health centre or community 
facility.
E. Capturing quantities related to time for staff (assessed by observations, 
interviews and timesheets) and usage for equipment, supplies and vehicles 
(observation and interviews), which are inputs for both top-down and  
bottom-up costing
Staff time used for TB service delivery is captured using three different methods: 
interviews, observations and timesheets. The Data Collection Tool caters for a sheet 
per data collection method (Staff timesheets, Observations and Interviews). 
Staff timesheets
■n When one understands the flow of the facility or laboratory then one can start to 
assess the staff time and costs. 
■n Personnel time could comprise the time of both clinical and non-clinical staff 
within clinics and hospitals (or different facility types), laboratory staff involved 
in TB technology, community health care workers involved in patient support and 
other TB services amongst others (see case study 3 as an example). 
■n The first step is to establish who is directly involved in TB services (such as a TB 
focal nurse) and who provides support to TB services (for instance an administrator 
or clinic manager). 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services
27/11/19
DAY	  1	  -­‐	   day-­‐off
Day	  (circle	  as	  
appropriate)
Date	  (dd/mm/yyyy)
INSTRUCTIONS:	  in	  each	  box	  wirte	  the	  number	  of	  minutes	  spent	  on	  each	  activity.
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Quantity	  performed	  
for	  entire	  day
7:00	  -­‐	  7:30	  am	  
7:30	  -­‐	  8:00	  am
8:00	  -­‐	  8:30	  am	  
8:30	  -­‐	  9:00	  am
9:00	  -­‐	  9:30	  am
9:30	  -­‐	  10:00	  am
Activities	  (in	  minutes)
??/??/????
M	  /	  T	  /	  W	  /	  TH	  /	  F	  /	  SA	  /	  SU
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■n For the staff that are directly involved in TB services, data can be collected about 
the time they spend with patients in several different ways using bottom-up 
methods. 
■n One can observe the hands-on time they spend with TB patients, measuring with a 
stopwatch over the course of week to assess what proportion of their time is spent 
on TB tasks. 
■n The type of task should be defined before one starts measuring. 
■n This is useful if one is able to easily calculate all the other aspects of the costing 
from a bottom-up perspective. Because one can then calculate for instance the 
cost of treating one DS-TB case (in terms of staff time, TB drugs, TB diagnostics, 
capital costs (time that specific area of building space, furniture and equipment 
were used), portion of recurrent costs).
■n Another bottom-up approach is to use work sampling, where a staff member is 
contacted (usually on a mobile phone) to ask what task they are currently busy 
with, in order to construct a picture of what tasks are being done and for how long.
■n The proportion of time spent on TB tasks can inform this calculation. Hypothetically, 
25% of a staff nurse’s time might be spent diagnosing new drug-sensitive TB cases, 
while 35% of his time is spent following up DS-TB cases, 10% of his time was taken 
up with dispensing medication, 5% was spent on record-keeping, 5% on other TB 
management such as meetings relating to TB., and the remaining 20% of his time 
was spent on tasks unrelated to TB services. Considering the salary of the staff 
member (in this case staff nurse), the cost of time per task can be estimated from 
these percentages. 
■n Another way to work out the proportion of time taken for specific tasks is to ask 
staff to estimate how much time it takes for them to perform the task on average, 
and how many times they perform the task in a week. This is usually done through 
a mixture of giving the staff a timesheet to complete and interviewing/discussing 
with the staff member how long tasks actually take them. 
■n A top-down way of allocation staff time is to again estimate the amount of time 
spent on tasks, which could be done by weighting tasks based on utilization or 
workload. For instance, the allocation of time to DS-TB treatment by using the 
allocation of number of patients treated for DS-TB treatment over all TB cases. 
— For more precise estimates, the time spent on DS-TB patients could be estimated 
using one or more of the following methods.:
— Firstly, timesheets could be completed by relevant staff for a relevant period of 
time (a month, or several months). 
— If the timesheets are returned incomplete, or certain estimates do not make 
sense, interviews could be conducted with staff members when they are asked 
how much of their time is spent seeing DS-TB patients in a particular day/
week/month. 
— Lastly, a researcher could estimate the time spent with DS-TB patients by 
observing how the services are provided in a facility, and then timing those 
services that are relevant to these patients. 
■n Often, a combination of these approaches is necessary in order to get the best 
estimate possible. 
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Recommendations
■n The data collector should provide verbal instructions on how to fill the timesheets. 
■n The health care worker (HCW) should fill in distributed physical timesheets where 
possible; if not possible, complete timesheets using interview format. 
■n Timesheet should be completed per cadre; however, if nurses perform different 
functions (such as only DS-TB and only MDR-TB) then one timesheet should be 
completed per function. 
■n If timesheets are absolutely not possible, estimate the proportion of staff time for 
the relevant service outputs. 
■n To determine which outputs are applicable to a particular health care worker, be 
guided by the bottom-up data (observations and interviews). 
■n Ensure that the total minutes per week in the timesheet add up to the working 
hours per week on average over the year when allocating minutes to the service 
outputs.
■n Note: The category ‘break/lunch’ should include any downtime when not working, even 
if that is because there were no TB patients or tests to perform.
Observations and Interviews
This data collection sheet facilitates two types of observations: 
A. identifying the resource – creating lists of staff, furniture, equipment and supplies 
used to provide TB services within a clinic or department (including laboratory); 
and
B. measuring the resources for each TB service output – i.e. time in minutes for staff 
and equipment, and quantities for supplies.
■n Tables have been developed in the Observation and Interview sheets to allow data 
collection for five outputs in each of five facility departments. 
■n Additional data collection is likely needed to obtain at least one staff time measure 
for every service output, so the tables can be replicated to accommodate as many 
measurements as needed. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 18.Observations
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Date	  of	  observation dd/mm/yyyy
District	  name	  and	  code
Facility	  name	  and	  code
Observer	  name
Start	  time	  of	  observation HH:MM
End	  time	  of	  observation HH:MM
Informed	  consent	  signed	  [use	  dropdown]
Example
INSTRUCTIONS:	  Indicate	  the	  test/service	  output,	  process	  (list	  tasks),	  staff	  involved,	  time	  taken	  for	  each	  task,	  supplies	  and	  equipment	  used	  and	  quantity	  used:
Service/Test
[use	  dropdown] Process	  (list	  tasks) Staff	  
Start	  time
(HH:MM)
End	  time
(HH:MM)
Total	  time	  
taken	  
(in	  mins) Location Supplies	  and	  reagents	  used
Quantity	  used	  (eg:	  
ml	  of	  reagent	  or	  #	  of	  
slides) Equipment	  used
Quantity	  
used	  
(in	  mins)
Smear	  microscopy
Stain	  sputum	  sample Lab	  TechII 9:50:00	  AM 10:12:00	  AM 12:22:00	  AM Staining	  room Staining	  reagent 5	  ml	  per	  slide
Wooden	  applicator 1
N95	  mask 1
Gloves	  (disposable) 2
Read	  slides Lab	  TechII 10:20:00	  AM 10:32:00	  AM 12:12:00	  AM Room	  A	  -­‐	  main	  lab Glass	  slides 2 Microscope 12
Record	  and	  report	  results Lab	  TechII 10:35:00	  AM 11:15:00	  AM 12:40:00	  AM Room	  A	  -­‐	  main	  lab A4	  paper 2
Discard	  or	  sterilise	  Z-­‐N	  
slides	  for	  re-­‐use Lab	  TechI 1:45:00	  PM 1:57:00	  PM 12:12:00	  AM Autoclave	  room Sterilising	  solution 10	  ml Autoclave 12
Infectious	  Bacteriology
(name)
(name)
Observations	  -­‐	  resource	  quantities
INSTRUCTIONS:	  
Identify	  (eg:	  staff,	  furniture,	  equipment)	  and	  measure	  resources	  (eg:	  time	  spent,	  supplies	  used	  per	  task)	  required	  to	  perform	  TB	  service	  outputs:	  itemise	  the	  tasks	  within	  each	  output	  and	  record	  the	  time	  taken	  to	  perform	  each	  task,	  making	  notes	  where	  relevant	  (e.g.	  outpatient	  
consultation	  with	  a	  paediatric	  TB	  patient;	  laboratory	  analysis	  for	  IGRA	  tests	  for	  9	  out	  of	  a	  maximum	  of	  16	  samples,	  etc.).
It	  may	  be	  easier	  to	  make	  your	  own	  notes	  during	  observations	  then	  complete	  the	  tables	  in	  this	  sheet.	  Please	  do	  whatever	  is	  most	  useful	  to	  you	  for	  capturing	  the	  information.
Please	  ensure	  you	  capture	  at	  least	  one	  type	  of	  staff	  time	  measure	  (interview,	  observation,	  time	  sheet)	  for	  every	  service	  output.
NAME	  OF	  DEPARTMENT	  1
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 19.Interviews
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Interviews	  -­‐	  health	  facility	  and	  laboratory	  staff
Date	  of	  interview dd/mm/yyyy
District	  name	  and	  code
Facility	  name	  and	  code
Interviewer	  name
Start	  time	  of	  interview HH:MM
End	  time	  of	  interview HH:MM
Informed	  consent	  signed	  [use	  dropdown]
EXAMPLE
Infectious	  Bacteriology
INSTRUCTIONS:	  Identify	  the	  test/service	  output,	  capture	  the	  process	  (list	  tasks),	  staff	  involved,	  total	  time	  taken	  for	  each	  task,	  supplies	  and	  equipment	  used	  and	  quantity	  used:
Service/	  Test
[use	  dropdown] Process	  (list	  tasks) Staff	  
Total	  time	  
taken	  
(in	  mins) Location
Supplies	  and	  reagents	  
used
Quantity	  used	  (eg:	  
ml	  of	  reagent	  or	  #	  
of	  slides) Equipment	  used
Quantity	  
used	  
(in	  mins)
Smear	  microscopy	  ZN
Stain	  sputum	  sample Lab	  TechII 20 Staining	  room Staining	  reagent 5	  ml	  per	  slide
Wooden	  applicator 1
N95	  mask 1
Gloves	  (disposable) 2
Read	  slides Lab	  TechII 10 Room	  A	  -­‐	  main	  lab Glass	  slides 2 Microscope 5
Record	  and	  report	  results Lab	  TechII 30 Room	  A	  -­‐	  main	  lab A4	  paper 2
Discard	  or	  sterilise	  Z-­‐N	  
slides	  for	  re-­‐use Lab	  TechII 12 Autoclave	  room Sterilising	  solution 10	  ml Autoclave 10
INSTRUCTIONS:	  For	  the	  staff	  time	  interviews	  in	  the	  departments	  or	  clinics	  where	  TB	  services	  are	  provided	  or	  the	  laboratory	  or	  radiology	  departments,	  ask	  one	  health	  care	  worker	  from	  each	  cadre	  of	  staff	  involved	  in	  the	  test	  or	  service	  output	  to	  
describe	  the	  entire	  process.	  Capture	  all	  staff	  involved,	  the	  length	  of	  time	  it	  takes	  and	  the	  supplies	  and	  equipment	  used,	  where	  applicable.
Please	  ensure	  you	  capture	  at	  least	  one	  type	  of	  staff	  time	  measure	  (interview,	  observation,	  time	  sheet)	  for	  every	  service	  output.
NAME	  OF	  DEPARTMENT	  1
(name)
(name)
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■n The sheets have also been formatted so that, when printed, there is one table per 
sheet. This means that data can be collected either electronically (inputted directly 
into the Data Collection Sheets) or on hard copies (information recorded on the 
printed sheets of paper). Use whichever data collection method is best suited.
■n When interviewing the doctor and/or nurse involved in TB inpatient services, ask 
if he or she can list other people (e.g. other clinicians) who are involved in this TB 
service and obtain interviews with these people where possible, or ask the ward 
nurse about their time spent on TB services (e.g. cleaners, porters, etc.).
■n Because the staff cost component of the unit costs derived by each method will be 
compared during analysis (Data Entry Tool), please try to use all three methods 
to measure the staff time for each service output. 
■n Recognizing that this is not always possible, it is important that at least one 
methodology is applied to each service output. A supply wastage proportion 
assumption needs to be documented. Based on the experience of Value TB study, 
an examples of waste proportions used for Xpert® MTB/RIF was 3–5%. 
■n Informed consent forms need to be given to every person from whom data is 
collected by interviews, observations and timesheets and kept separately in a 
secure location. As a reminder within the tool, there is a drop down to indicate 
whether consent has been obtained.
■n All staff time measures (interviews, observation and timesheets) should be given 
to at least one health care worker in each cadre of staff involved in every service 
output. 
■n It may sometimes not be possible to administer all three methods (interviews, 
observation and timesheets) to each health care worker, however, please ensure 
that each health care worker’s time is measure by at least one method.
■n Information on utilization within the health facility, such as the annual number of 
outpatient and community visits for TB-related services and for the entire facility, 
can be collected and entered in this sheet. 
■n A breakdown is also provided for top-down and bottom-up relevant quantities. 
For example, for drugs, the top-down quantities refer to the total amount of each 
TB medication disbursed within the facility, while for the bottom-up quantities 
sampled usage by patients is collected.
■n The template for staff-time interviews is used as one method to capture the 
quantity and allocation of staff time. 
■n The second method is that of weekly timesheet templates, also printable. 
■n During the detailed costing, these would be printed out or provided on electronic 
tablets to staff members at the beginning of the data collection week and collected 
at the end of the week.
■n An example of total staff time for a chest x-ray would be the staff time including 
taking the chest x-ray; reading, interpreting and noting results.
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Supplies
■n This datasheet includes on an exhaustive list of supplies (mostly laboratory supplies 
and infection control) used for TB services at a facility (with prices collected as 
mentioned above). 
■n For each supply category, the annual expenditure and percentage use for TB will 
be collected.
■n ‘Wastage of supplies’ refers to the percent of supplies discarded (expired or thrown 
out). 
■n The value should be for the facility in question; if this value cannot be obtained, an 
estimated value for the country can be used.
Price list-equipmentValue	  TB	  -­‐	  Estimating	  unit	  costs	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  TB	  services 23.Price	  list-­‐Equipment
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Equipment	  or	  furniture	  name	  or	  description Manufacturer Model
Unit	  price
(local	  currency)
Unit	  price
(USD) Useful	  life
Analytical	  balance
Analytical	  balance	  (electronic)	  for	  DST
Autoclave	  -­‐	  horizontal
Autoclave	  -­‐	  vertical
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  1
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  2
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  3
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  4
Automatic	  filling	  station
AVR	  (for	  autoclave)
BACTEC	  -­‐	  starter	  kit
BACTEC	  MGIT	  320	  System
BACTEC	  MGIT	  960	  system
BACTEC	  printer
Balance	  (analytical)
Balance	  (precision)
Balance	  (precision)	  -­‐	  electronic
Biosafety	  cabinet	  -­‐	  2	  filters
Biosafety	  cabinet	  -­‐	  3	  filters
Biosafety	  cabinet	  -­‐	  BSC	  Type	  II	  A
Biosafety	  cabinet,	  with	  horizontal	  laminar	  airflow	  
hood	  and	  UV	  light
Biosafety	  cabinet,	  with	  vertical	  laminar	  flow	  hood	  and	  
UV	  light
Blender	  with	  glass	  jar
Bottle	  washer
Price	  List	  for	  Equipment	  and	  furniture
This	  sheet	  can	  be	  used	  to	  get	  prices	  of	  equipment	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	  
INSTRUCTIONS:	  Please	  provide	  data	  for	  the	  yellow	  cells.	  The	  list	  of	  equipment	  is	  not	  exhaustive	  so	  please	  provide	  any	  additional	  equipment	  or	  furniture	  that	  has	  been	  purchased	  
for	  health	  facilities	  to	  provide	  TB	  services.
The	  unit	  price	  (local	  currency)	  should	  be	  used	  for	  any	  equipment	  purchased	  or	  available	  locally;	  for	  any	  purchased	  or	  only	  available	  outside	  the	  country,	  input	  the	  unit	  price	  in	  
USD.
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Name	  or	  description	  of	  supply
Annual	  
expenditure
(local	  currency) %	  use	  for	  TB
TB	  service	  output	  
type	  1
[use	  dropdown]
%	  use	  for	  TB	  service	  
output	  type	  1
TB	  service	  output	  
type	  2
[use	  dropdown]
%	  use	  for	  TB	  service	  
output	  type	  2
TB	  service	  output	  
type	  3
[use	  dropdown]
%	  use	  for	  TB	  service	  
output	  type	  3 Notes
0.5-­‐10	  μl	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  (Long	  tip)	  
10-­‐100	  μl	  tips	  
1-­‐20	  μl	  tips	  
1-­‐200	  μl	  pipette	  tips	  
1-­‐200	  μl	  tips	  
20-­‐200	  μl	  pipette	  tips	  
20-­‐200	  μl	  pipette	  tips	  
2ml	  standard	  reaction	  tube	  
Applicator	  stick	  (disposable)
BACTEC	  MGIT	  960	  AST	  transport	  
rack	  –	  445942.	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  
(100	  tests,	  PANTA	  and	  OADC	  
combined)	  Catalogue	  No:	  245124	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  
(PANTA	  and	  OADC	  combined)
BACTEC	  MGIT	  OADC	  Kit	  for	  Manual	  
MGIT	  Catalogue	  No:	  245116	  
BACTEC	  MGIT	  PANTATM	  Kit	  for	  
Manual	  MGIT	  Catalogue	  No:	  
245114	  
BACTEC	  MGIT	  PZA	  kit
BACTEC	  MGIT	  PZA	  tubes
BACTEC	  MGIT	  S.I.R.E.	  Kit	  for	  
Manual	  MGIT	  Catalogue	  No:	  
245119	  
BACTEC™	  MGIT™	  960	  SIRE	  kit,	  One	  
kit	  is	  sufficient	  for	  40	  test	  
Catalogue	  No:	  245123	  
Bags	  for	  waste	  bin	  –	  30	  Litres	  
Bags	  for	  waste	  bin-­‐	  2	  Litres	  
Balloon	  HDPE	  -­‐	  10l
Balloon	  HDPE	  -­‐	  30l
Price	  List	  for	  Supplies
This	  sheet	  can	  be	  used	  to	  get	  prices	  on	  supplies	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	  
INSTRUCTIONS:	  The	  list	  of	  supplies	  is	  not	  exhaustive	  so	  please	  insert	  any	  additional	  supplies	  that	  have	  been	  provided	  to	  health	  facilities	  to	  provide	  TB	  services	  at	  the	  bottom	  of	  the	  appropriate	  supplies	  section.
Also	  ensure	  that	  this	  list	  matches	  the	  list	  in	  sheet	  '22.Price	  list-­‐Supplies'.
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■n The equipment price list should be collected centrally and used for each facility. 
■n The Data Collection Tool’s default equipment labels should be preserved.
■n If the prices paid for the equipment are known, inflate using CPI and convert to 
USD using the exchange rate of that year. 
■n The standard and most appropriate value for the unit price is the replacement cost. 
Lists
■n The Lists sheet provides the selections for the dropdowns used throughout the 
tool. Only enter relevant data in the yellow cells of this sheet, namely columns Q 
“Possible additional units” and R “Possible additional tests (lab and radiology)”. 
■n Do not make any other edits to this sheet.
■n This sheet asks for the time taken (in minutes) to collect all the data needed to 
complete the respective sheets in the Data Entry Tool, as well as time it takes to 
transfer data from the Data Collection Tool to the Data Entry Tool. 
■n To facilitate this documentation, several of the data collection sheets include space 
at the top to input the start and end dates and times for the data collection. 
■n Appreciating that in many instances the data collection for a sheet may not happen 
in one discrete time period, the dates and times included in some sheets are meant 
to be an aid in capturing this information. 
■n Complete times will likely also require piecing together time spent based on input 
from each data collector. 
■n A template for data collector timesheets has been included in the Data Collection 
Tool as a way to collect more detailed time information from each data collector. 
■n Using it is optional, but it may also be useful for the study to use it during the 
piloting stage as a way of estimating the time needed to for data collection in each 
facility. 
■n A pilot would take approximately a week and would test the tool adaption and data 
availability.
Country Facility	  level Geography
Ethiopia Community	  health	  unit Urban
India Health	  post/dispensary Rural
Kenya Health	  centre
Philippines Primary	  (sub-­‐county/district)	  hospital
Georgia Secondary	  (county/general)	  hospital
Tertiary	  (national/	  teaching/	  referral/	  specialised)	  hospital
Basic	  laboratory	  (stand	  alone)
Basic	  laboratory	  (linked	  to	  facility)
Laboratory	  (full)
Reference	  laboratory
INSTRUCTIONS:	  Please	  DO	  NOT	  make	  changes	  to	  this	  sheet.	  This	  sheet	  should	  remain	  locked.
Drop-­‐down	  lists
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Data Entry Tool 
The next section is an overview of the (generic/unadapted) Data Entry 
Tool (see Figure 10b), which is used for data analysis at the facility level to 
generate bottom-up and top-down unit costs. When clean and finalised, Data 
Entry Tools for each of the facilities should be safely stored and shared with 
study investigators for pooled analysis.
■n The Data Entry Tool, used by data analysts, aims to distill the information from 
the Data Collection Tool and to generate unit cost per patient per output, top-
down and bottom-up (Appendix 9). It also allows users to drill down into the cost 
components of a unit cost. It gives the data analyst the opportunity to clean and 
review the data collected and review the ingredients and method to calculate unit 
costs.
■n Practically, the Data Entry Tool (provided in Excel) has calculations and links 
which summarize the cost data by service outputs in capital and recurrent 
categories (‘Dataset output’) and intervention type by TB services, laboratory 
and radiology tests (‘Dataset patient’). These datasets can be explored in Excel or 
exported into software such as STATA or RStudio for pooled analysis. 
Box B. Transferring data from Data Collection Tool to Data Entry Tool: the process
Data should be transferred from the data collection to the data entry sheets by pasting the Values or Values & 
Number Formatting only. This will ensure that the cell format is not changed and that there are no links to other 
files. Do not enter data in any non-yellow cells or make any edits to this sheet as it provides the selections for the 
dropdowns used throughout the tool.
Identical sheets in Data Collection and Data Entry Tools are listed here and mere copying (as described above) is 
sufficient. Ensure that any edits or additions made to the lists are replicated (with the same spelling and order).
Fig. 10a. The Value TB Costing Tool Suite (Data Collection Tool highlighted in orange)
Value TB generic facility 
provider cost 
Data Collection Tool 
Facility provider cost Data Collection Tool 
(Country-specific assumptions & parameters,
facility-selection of relevant TB service delivery outputs)
Costing Guidelines 
for Tuberculosis 
Interventions (for facility 
provider costing)
Facility provider cost Data Entry Tool 
for one facility used for initial analysis 
tool (generic/no adaptation required)
Number 
of 
facilities 
in sample
Extraction of 
P’s and Q’s for 
analysis in a 
statistical package
Value TB cost 
model – analysis
Unit costs for all TB 
interventions/services for 
one country
• Per visit/test BU and TD
• Per patient BU and TD
X
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General information 
■n The sheets for collecting information about the facility, including capital assets 
(buildings, equipment, furniture, vehicles and training) and recurrent costs (staff 
and other expenditure) are in blue, while price lists for drugs, equipment and 
supplies are colour-coded in green. 
■n Service utilization data are in light grey and calculation sheets are in orange. 
Data should not be inputted into these orange sheets as they calculate unit costs 
and generate results. 
■n There is an additional yellow sheet that should be used for capturing the time 
taken by data collectors to perform the data collection.
■n Title page, Glossary and Instructions sheets are similar to those in the Data 
Collection Tool, but the instructions have been adapted to give guidance on how 
to use the Data Entry Tool.
Title page
■n This provides an overview of the Value TB study, outlining the aims of the study 
and the tool, as well as how the data can be used. 
Country Facility	  level Geography
Ethiopia Community	  health	  unit Urban
India Health	  post/dispensary Rural
Kenya Health	  centre
Philippines Primary	  (sub-­‐county/district)	  hospital
Georgia Secondary	  (county/general)	  hospital
Tertiary	  (national/	  teaching/	  referral/	  specialised)	  hospital
Basic	  laboratory	  (stand	  alone)
Basic	  laboratory	  (linked	  to	  facility)
Laboratory	  (full)
Reference	  laboratory
INSTRUCTIONS:	  Please	  DO	  NOT	  make	  changes	  to	  this	  sheet.	  This	  sheet	  should	  remain	  locked.
Drop-­‐down	  lists
COUNTRY	  A
VALUE-­‐TB	  is	  a	  three-­‐year	  project,	  funded	  by	  the	  Bill	  and	  Melinda	  Gates	  Foundation,	  established	  to	  work	  with	  National	  
VALUE-­‐TB
Data	  entry	  and	  calculation	  tool	  for	  estimating	  unit	  costs	  of	  TB	  services	  in	  
Project	  overview:
Tuberculosis	  Programmes	  (NTPs)	  from	  high	  TB	  burden	  countries	  to	  collect	  unit	  cost	  data,	  using	  new	  standardised	  methods.	  
The	  included	  TB	  interventions	  are	  those	  that	  are	  most	  relevant	  for	  future	  local	  planning	  and	  resource	  requirement	  projections	  and	  have	  been	  jointly	  defined	  by	  the	  NTP	  and	  the	  VALUE-­‐
TB	  team.
There	  are	  two	  tools	  required	  to	  estimate	  the	  unit	  costs	  of	  TB	  services	  at	  the	  facility	  level:	  this	  is	  the	  Data	  Entry	  Tool,	  which	  accompanies	  the	  data	  collection	  tool.	  The	  data	  collection	  
tool	  was	  used	  first	  by	  data	  collectors	  at	  the	  facility	  to	  gather	  the	  required	  data.	  Then	  this	  Data	  Entry	  Tool	  should	  be	  compiled	  by	  the	  study	  principal	  investigator	  or	  study	  coordinator	  to	  
produce	  the	  calculated	  unit	  costs.
This	  cost	  Data	  Entry	  Tool	  has	  been	  developed	  to	  estimate	  the	  unit	  costs	  of	  a	  comprehensive	  set	  of	  TB	  services	  from	  the	  providers'	  perspective.	  Once	  the	  data	  from	  the	  data	  collection	  
tool	  have	  been	  entered	  into	  the	  relevant	  sheet	  in	  this	  tool,	  unit	  costs	  are	  produced	  for	  bottom-­‐up	  and	  top-­‐down	  as	  well	  as	  economic	  and	  financial	  costs	  of	  the	  TB	  services	  offered	  at	  
this	  facility.
The	  estimated	  time	  for	  transferring	  data	  from	  the	  data	  collection	  tool	  into	  this	  Data	  Entry	  Tool,	  including	  data	  management	  of	  the	  sheets	  and	  validation	  of	  the	  calculations,	  is	  1	  day	  for	  
smaller	  facilities	  and	  up	  to	  3	  days	  for	  larger	  facilities.	  
The	  cost	  data	  collected	  in	  this	  tool	  can	  further	  be	  used:
for	  programme	  management,	  funding	  and	  planning
to	  inform	  the	  estimates	  of	  the	  costs	  of	  TB	  services	  globally
March	  13,	  2019
Version	  2.0
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Glossary
■n The glossary defines the acronyms and abbreviations used within the tool.
Instructions
■n Instructions describe the colour-coding of the sheets and the cells in the tool, and 
how they should be used. 
Parameters
■n This sheet contains key data on the year of assessment, country name, factors for 
valuing assets and prices (e.g. useful life, discount rates, exchange rates, monthly 
minimum wage, etc). There are also factors for converting measures of time to 
common units (e.g. minutes in an hour, average days in a month, etc.). 
■n The source of all the data needs to be provided, whether it is from a specific agency, 
website, established methodology or an assumption. 
■n The ‘useful life’ values (Data Collection Tool, column G for both Price List-
Equipment and Equipment Inventory) can be obtained from WHO CHOICE or 
Parameters of the Data Entry Tool for different sizes of equipment. 
■n The country in which this tool is being used (Title Page, cell M3) will be updated 
when the country name has been included in the Parameters sheet (cell C16).
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 2.Glossary
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  1
AE adverse	  events
ACF active	  case	  finding
AFB acid-­‐fast	  bacilli
ALT alanine	  aminotransferase	  (also	  known	  as	  SGPT)
AST asparate	  aminotransferase	  (also	  known	  as	  SGOT)
BCG bacille	  Calmette-­‐Guérin
BSC biosafety	  cabinet
BU bottom-­‐up	  cost	  estimation/allocation
BUN blood	  urea	  nitrogen
CBC complete	  blood	  count
CCC comprehensive	  care	  clinic
Glossary
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  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 3.Instructions
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1.
2.
Instructions
The	  black,	  blue,	  grey	  and	  green	  sheets	  are	  for	  inputting	  data	  collected	  in	  the	  data	  collection	  tool.	  
Generic	  data	  for	  the	  country	  should	  be	  entered	  in	  the	  4.Parameters	  sheet	  and	  then	  locked.
The	  orange	  sheets	  are	  where	  the	  results	  are	  generated;	  data	  should	  not	  be	  entered	  in	  these	  sheets.	  
The	  yellow	  sheet	  is	  for	  capturing	  the	  time	  it	  takes	  to	  collect	  all	  the	  cost	  data,	  including	  transfering	  the	  data	  from	  the	  data	  collection	  to	  the	  data	  
entry	  sheets.
One	  data	  entry	  workbook	  should	  be	  used	  for	  each	  facility	  being	  costed.
There	  is	  a	  'List'	  sheet	  at	  the	  end	  of	  this	  workbook	  is	  linked	  to	  data	  throughout	  the	  tool.	  Please	  do	  not	  enter	  data	  or	  edit	  this	  sheet.
The	  'Notes'	  sheet	  is	  a	  free	  space	  in	  the	  tool	  for	  you	  to	  keep	  track	  of	  any	  unresolved	  issues	  and	  is	  not	  linked	  to	  data	  in	  the	  rest	  of	  the	  tool.	  Please	  
feel	  free	  to	  use	  so	  that	  it	  best	  suits	  your	  needs.
Value	  TB	  -­‐	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  TB	  services 4.Parameters
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Parameter	  name Value Source
Year	  of	  assessment Latest	  financial	  or	  calendar	  year	  of	  complete	  data
No.	  of	  months	  evaluated 12 Assumption
No.	  of	  days	  in	  a	  month 30 Assumption
No.	  of	  weeks	  in	  a	  month 4.348214286 Julian	  calender
No.	  of	  weeks	  in	  a	  year 52 Assumption
No.	  of	  days	  in	  a	  year 365 Assumption
No.	  workdays	  in	  a	  year 250 Based	  on	  holiday	  calendar	  for	  the	  country
No.	  workdays	  in	  a	  month 22
No.	  working	  hours	  in	  a	  day 8 B s d	  on	  fa ility	  or	  country	  regulations	  or	  contracts
No.	  minutes	  in	  an	  hour 60 Assumption
No.	  of	  working	  minutes	  in	  a	  year 120000 Calculation
Country COUNTRY	  A
INSTRUCTIONS:	  Validate	  the	  values;	  then	  lock	  the	  entire	  sheet
Parameter	  Assumptions
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■n Values in this sheet should only be entered once for a particular country. Once 
this has been done, no edits should be made to this data and the tool can then 
be replicated for all facilities with the same parameter data. To ensure the sheet 
is not edited, it should be locked: [Review tab>Protect Sheet (in the Changes 
menu)>’Select locked cells’ should be ticked>select ‘OK’]. 
Facility characteristics
■n The values from the data collection Facility Characteristics should be copied and 
pasted into this Data Entry Tool. 
■n Do not transfer data from the source, year of data or notes cells in the Data 
Collection Tool. 
■n Ensure that the dropdown selections for the additional service output types have 
been selected properly.
A. Reviewing completed sheets
The following review and calculations for unit cost generation will be performed 
using the Data Entry Tool. This section of the guidelines will cover (A) reviewing 
completed sheets and (B) generation of unit costs using the associated Data 
Entry Tool.
Building space
Amortizing capital costs: 
■n Check the calculations for the annualized economic and financial costs, as well 
as the allocations of the building costs to the direct, support and indirect facility 
departments (see Box A). 
■n The useful life years of the building (from Parameters) feeds into the calculation 
for ‘Annualized economic costs (local currency)’ taking the standard discount rate 
(from Parameters),‘Value if sold today (local currency)’, and useful life years of the 
building, and running a PMT function which calculates the annualized/amortized 
amount. 
Value	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Facility	  name
Facility	  location/address	  1
Facility	  location/address	  2
Geography	  1	  -­‐	  urbanicity	  (see	  dropdown)
Geography	  2
Geography	  3
Facility	  level	  (see	  dropdown)
Ownership	  (see	  dropdown)
Size	  (approximate)	  of	  facility	  buildings	  (m2)
Size	  (approximate)	  of	  land	  (m2)
Operating	  hours	  of	  facility (total	  opening	  hours	  per	  week)
Operating	  hours	  for	  TB	  services (total	  opening	  hours	  per	  week)
Total	  hospital	  beds	  (inpatient) (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Total	  day	  beds	  (outpatient) (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Total	  outpatient	  visits (all) (DS-­‐TB) (MDR-­‐TB) (TB-­‐HIV)
Size	  of	  catchment	  population
Total	  clinical,	  alli d,	  and	  auxiliary	  staff	  FTE
Total	  support	  and	  administrative	  staff	  FTE
Total	  staff	  FTE
Facility	  Characteristics
INSTRUCTIONS:	  Data	  from	  the	  '6.Facility	  characteristics'	  sheet	  from	  the	  data	  collection	  workbook	  should	  be	  pasted	  here.
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(days	  of	  the	  week)
(days	  of	  the	  week)
Owned,	  rented	  or	  donated	  
[dropdown]
Value	  if	  sold	  today
(local	  currency)
Builiding	  -­‐	  general	  information
Name	  of	  department	  or	  clinic	  or	  room	  or	  area	  or	  building
Name	  of	  department/	  clinic/	  
room/	  area/	  building	  in	  
language	  of	  site
Size	  of	  department/	  clinic/	  
room/	  area/	  building
(m2)
Outpatient	  Department	  (OPD) -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
OPD:	  General
OPD:	  Registration	  office/reception	  area
OPD:	  TB	  clinic
TB:	  Common/waiting	  area
TB:	  Sputum	  collection	  room	  or	  space
TB:	  Consultation	  area	  (with	  doctor)
TB:	  Convalesing	  area	  (with	  nurse)
TB:	  Dispensary	  for	  medication
TB:	  Laboratory
TB:	  Management	  of	  TB	  services	  (eg:	  office(s)	  of	  
nurse	  in	  charge	  for	  TB	  clinics)
Ph
ys
ic
al
	  fa
ci
lit
ie
s
Building	  	  space	  
INSTRUCTIONS:	  Data	  collected	  in	  the	  '7.Building	  Space'	  sheet	  should	  be	  pasted	  in	  the	  yellow	  cells	  of	  this	  sheet.
Departments	  are	  in	  bolded	  font	  in	  column	  B.	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■n The same calculation is done for the local discount rate (from the Parameters sheet). 
■n There are check cells in column AO, which ensure that the proportion of building 
space allocated to each department adds up to 100%. If this is not the case, 
‘ERROR’ will be returned in the check cell and the department allocations need to 
be amended.
Equipment top-down
Equipment time (top-down) calculation: 
■n The proportion of time for each relevant TB service output should be calculated 
using service statistics for that particular output divided by the service statistics 
for all tests (outputs) performed using that piece of equipment. If the tests 
(outputs) performed by that piece of equipment are not known, all tests in the lab 
can be used.
■n Using a top-down approach, the expenditure of all the equipment and furniture 
are allocated to TB services using an allocation factor (for instance, number of TB 
tests processed divided by the total number of tests processed in a laboratory). 
■n If the equipment was used for more than three service outputs, information can be 
entered for the same piece of equipment on two separate rows, ensuring that the 
percent usage for TB has been split between the two rows. 
■n The values in columns I, K and M should total 100%.
Equipment BU
Equipment	  name Department Clinic	  or	  room
Manufacturer
[if	  applicable]
Model
[if	  applicable]
Analytical	  balance
Analytical	  balance	  (electronic)	  for	  DST
Autoclave	  -­‐	  horizontal
Autoclave	  -­‐	  vertical
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  1
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  2
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  3
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  4
Automatic	  filling	  station
AVR	  (for	  autoclave)
BACTEC	  -­‐	  starter	  kit
BACTEC	  MGIT	  320	  System
BACTEC	  MGIT	  960	  system
BACTEC	  printer
Balance	  (analytical)
Balance	  (precision)
Balance	  (precision)	  -­‐	  electronic
Po
w
er
ed
	  e
qu
ip
m
en
t
Equipment	  and	  furniture
INSTRUCTIONS:	  This	  should	  be	  a	  complete	  list	  of	  all	  equipment	  and	  furniture	  used	  in	  any	  of	  the	  TB	  inteventions,	  taken	  from	  sheet	  '8.Equipment	  Inventory'	  from	  the	  data	  collection	  tool.
The	  list	  of	  equipment	  in	  this	  sheet	  should	  match	  (same	  names	  and	  same	  order)	  the	  'Price	  list-­‐Equipment'	  sheet	  in	  this	  tool.
TOTAL	  CLINIC	  OPENING	  MINUTES	  PER	  WEEK
Enter	  method	  for	  time	  measurement
Equipment	  
category Name	  or	  description	  of	  equipment	  or	  furniture
Financial	  price	  
per	  minute
Economic	  price	  
per	  minute
Outpatient	  
vaccinations
Outpatie
nt	  cough	  
triage
Outpatie
nt	  
screenin
g	  visit
Outpatie
nt	  
diagnosti
c	  visit
Outpatie
nt	  visit	  
type	  1
Outpatie
nt	  visit	  
type	  2
Analytical	  balance 0.00 0.00
Analytical	  balance	  (electronic)	  for	  DST 0.00 0.00
Autoclave	  -­‐	  horizontal 0.00 0.00
Autoclave	  -­‐	  vertical 0.00 0.00
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  1 0.00 0.00
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  2 0.00 0.00
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  3 0.00 0.00
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  4 0.00 0.00
Automatic	  filling	  station 0.00 0.00
AVR	  (for	  autoclave) 0.00 0.00
BACTEC	  -­‐	  starter	  kit 0.00 0.00
INSTRUCTIONS:	  All	  equipment	  and	  furniture	  allocation	  estimates	  should	  be	  summarised	  from	  the	  data	  collection	  "19.Observations"	  sheet,	  and	  entered	  into	  this	  input	  sheet	  after	  observations	  have	  been	  completed.
DO	  NOT	  insert	  rows	  in	  this	  sheet	  as	  the	  list	  of	  equipment/furniture	  in	  column	  B	  is	  linked	  to	  the	  'Price	  list-­‐Equipment'	  sheet	  in	  this	  tool,	  which	  is	  where	  all	  edits	  to	  the	  list	  should	  be	  made.
Equipment	  and	  furniture	  observations	  entry
Minutes	  per	  service	  output
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Equipment time (bottom-up) calculation: 
■n From the observations and/or interviews performed during data collection, enter 
the quantity of time (in minutes) that the relevant pieces of equipment were used 
to perform each service output.
■n The method used to measure the time each piece of equipment was utilized for 
each service output needs to be selected. 
■n It is possible to select a combination of observation and interview in cases where 
observation of the entire service was not possible because of ethical issues or if the 
entire service did not naturally occur during the data collection period.
Training
Allocate training across departments: 
■n After copying data from Data collection, check that the correct proportions and 
service outputs appear in the relevant department and service output allocation 
boxes to the right of the sheet.
Staff top-down
Name	  of	  training
Facility,	  or	  if	  offsite	  
provide	  location
Training	  
provider	  
(institution	  or	  
programme	  
name)
Date	  of	  
training
Duration
(days)
Number	  of	  
partipants	  from	  this	  
facility
1
2
3
4
5
6
7
8
9
10
11
12
Training	  
INSTRUCTIONS:	  Training	  data	  should	  be	  TB	  related,	  for	  the	  entire	  facility.	  A	  value	  of	  3	  years	  has	  been	  used	  from	  the	  '4.Parameters'	  sheet	  as	  the	  useful	  life	  for	  training	  as	  this	  is	  a	  commonly	  used	  value	  but	  if	  a	  different	  value	  is	  applicable	  to	  your	  context,	  please	  enter	  it	  in	  cell	  C25	  
of	  '4.Parameters'.
Health	  care	  worker	  category
Gross	  annual	  salary	  
(local	  currency)
Gross	  annual	  
benefits
(local	  currency)
Total	  working	  
hours	  per	  week	  or	  
full-­‐time	  
equivalent	  (FTE) Quantity
Clinical,	  allied	  and	  auxiliary	  staff
Support	  and	  administrative	  staff
Total	  Staff
PERCENT	  TIMESHEETS,	  %
Staff	  
category Staff	  title
Gross	  annual	  salary	  
received
(local	  currency)
Gross	  annual	  
benefits	  received
(local	  currency)
Working	  hours	  per	  
week	  on	  average	  
over	  the	  year
Staff	  time	  
measurement	  
method	  -­‐	  TD
Outpatient	  
vaccinations
Head	  of	  facility
Registrar
Doctor	  1
Doctor	  2
Doctor	  3
Clinical	  Officer	  1	  (TB/CCC)
Clinical	  Officer	  2	  (OPD)
TB	  Nurse	  in	  Charge
MCH	  Nurse
Nurse	  2
Nurse	  3
Nurse	  4
Nurse	  5
Cl
in
ic
al
,	  a
lli
ed
	  a
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  a
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Staff	  timesheet	  entry	  -­‐	  TOP-­‐DOWN
INSTRUCTIONS:	  The	  salary,	  benefits	  and	  working	  hours	  per	  average	  week	  for	  each	  health	  care	  worker	  in	  the	  facility	  should	  be	  pasted	  from	  the	  '9.Staff	  Salaries'	  sheet	  in	  the	  data	  collection	  tool.
Using	  the	  total	  staff	  time	  values	  (in	  minutes)	  from	  the	  data	  collection	  sheet	  '20.Staff	  time	  sheets',	  calculate	  the	  the	  equivalent	  time	  (in	  minutes)	  per	  week	  spent	  on	  each	  output.	  Then	  insert	  those	  values	  into	  the	  corresponding	  yellow	  cells	  of	  this	  sheet.	  The	  proportion	  of	  time	  spent	  on	  each	  output	  will	  then	  be	  calculated	  in	  this	  sheet.
Total	  minutes	  per	  week	  (from	  timesheets)
Fa
ci
lit
y	  
St
af
f
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Review automatically calculated proportions of health care worker time spent on 
each service output – top-down method: 
■n For staff performing TB services within a cadre who were not given timesheets, 
one can assume their time distribution is the same as the staff member within that 
cadre (in the same department or clinic) who did complete a timesheet. Therefore, 
the minutes per week for each service output should be duplicated from the 
timesheet collected for the staff member within that cadre at the facility. In this 
situation, the top-down staff time measurement method will also be ‘timesheet’. 
■n The top-down method will be ‘interview’ if the timesheet was completed by sitting 
with the staff member and asking them how they spend their time over a specific 
period of time. 
■n For support and administrative staff, top-down measurement is likely to be based 
on ‘assumption’, where their total working hours per week can be allocated to TB 
versus non-TB services by using service statistics. 
■n For example, for a driver attached to the facility, time allocated to ‘Other overhead 
services’ can be allocated by ((TB outpatient visits + TB inpatient bed-days)/(total 
facility outpatient visits + total facility inpatient bed-days)) * total minutes worked 
per week. The remaining minutes in their work week should be allocated to ‘Non-
TB services’.
■n At the end of the staff categories “clinical, allied and auxiliary staff” and “support 
and administrative staff”, there is space to include the title of 15 and 10 additional 
staff members, respectively. This has been indicated in blue font. 
■n Only change text in the cells with blue font in column B. 
■n This sheet contains the original list of health care workers used throughout the 
tool. 
■n The list in Staff BU has been linked to the list in this sheet.
Staff BU
Review automatically calculated the proportion of health care worker time spent on 
each service output – bottom-up method: 
■n The minutes per service output should be entered based on observations or 
interviews performed for each service output at the facility. 
TOTAL	  CLINIC	  OPENING	  MINUTES
PERCENT	  OBSERVATIONS,	  %
Enter	  method	  for	  time	  measurement
Staff	  
category Health	  care	  worker	  type Financial	  salary	  per	  minute
Outpatient	  
vaccinations
Outpatie
nt	  cough	  
triage
Outpatie
nt	  
screenin
g	  visit
Outpatient	  
diagnostic	  
visit
Outpatie
nt	  visit	  
type	  1
Outpatie
nt	  visit	  
type	  2
Outpatie
nt	  visit	  
type	  3
Head	  of	  facility
Registrar
Doctor	  1
Doctor	  2
Doctor	  3
Clinical	  Officer	  1	  (TB/CCC)
Clinical	  Officer	  2	  (OPD)
TB	  Nurse	  in	  Charge
MCH	  Nurse
Nurse	  2
Nurse	  3
Nurse	  4
Minutes	  per	  service	  output
INSTRUCTIONS:	  All	  staff	  time	  estimates	  for	  each	  service	  output	  should	  be	  summarised	  from	  the	  "18.Interviews"	  and	  "19.Observations"	  data	  collection	  sheets	  and	  entered	  into	  this	  input	  sheet	  after	  all	  interviews	  and	  observations	  have	  been	  completed.
To	  ensure	  there	  is	  no	  double	  counting	  of	  staff	  time	  values,	  if	  more	  than	  one	  of	  a	  particular	  health	  care	  worker	  category	  has	  been	  interviewed	  or	  observed	  for	  a	  service	  output,	  distinguish	  the	  type	  of	  output	  (e.g.	  outpatient	  treatment	  visit	  in	  OPD	  versus	  outpatient	  treatment	  visit	  in	  DOTS	  clinic)	  and	  assign	  the	  staff	  time	  to	  the	  appropriate	  output.	  If	  more	  than	  one	  health	  care	  worker	  was	  interviewed	  or	  observed	  for	  a	  service	  output	  in	  the	  same	  department/clinic,	  calculate	  the	  average	  of	  their	  time.
Staff	  time	  observations	  and	  interviews	  entry	  -­‐	  BOTTOM-­‐UP
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■n Only enter values for the person(s) who actually perform the job. 
■n Be sure to select the method used for staff time measurement for each output in 
row 6.
■n The list of healthcare workers is linked to the list of staff in the Staff top-down 
sheet. 
■n Check that the correct value for ‘financial salary per minute’ appears for the 
corresponding health care worker from the Staff sheet.
Review drug quantities:
The analyst will review:
— Total annual quantity disbursed for TB (in units) (Data Entry Tool – Drugs 
top-down) 
— Average number of drugs per patient (Data Entry Tool – Drugs bottom-up)
Supplies top-down
Review supplies quantities (top-down) and allocation of office and general supplies: 
■n In the method embedded in the Data Entry Tool, 100% of ‘Office supplies’ and 
‘General supplies’ have been allocated to ‘Admin & Management’ and ‘Other 
Overhead’, respectively. 
■n Ensure that the proportions for each category of supplies is accurate and that the 
economic costs have been properly allocated. 
■n All other supplies (‘Medical supplies’ and ‘Chemicals and reagents’) have been 
allocated to the service outputs identified during observations or interviews. 
■n Do a spot check to ensure that the service outputs and proportions for each supply 
item with data is being pulled into the correct department and service output cost 
calculation.
Wastage	  of	  supplies,	  %
Name	  or	  description	  of	  supply
Annual	  expenditure
(local	  currency)
%	  use	  for	  TB
[eg.	  based	  on	  TB	  
tests/all	  tests	  
performed	  by	  total	  
numbers	  of	  machines]
TB	  service	  output	  type	  
1
[see	  dropdown]
%	  use	  for	  TB	  
service	  output	  
type	  1
TB	  service	  output	  
type	  2
[see	  dropdown]
0.5-­‐10	  μl	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  (Long	  tip)	  
10-­‐100	  μl	  tips	  
1-­‐20	  μl	  tips	  
1-­‐200	  μl	  pipette	  tips	  
1-­‐200	  μl	  tips	  
20-­‐200	  μl	  pipette	  tips	  
20-­‐200	  μl	  pipette	  tips	  
2ml	  standard	  reaction	  tube	  
Applicator	  stick	  (disposable)
BACTEC	  MGIT	  960	  AST	  transport	  rack	  –	  
445942.	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  (100	  tests,	  
PANTA	  and	  OADC	  combined)	  Catalogue	  No:	  
245124	  
M
ed
ic
al
	  s
up
pl
ie
s
Supplies	  expenditures
INSTRUCTIONS:	  Columns	  C-­‐J	  in	  the	  data	  collection	  '17.Supplies'	  sheet	  should	  be	  copied	  and	  pasted	  into	  the	  corresponding	  columns	  in	  this	  data	  entry	  sheet.
The	  list	  of	  supplies	  in	  this	  sheet	  should	  match	  (same	  names	  and	  same	  order)	  the	  'Price	  list-­‐Supplies'	  sheet	  in	  this	  tool.
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Supplies BU
Complete supplies bottom-up calculations: 
■n From the observations and/or interviews performed during data collection, enter 
the quantity of each supply (in units) that was utilized for each service output.
■n The analyst selects whether these quantitates have been obtained by observation, 
interview or a mixture of the two. 
■n This value is applicable to all the supply quantity values obtained for the entire 
facility. 
■n Selection of the method should be based on whether the majority of values were 
obtained by observation (select ‘Observation’), interview (select ‘Interview’) or 
about equal (select ‘Mix’). 
■n For the ‘Mix’ method, the default in the tool is 50% observation to 50% interview 
but this can be changed by varying the ‘Time measurement allocation for ‘Mix’ 
method’ in cell C24 of the Parameters sheet.
■n Do a spot check that the price per unit for each supply is being pulled in correctly 
from Price list-supplies and that the calculation for the cost of supplies for each 
output is being applied to the correct quantity.
Review drug, supplies and equipment prices
In this tool, drugs used to treat adverse events have not been included in the unit 
costs. 
Data collection time
(Optional) Review data collection time if one wishes to analyse the time invested in 
the costing study itself and use the evidence to inform the data collection.
■n This sheet asks for the time taken (in minutes) to collect all the data needed to 
complete the respective sheets in the Data Entry Tool as well as time it takes to 
transfer data from the Data Collection Tool to the Data Entry Tool. 
■n To facilitate documentation, several of the data collection sheets include space at 
the top to input the start and end dates and times for the data collection. 
Method	  of	  quantity	  measurement
Type	  of	  
supply Name	  or	  description	  of	  supply Price	  per	  unit
Outpatie
nt	  
vaccinati
ons
Outpatie
nt	  cough	  
triage
Outpatie
nt	  
screenin
g	  visit
Outpatie
nt	  
diagnosti
c	  visit
Outpatie
nt	  visit	  
type	  1
Outpatie
nt	  visit	  
type	  2
Outpatie
nt	  visit	  
type	  3
Inpatient	  
bed-­‐day	  
type	  1
Inpatient	  
bed-­‐day	  
type	  2
0.5-­‐10	  μl	  tips	   0.00
100-­‐1000	  μl	  pipette	  tips	   0.00
100-­‐1000	  μl	  pipette	  tips	   0.00
100-­‐1000	  μl	  pipette	  tips	  (Long	  tip)	   0.00
10-­‐100	  μl	  tips	   0.00
1-­‐20	  μl	  tips	   0.00
1-­‐200	  μl	  pipette	  tips	   0.00
1-­‐200	  μl	  tips	   0.00
20-­‐200	  μl	  pipette	  tips	   0.00
20-­‐200	  μl	  pipette	  tips	   0.00
2ml	  standard	  reaction	  tube	   0.00
Applicator	  stick	  (disposable) 0.00
BACTEC	  MGIT	  960	  AST	  transport	  rack	  –	   0.00
Quantity	  (units)	  per	  service	  output
Supplies	  observation	  entry
INSTRUCTIONS:	  All	  supply	  allocation	  estimates	  should	  be	  summarised	  from	  the	  data	  collection	  "18.Interviews"	  and	  "19.Observations"	  sheets,	  and	  entered	  into	  this	  input	  sheet	  after	  interviews	  and	  observations	  have	  been	  completed.
The	  list	  of	  supplies	  in	  this	  sheet	  should	  match	  (same	  names	  and	  same	  order)	  the	  'Price	  list-­‐Supplies'	  sheet	  in	  this	  tool.
M
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Aluminium	  foil 0.00
Bags	  (transparent	  polypropylene) 0.00
Bottle	  brush 0.00
Bowl 0.00
Broom 0.00
Bubble	  wrap	  (packing) 0.00
Bucket	  -­‐	  heavy	  duty	  plastic 0.00
Bucket	  (stainless	  steel) 0.00
Bucket	  with	  lid	  (stainless	  steel) 0.00
Cotton	  balls 0.00
Cotton	  wool 0.00
Cryobox 0.00
Desiccator 0.00
Detergent/washing	  powder 0.00
Disinfectant	  -­‐	  liquid 0.00
Disinfectant	  for	  BSC	  surface 0.00
Disinfectant	  for	  cleaning	  instruments 0.00
Disinfectant	  for	  floors 0.00
Disinfectant	  for	  hands 0.00
Dustpan 0.00
Hand	  cleanser 0.00
Hand	  sanitiser 0.00
Liquid	  soap 0.00
Mop 0.00
Mop	  head 0.00
Paper	  towels 0.00
Rinse	  aid	  for	  dish	  washer 0.00
Salt	  for	  dish	  washer 0.00
Silica	  gel	  (for	  desiccator) 0.00
Spatula 0.00
Styro	  box 0.00
Surface	  cleaner 0.00
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■n Appreciating that in many instances the data collection for a sheet may not happen 
in one discrete time period, the dates and times included in some sheets are meant 
to be an aid in capturing this information. 
■n Complete times will likely also require piecing together time spent based on input 
from each data collector. 
■n A template for data collector timesheets has been included in the Data Collection 
Tool as a way to collect more detailed time information from each data collector. 
Using it is optional, but it may also be useful for the study to use it during the 
piloting stage as a way of estimating the time needed to for data collection in each 
facility. 
■n A pilot study would take approximately a week and would test the tool adaption 
and data availability.
Service statistics 
Review service statistics and allocations of main cost components in the unit costs. 
■n The Data Entry Tool will generate automatic calculations, but the analyst will be 
making choices in the two options available for allocation keys depending on data 
available at the facility.
Start	  date:
End	  date:
Sheet	  name
Collected	  for	  this	  
facility	  
(see	  dropdown)
Time	  taken	  to	  complete	  data	  
collection
(in	  minutes)
4.Parameters
5.Facility	  Characteristics
6.Building	  Space
7a.Building
7b.Building	  BU
8.Transport
9.Training
10a.Staff	  TD
10b.Staff	  BU
11.Recurrent	  Other
12a.Drugs	  TD
12b.Drugs	  	  BU
13a.Supplies
13b.Supplies	  OBSERVATION
14.Service	  Statistics
15.Service	  Description
17.Price	  list-­‐Drugs
18.Price	  list-­‐Equipment
19.Price	  list-­‐Supplies
INSTRUCTIONS:	  Report	  the	  time	  taken,	  in	  minutes,	  to	  collect	  all	  the	  data	  in	  each	  sheet	  listed	  below.	  
Also	  include	  the	  time	  taken	  to	  transfer	  from	  data	  collection	  to	  date	  entry	  tool.
Data	  Collection	  time
Year	  of	  data	  (latest	  financial	  or	  calendar	  year)
Unit Annual	  quantity	  -­‐	  entire	  facility Annual	  quantity	  -­‐	  TB	  services	  only
Outpatient	  visits
TB	  Clinic
MCH	  Clinic
Paediatric	  Clinic
HIV	  Clinic
Chronic	  Disease	  (diabetes)	  Clinic
Comprehensive	  Care	  Clinic
Inpatient	  beddays
Inpatient	  admissions
Laboratory	  tests	  (all	  labs)
Microbiology	  Lab	  -­‐	  tests
Bacteriology	  Lab	  -­‐	  tests
Laboratory:	  main	  (clinical	  path,	  incl	  haematology)	  -­‐	  tests
Area	  for	  blood,	  serum,	  plasma	  collection	  -­‐	  samples
Area	  for	  sputum	  sample	  collection	  -­‐	  samples
Area	  for	  AFB	  and	  GeneXpert	  -­‐	  tests
Area	  for	  biopsy	  -­‐	  tests
Area	  for	  LPA	  -­‐	  tests
Laboratory:	  culture	  -­‐	  tests
Radiology	  tests
Service	  Statistics	  and	  Allocation	  Keys
INSTRUCTIONS:	  Copy	  and	  paste	  data	  from	  the	  '14.Service	  Statistics'	  sheet	  in	  the	  data	  collection	  tool.
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■n Here is a description of the allocation of all the main cost categories (i.e. space, 
equipment, staff time, drugs, transport). 
■n It will be followed by a description of its implementation in the Data Entry Tool 
through sheets on Service statistics, Summary top-down and Summary 
bottom-up.
Description of cost components allocations
Space
■n For comprehensive care clinics in OPD where services are integrated, such as TB 
screening for all patients with HIV, questions could address the proportion of time 
spent screening for TB (or work out the proportion based on number of minutes for 
screening/total time for HIV consultation) and use this time to allocate a portion 
of the space (i.e. incorporate time where spaces are shared, with the assumption 
that visits take the same amount of time).
■n The top-down allocation is calculated using TB visits over total clinic headcount 
multiplied by the total building space (for example TB visits/total clinic 
headcount*total building space (500/5000)*100m2=10m2).
Box C. Allocation for space 
Ideal: measure bottom-up space directly – i.e. the proportion of space used for a service
If direct measurement is not possible, use visits for the allocation or ask staff who use the space to estimate the 
proportion for TB versus non-TB services
For general OPD, recommended allocation = total TB outpatient visits/total outpatient visits 
For MCH in OPD where BCG vaccination and screening occurs, the recommended allocation = (total BCG vaccine 
visits + total TB screening visits)/total MCH OP visits
For inpatient department (IPD), recommended allocation = total TB inpatient bed-days/total department inpatient 
bed-days
For laboratory or radiology departments, recommended allocation = total TB tests/total department tests
Box D. Allocation for equipment 
To allocate equipment cost to TB service:
Ideal: use the number of tests to calculate the allocation. If one knows which tests the equipment is used for, 
denominator=sum of those test numbers; if one does NOT know which tests it is used for, denominator=all tests in 
that laboratory (i.e. microscope: used for ZN/Malaria/Stool testing only)
EXCEPT: for equipment for culture and DST tests, including MGIT, incubator, Xpert® MTB/RIF if also used for HIV, 
influenza, etc. testing. Here time can be included in the calculation. 
Observation should be the default; if not available then use interview data. For instance, if MDR-TB testing is not 
done frequently then interview data may be the only option. It is also possible to ask for a demonstration which can 
be observed.
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Drugs top-down and Drugs bottom-up
■n Top-down drug cost is estimated as the total annual quantity of drugs disbursed at 
the facility by the unit price of the drugs. 
■n Top-down costing would involve looking at the expenditure of TB medication 
divided by the number of patients taking the medication. 
■n This would usually involve step down accounting methods or allocation to move 
from an aggregate value to disaggregated costs for different regimens or individual 
drugs. 
Box E. Allocation for staff time using a top-down measurement method
Ideal: Staff timesheets for at least one cadre of health care worker performing each TB service output. Based on 
the total time spent on each output, the proportion of time for each TB output will be calculated in the Data Entry 
Tool.
Alternatives: For direct service personnel without timesheets, the assumption is that the proportion of time spent 
on TB should be the same as other personnel in that cadre of health professional. For example, if timesheets 
were collected for one doctor, nurse and nursing assistant, but there are additional doctors, nurses and nursing 
assistants providing TB services in the facility, it can be assumed that the timesheet values for “doctor 1” can be 
used for “doctor 2” and “doctor 3” as well. The same assumptions will also apply for the other cadres.
For support staff, the head of facility or registrar, the proportion of time for TB is estimated (assumption) based on 
the total TB outpatient visits divided by the total facility outpatient visits:
— % time for TB (support staff, facility head, registrar) = total TB outpatient visits/total outpatient visits for facility
For head of laboratory, radiology and the inpatient department, use laboratory tests, radiology tests and bed-days, 
respectively.
— % time for TB (laboratory head) = total TB laboratory tests/total laboratory tests in facility
— % time for TB (radiology head) = total TB radiology tests/total radiology tests in facility
— % time for TB (inpatient department head) = total TB bed-days/total bed-days for facility
Specialized personnel providing direct services (e.g. phlebotomists, pharmacists, social workers, etc.) should be 
interviewed to provide an estimate of the proportion of time spent on TB, and of that time, how it is split between 
various departments (e.g. outpatient and inpatient departments for social workers).
Other options: If one cannot measure directly, then use service statistics for the allocation. If the health care 
worker provides outpatient services, estimate using number of TB outpatient visits/Total outpatient visits. If 
the health care worker provides both outpatient and inpatient services, estimate using number of TB outpatient 
visits+TB inpatient bed-days/Total outpatient visits+Total inpatient bed-days
Box F. Allocation for staff time using a bottom-up measurement method 
Ideal: Number of hours measured directly, and proportion of time spent on each task will be calculated in the Data 
Entry Tool 
Alternatives: a rough estimate given by the staff interviewed, or the percentage time for TB (%)= Department 1+ 2.
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 12a.Drugs	  TD
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Drug/pharmaceutical	  product	  description
(medicine,	  strength,	  formulation,	  packaging)
Product	  code Unit	  of	  measure Total	  annual	  quantities	  
disbursed	  for	  TB	  (in	  units)
Estimated	  expenditure
(local	  currency)
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  tablet(s),	  Blister(s) 3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  (28x3) Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐336 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	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INSTRUCTIONS:	  Total	  quatity	  of	  drugs	  disbursed	  for	  TB	  should	  be	  taken	  from	  column	  E	  of	  the	  data	  collection	  sheet	  '16.Drug	  Services'	  and	  copied	  in	  the	  yellow	  cells	  of	  this	  data	  entry	  sheet.
NOTE:	  If	  any	  drug	  was	  added	  to	  the	  data	  collection	  sheets	  '16.Drug	  Services'	  and	  '21.Price	  list-­‐Drugs',	  please	  ensure	  that	  they	  are	  also	  included	  (extra	  yellow	  rows)	  in	  the	  appropriate	  section	  of	  this	  data	  entry	  sheet.
Drugs	  -­‐	  quantities
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 12b.Drugs	  BU
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VACCINATION
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PHASE
Price	  per	  dose	  
(local	  price) In
te
ns
iv
e
Co
nt
in
ua
ti
on
In
te
ns
iv
e
Co
nt
in
ua
ti
on
In
te
ns
iv
e
Co
nt
in
ua
ti
on
In
te
ns
iv
e
Co
nt
in
ua
ti
on
Drug/pharmaceutical	  product	  description
(medicine,	  strength,	  formulation,	  packaging)
Product	  code Unit	  of	  measure
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) Per	  pack/blister 0.00
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 Per	  pack/blister 0.00
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 Per	  pack/blister 0.00
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  
tablet(s),	  Blister(s)
3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐672 Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  
tablet(s),	  Blister(s)
3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  
(28x3)
Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐
672
Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐
336
Per	  pack/blister
0.00
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister 0.00
0 0 0 0.00
0 0 0 0.00
0 0 0 0.00
0 0 0 0.00
Infant
Quantities	  (doses)	  per	  (average)	  patient…
Adult
PTB EPTB PTB EPTB
Drugs	  -­‐	  Interview	  entry	  form
INSTRUCTIONS:	  For	  each	  TB	  regimen	  and	  phase	  the	  quantity	  of	  each	  drug	  (item)	  prescribed	  or	  given	  to	  an	  average	  patient	  should	  be	  obtained	  from	  the	  data	  collection	  sheet	  '16.Drug	  Services'.
If	  a	  drug	  used	   t	  this	  facility	  is	   ot	  included	  in	   he	  list,	  please	   ncluded	  i 	  at	  the	  bottom	  of	  the	  relevant	  section	  and	  add	  to	  the	  corresponding	  section	  in	  the	  'Price	  list-­‐Drugs'	  sheet	  in	  this	  tool.
1st	  Line	  TB	  TREATMENTINTERVENTION	  CLASS	  (TREATMENT	  ONLY)
INTERVENTION	  POPULATIONS
DS-­‐TB
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REGIMEN New	  and	  relapse Previously	  treated
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■n Similarly, to cost diagnostic tests one may need to allocate the cost of TB drugs from 
the expenditure of all drugs in a facility, and then further allocate costs to specific 
TB regimens i.e. first-line, retreatment, second-line and third-line treatment.
■n Bottom-up drug cost is calculated as the product of the drug prices and the average 
quantity per average patient for each TB treatment and prevention regimen by 
phase.
■n For a bottom-up costing, one would look at the patient TB drug usage. 
■n For smaller facilities, this may include abstraction of all the patients’ medication 
records; for larger facilities a sample of patient records might be used. 
■n Together with a price list for TB medication, one could calculate the average cost 
of TB medication (e.g. first-time treatment) for a relevant amount of time, for 
instance per month or per annum. 
Transport
■n Care should be taken that transport is captured either in overhead costs; or above 
service level costs or in vehicle costs (capital costs), and that it is not double counted.
■n The ‘Life expectancy (years)’ needs to be provided for each vehicle being costed in 
this sheet. 
■n If there is no locally specific value, be sure to include the value provided in 
Parameters.
Recurrent other
■n The proportion of recurrent costs allocated to TB services has been calculated using 
service statistics for outpatient visits (TB outpatient visits/total facility outpatient 
visits).
■n In a cost analysis, overhead inputs are allocated accordingly to various departments 
or activities. Inputs could be allocated to ‘cost centres’ (depending on how cost data 
are organized, and cost centres are defined). 
■n An allocation basis needs to be defined for allocating each input to various cost 
centres. For instance, some costs can be assigned directly to certain cost centres. 
Vehicle	  name
Number	  of	  
vehicles
Life	  expectancy	  
(years)
Own,	  rent	  or	  
donated
If	  own	  or	  donated,	  
Current	  market	  
value	  of	  all	  
vehicles
(local	  currency)
If	  rent,	  total	  
annual	  rental	  
value
(local	  currency)
Total	  annual	  
maintenance	  
costs	  
(insurance,	  
repairs	  etc.)
(local	  currency)
Ambulance
Bicycle
Motorcycle	  
Small	  car
Large	  car
SUV
Mini-­‐van
Van
Mobile	  clinic
Bus
Other
Total	  Veh cl 	  Costs
Transport
INSTRUCTIONS:	  All	  transportation	  costs	  and	  proportions	  should	  be	  transferred	  from	  the	  data	  collection	  sheet	  "11.Transportation"	  into	  this	  input	  sheet.
95 Section F. Appendices
■n If ‘inpatient care’ is a cost centre, then the line item ‘laundry’ could be allocated to 
that centre, using ‘a patient day equivalent’ as an allocation method. 
■n If ‘maintenance’ is a cost centre, then ‘floor space utilized by department’ could be 
a useful allocation method. 
■n Allocation of overhead inputs usually requires step down costing.
Service description
■n The values in cells C13 to CE84 of Service Description should be copied and 
pasted into C14 to CE85 of this Data Entry Tool.
Price list-drugs
■n The transportation mark-up values for first-line and second-line drugs are linked 
to the formulae in column N. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 11.Recurrent	  Other
27/11/19 Page	  1
Recurrent	  overhead	  costs	  (ENTIRE	  FACILITY)	  
-­‐	  disaggregated
Annual	  expenditure
(Local	  currency)
Percent	  allocated	  to	  TB	  
services,	  %
Water
Sewerage	  and	  sanitation
Electricity	  (light	  and	  heat)
Gas
Bio-­‐safety	  disposal
Other
TOTAL	  UTILITIES
Internet
Telephone
Post
TV	  and	  radio
Other
TOTAL	  COMMUNICATIONS
Stationery	  and	  general	  office	  supplies
Printing
Subscriptions
Packaging
Photocopying
Other	  admin	  costs
TOTAL	  ADMINISTRATIVE
INSTRUCTIONS:	  Annual	  expenditure	  from	  the	  '10.Recurrent	  Expenditure'	  data	  collection	  sheet	  should	  be	  pasted	  into	  column	  C	  in	  this	  data	  entry	  sheet.
Other	  recurrent	  expenditures
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INTERVENTION	  CLASS VACCINATION
INTERVENTION	  TYPE BCG	  Vaccination
PTB EPTB PTB EPTB PTB EPTB PTB EPTB PTB
REGIMEN
PHASE
Service	  output
Outpatient	  vaccinations
Outpatient	  cough	  triage
Outpatient	  screening	  visit
Outpatient	  diagnostic	  visit
Outpatient	  visit	  type	  1
Outpatient	  visit	  type	  2
Outpatient	  visit	  type	  3
Inpatient	  bed-­‐day	  type	  1
Inpatient	  bed-­‐day	  type	  2
Community	  vaccinations
Community	  screening	  visit
Community	  diagnostic	  visit
Community	  treatment	  visit
Service	  Description
TB
	  s
er
vi
ce
s
INTERVENTION	  POPULATIONS
Adult Child HIV+ High-­‐risk	  population
INSTRUCTIONS:	  The	  data	  from	  the	  '15.Service	  Description'	  sheet	  in	  the	  data	  collection	  tool	  should	  entered	  into	  the	  corresponding	  cell	  in	  this	  input	  sheet.
Quantity	  per	  patient	  (visits,	  beddays	  or	  tests)	  for	  year	  of	  assessment
TB	  CASE	  DETECTION	  &	  DIAGNOSIS
Passive	  Case	  Finding Intensified	  Case	  Finding	  -­‐	  cough	  triage Intensified	  Case	  Finding	  -­‐	  screening
Infant HIV+
First-­‐line	  drugs Second-­‐line	  drugs
Transportation	  mark-­‐up	  (within	  country),	  %
Drug/pharmaceutical	  product	  description
(medicine,	  strength,	  formulation,	  packaging)
Product	  code	  (eg	  
GDF) Unit	  of	  measure Strength
Unit	  of	  
measure
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐
84	  (28x3)
Per	  pack/blister
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐
(B)-­‐672
Per	  pack/blister
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐
(B)-­‐336
Per	  pack/blister
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  tablet(s),	  
Blister(s)
3-­‐FDC/RHE-­‐
150/75/275-­‐(B)-­‐672
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  tablet(s),	  
Blister(s)
3-­‐FDC/RHZ-­‐
75/50/150-­‐(B)-­‐84	  
(28x3)
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐
150/75/400/275-­‐(B)-­‐
672
Per	  pack/blister
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐
150/75/400/275-­‐(B)-­‐
336
Per	  pack/blister
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister
Price	  List	  for	  Drugs
INSTRUCTIONS:	  Copy	  and	  paste	  data	  from	  the	  '21.Price	  list-­‐Drugs'	  sheet	  in	  the	  data	  collection	  tool	  into	  the	  yellow	  cells.	  
Please	  enter	  a	  transportation	  and	  logistics	  mark-­‐up	  for	  the	  facility.
This	  sheet	  can	  be	  used	  to	  get	  prices	  on	  drugs	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	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Costing guidelines for Tuberculosis interventions96
■n Check that the list of drugs is being linked to the correct mark-up value based on 
which regimen they are used for. 
■n Also do a spot check of the calculations of the unit prices and costs per tablet/dose 
(local currency and USD) to ensure values from different rows are not being pulled 
in.
■n In this tool, drugs used to treat adverse events have not been included in the unit 
costs. 
■n If this data is easily available and one does not wish to lose it, one can enter them 
in the ‘DRUGS: vaccines’ section (rows 160–165).
Drugs top-down and Drugs bottom-up
■n Ensure that any edits or additions made to this sheet are replicated (with the same 
spelling and order) in Drugs top-down and Drugs bottom-up sheets.
Price list-equipment  
■n Vehicles, equipment and furniture costs can be found in the facility records and 
inflated to the costed year, or by contacting local medical and furniture supplies 
for prices. 
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 12a.Drugs	  TD
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Drug/pharmaceutical	  product	  description
(medicine,	  strength,	  formulation,	  packaging)
Product	  code Unit	  of	  measure Total	  annual	  quantities	  
disbursed	  for	  TB	  (in	  units)
Estimated	  expenditure
(local	  currency)
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  tablet(s),	  Blister(s) 3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  (28x3) Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐672 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  coated	  tablet(s),	  Blister(s) 4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐336 Per	  pack/blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
0 0 0 -­‐	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INSTRUCTIONS:	  Total	  quatity	  of	  drugs	  disbursed	  for	  TB	  should	  be	  taken	  from	  column	  E	  of	  the	  data	  collection	  sheet	  '16.Drug	  Services'	  and	  copied	  in	  the	  yellow	  cells	  of	  this	  data	  entry	  sheet.
NOTE:	  If	  any	  drug	  was	  added	  to	  the	  data	  collection	  sheets	  '16.Drug	  Services'	  and	  '21.Price	  list-­‐Drugs',	  please	  ensure	  that	  they	  are	  also	  included	  (extra	  yellow	  rows)	  in	  the	  appropriate	  section	  of	  this	  data	  entry	  sheet.
Drugs	  -­‐	  quantities
Value	  TB	  -­‐	  Estimating	  unit	  costs	  of	  TB	  services 12b.Drugs	  BU
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VACCINATION
BCG	  
PHASE
Price	  per	  dose	  
(local	  price) In
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e
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on
Drug/pharmaceutical	  product	  description
(medicine,	  strength,	  formulation,	  packaging)
Product	  code Unit	  of	  measure
Rifampicin/Isoniazid,	  Dispersible	  tablet(s),	  Strip(s) 2-­‐FDC/RH-­‐75/50-­‐(B)-­‐84	  (28x3) Per	  pack/blister 0.00
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐672 Per	  pack/blister 0.00
Rifampicin/Isoniazid,	  Film	  coated	  tablet(s),	  Blister(s) 2-­‐FDC/RH-­‐150/75-­‐(B)-­‐336 Per	  pack/blister 0.00
Rifampicin/Isoniazid/Ethambutol,	  Film	  coated	  
tablet(s),	  Blister(s)
3-­‐FDC/RHE-­‐150/75/275-­‐(B)-­‐672 Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide,	  Dispersible	  
tablet(s),	  Blister(s)
3-­‐FDC/RHZ-­‐75/50/150-­‐(B)-­‐84	  
(28x3)
Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐
672
Per	  pack/blister
0.00
Rifampicin/Isoniazid/Pyrazinamide/Ethambutol,	  Film	  
coated	  tablet(s),	  Blister(s)
4-­‐FDC/RHZE-­‐150/75/400/275-­‐(B)-­‐
336
Per	  pack/blister
0.00
Cat	  I	  &	  III	  Kit	  A,	  Film	  coated	  tablet(s),	  Blister(s) PK-­‐Cat	  I	  &	  III-­‐A Per	  blister 0.00
0 0 0 0.00
0 0 0 0.00
0 0 0 0.00
0 0 0 0.00
Infant
Quantities	  (doses)	  per	  (average)	  patient…
Adult
PTB EPTB PTB EPTB
Drugs	  -­‐	  Interview	  entry	  form
INSTRUCTIONS:	  For	  each	  TB	  regimen	  and	  phase	  the	  quantity	  of	  each	  drug	  (item)	  prescribed	  or	  given	  to	  an	  average	  patient	  should	  be	  obtained	  from	  the	  data	  collection	  sheet	  '16.Drug	  Services'.
If	  a	  drug	  used	   t	  this	  facility	  is	   ot	  included	  in	   he	  list,	  please	   ncluded	  i 	  at	  the	  bottom	  of	  the	  relevant	  section	  and	  add	  to	  the	  corresponding	  section	  in	  the	  'Price	  list-­‐Drugs'	  sheet	  in	  this	  tool.
1st	  Line	  TB	  TREATMENTINTERVENTION	  CLASS	  (TREATMENT	  ONLY)
INTERVENTION	  POPULATIONS
DS-­‐TB
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REGIMEN New	  and	  relapse Previously	  treated
Equipment	  or	  furniture	  name	  or	  description Manufacturer Model
Unit	  price
(local	  currency)
Unit	  price
(USD)
Useful	  life
(in	  years)
Analytical	  balance
Analytical	  balance	  (electronic)	  for	  DST
Autoclave	  -­‐	  horizontal
Autoclave	  -­‐	  vertical
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  1
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  2
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  3
Autoclave	  (basic	  unit	  for	  media	  kitchen)	  -­‐	  4
Automatic	  filling	  station
AVR	  (for	  autoclave)
BACTEC	  -­‐	  starter	  kit
BACTEC	  MGIT	  320	  System
BACTEC	  MGIT	  960	  system
BACTEC	  printer
Balance	  (analytical)
Balance	  (precision)
Balance	  (precision)	  -­‐	  electronic
Biosafety	  cabinet	  -­‐	  2	  filters
Biosafety	  cabinet	  -­‐	  3	  filters
Biosafety	  cabinet	  -­‐	  BSC	  Type	  II	  A
Biosafety	  cabinet,	  with	  horizontal	  laminar	  airflow	  
hood	  and	  UV	  light
Biosafety	  cabinet,	  with	  vertical	  laminar	  flow	  hood	  and	  
UV	  light
Blender	  with	  glass	  jar
Bottle	  washer
Camera	  1	  -­‐	  digital
Price	  List	  for	  Equipment	  and	  furniture
This	  sheet	  can	  be	  used	  to	  get	  prices	  of	  equipment	  from	  the	  facility	  or	  from	  a	  central	  source	  such	  as	  the	  Ministry	  of	  Health	  or	  Regional	  Health	  Authority.	  
INSTRUCTIONS:	  Please	  provide	  data	  for	  the	  yellow	  cells.	  The	  list	  of	  equipment	  is	  not	  exhaustive	  so	  please	  provide	  any	  additional	  equipment	  
or	  furniture	  that	  has	  been	  purchased	  for	  health	  facilities	  to	  provide	  TB	  services.
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Price list-supplies
■n Check that the calculations for the unit prices (local currency and USD) are not 
pulling values from different rows.
Notes
■n Any questions, unresolved issues or queries about unit cost values can be listed in 
this sheet. 
■n This provides one central place to store this information for each facility and 
incorporates the contact and resolution. 
Name	  or	  description	  of	  supply
Unit	  of	  
measure
Package	  
amount	  or	  
volume
Annual	  
Quantity
Price	  per	  package
(local	  currency)
Price	  per	  
package
(USD)
0.5-­‐10	  μl	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  
100-­‐1000	  μl	  pipette	  tips	  (Long	  tip)	  
10-­‐100	  μl	  tips	  
1-­‐20	  μl	  tips	  
1-­‐200	  μl	  pipette	  tips	  
1-­‐200	  μl	  tips	  
20-­‐200	  μl	  pipette	  tips	  
20-­‐200	  μl	  pipette	  tips	  
2ml	  standard	  reaction	  tube	  
Applicator	  stick	  (disposable)
BACTEC	  MGIT	  960	  AST	  transport	  rack	  –	  445942.	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  (100	  tests,	  PANTA	  and	  
BACTEC	  MGIT	  960	  Supplement	  Kit	  (PANTA	  and	  OADC	  
BACTEC	  MGIT	  OADC	  Kit	  for	  Manual	  MGIT	  Catalogue	  No:	  
BACTEC	  MGIT	  PANTATM	  Kit	  for	  Manual	  MGIT	  Catalogue	  
BACTEC	  MGIT	  PZA	  kit
BACTEC	  MGIT	  PZA	  tubes
BACTEC	  MGIT	  S.I.R.E.	  Kit	  for	  Manual	  MGIT	  Catalogue	  No:	  
BACTEC™	  MGIT™	  960	  SIRE	  kit,	  One	  kit	  is	  sufficient	  for	  40	  
Bags	  for	  waste	  bin	  –	  30	  Litres	  
Bags	  for	  waste	  bin-­‐	  2	  Litres	  
Balloon	  HDPE	  -­‐	  10l
Balloon	  HDPE	  -­‐	  30l
BBL	  MGIT	  Tubes	  for	  use	  in	  Bactec	  MGIT	  960	  (7ml)	  -­‐	  100	  
BCG	  vaccines
Price	  list	  for	  Supplies
INSTRUCTIONS:	  Any	  additional	  supplies	  that	  are	  not	  already	  included	  in	  this	  sheet	  should	  be	  added	  to	  the	  bottom	  of	  the	  appropriate	  section.
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Sheet	  name Outstanding	  data	  or	  question Who	  to	  ask
Notes	  or	  outstanding	  issues
Figure 11. Shared above service level costs
Weighting based on staff numbers:
2 staff at this facility working on TB
= 100 000*2/12
=$16 667 above service level cost for facility 1
3 staff at this facility working on TB
= 100 000*3/12
=$25 000 above service level cost for facility 2
1 staff at this facility working on TB
= 100 000*1/12
=$8 333 above service level cost for facility 3
2 staff at this facility working on TB
= 100 000*2/12
=$16 667 above service level cost for facility 4
4 staff at this facility working on TB
= 100 000*4/12
=$33 333 above service level cost for facility 5
Above service level  
cost for district 
= $100 000
 Only 5 laboratories  
in the district with a  
total of 12 staff 
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B. Generation of unit costs
Service statistics caters for some these allocation calculations
■n The percent allocation of healthcare worker time spent on TB directly is calculated 
from the timesheets, adding together the values by facility department (Outpatient, 
Inpatient, Community, Other TB, Admin & Management, Other Overhead and 
Pharmacy). 
■n It then allocates a proportion of the total for each department to the service 
outputs provided in that department, then allocates to each department based on 
the proportion of time spent on TB in the entire facility.
■n It estimates the number of minutes for all TB services, i.e. minutes per service 
(derived from either observation or interview) * number of each TB service output. 
■n The tool then allocates a proportion of the services within the relevant department 
to each service output type in that department.
■n It provides the size of the facility departments allocated to TB services and column 
M then calculates the proportion of all facility space used for TB by department.
■n It calculates the proportion of services utilized for each service output within each 
facility departments.
■n The ‘Drug wastage factor’ is documented
■n The human resources bottom-up to top-down (HR bottom-up/top-down) capacity 
adjustment factor documents what proportion of the top-down estimate of staff 
time use is equivalent to the bottom-up estimate of staff time use.
Capacity adjustment factor
■n The HR BU/TD capacity adjustment factor, automatically generated in the 
Data Entry Tool, tells us what proportion of the top-down estimate of staff time 
use is equivalent to the bottom-up estimate of staff time use.
■n The numerator is the total hours per week estimated using the bottom-up approach 
for all TB services in the facility = [(Total minutes in the year for all TB services) + 
(an administration factor for admin & management, other overhead and pharmacy 
costs), converted to hours per week].
Year	  of	  data	  (latest	  financial	  or	  calendar	  year)
Unit Annual	  quantity	  -­‐	  entire	  facility Annual	  quantity	  -­‐	  TB	  services	  only
Outpatient	  visits
TB	  Clinic
MCH	  Clinic
Paediatric	  Clinic
HIV	  Clinic
Chronic	  Disease	  (diabetes)	  Clinic
Comprehensive	  Care	  Clinic
Inpatient	  beddays
Inpatient	  admissions
Laboratory	  tests	  (all	  labs)
Microbiology	  Lab	  -­‐	  tests
Bacteriology	  Lab	  -­‐	  tests
Laboratory:	  main	  (clinical	  path,	  incl	  haematology)	  -­‐	  tests
Area	  for	  blood,	  serum,	  plasma	  collection	  -­‐	  samples
Area	  for	  sputum	  sample	  collection	  -­‐	  samples
Area	  for	  AFB	  and	  GeneXpert	  -­‐	  tests
Area	  for	  biopsy	  -­‐	  tests
Area	  for	  LPA	  -­‐	  tests
Laboratory:	  culture	  -­‐	  tests
Radiology	  tests
Service	  Statistics	  and	  Allocation	  Keys
INSTRUCTIONS:	  Copy	  and	  paste	  data	  from	  the	  '14.Service	  Statistics'	  sheet	  in	  the	  data	  collection	  tool.
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■n The denominator is the total hours per week estimated using the top-down 
approach for all TB services in the facility = (total working hours per week over the 
year for staff included in the study * proportion of their working hours per week 
over the year allocated to TB) * 80%.
■n If HR bottom-up/top-down capacity adjustment factor <1, the bottom-up 
estimates are lower than the top-down estimates.
■n If HR bottom-up/top-down capacity adjustment factor >1, the top-down 
estimates are lower than the bottom-up estimates.
Summary bottom-up, Summary top-down, Patient top-down, Patient bottom-up
Results (automatized in Data Entry Tool): unit cost generation: 
■n Summary top-down, Summary bottom-up, and Patient bottom-up sheets 
show intermediate results. They are auto-populated and do not need the analyst to 
do anything, as the formulae generate unit costs for the facility.
■n The bottom-up approach to costing these items is by auditing/counting how many 
there are within the facility. 
■n The allocation of these costs to TB services is standardized within the sheets. 
First estimation is done through output (i.e. visits) and then cost per patient is 
estimated in the Patient top-down and Patient bottom-up sheets. 
■n This sheet calculates the bottom-up unit costs for an average patient by pulling 
in the service output bottom-up unit costs (from Summary bottom-up) and the 
quantities of each output per patient Service description.
■n To check the sheet, do a spot check to ensure the formulae are pulling in the correct 
values and that there are no missing or error values due to missing unit cost or 
quantity data.
■n The top-down approach would list all the equipment and furniture (or expenditure 
of all the equipment and furniture) and allocate these to TB services using a 
standardized allocation factor specific to the different inputs.
■n This sheet multiplies the top-down unit costs of the service outputs (from 
Summary top-down) by the quantity of each service output (from Service 
description) for an average patient for each of the populations and regimen 
within each intervention type. 
■n The patient costs are also provided by phase of treatment and includes the costs of 
drugs specific to the regimen and phase.
■n To check the results in this sheet, the analyst will do a spot check to ensure the 
cells contain the correct values and that there are no missing or error values due to 
missing unit cost or quantity data.
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Summary top-down
Total costs for TB services are allocated for different input categories: The 
allocation criteria for the input categories comprising the unit costs is indicated. 
A stepped approach has been used to obtain the unit costs for each cost centre and 
service output:
1. (columns C–S): costs are initially pulled in from the departments for the equip-
ment/furniture, training, staff, and supplies input categories. 
 For the remaining inputs, the costs are allocated based on the criteria indicated 
in row 5. For example, for ‘Building space’ (column C), the total economic costs 
allocated to each department are pulled in from Buildings space, then within 
each department these costs are allocated to each service output using the services 
statistics allocation keys in Service statistics (column I). 
 The same process is repeated for vehicles; other (non-medical) supplies; capital 
maintenance; utilities; fuel and other recurrent transport (including maintenance 
and courier services); food (including food services), supplements; including food 
services; and other recurrent.
 The costs of drugs have not been included in the summary sheets but pulled in to 
the Patient top-down sheet.
2. (columns T–AJ): administration and management, other overhead and pharmacy 
costs (columns C–S) are allocated to each department based on the TB versus total 
facility service utilization. Then these department costs are allocated based on the 
quantity of service outputs provided in that department for the year.
3. (columns AK-BA): direct costs (columns C–S) and administration and management, 
other overhead and pharmacy costs (columns T–AJ) are summed.
4. (column BB): ‘unit’ or service output quantities are pulled in from Service 
statistics.
5. (columns BC–BS): the unit costs are calculated by dividing the total unit costs 
(columns AK–BA) for each service output by the total units for each service output.
6. (column BT): total unit cost for each service output is obtained by adding the unit 
cost for each input. 
■n There are check cells in row 92 of this sheet.
Allocation	  criteria Service	  statistics Direct Direct Direct Service	  statistics
Cost	  Centres/	  Services Buildings
Laboratory	  and	  
Medical	  
equipment Other	  equipment Furniture Vehicles
OVERHEAD	  AND	  SUPPORT	  DEPARTMENTS 0.00 0.00 0.00 0.00 0.00
Admin	  and	  management	   0.00 0.00 0.00 0.00 0.00
Other	  overheads 0.00 0.00 0.00 0.00 0.00
PHARMACY 0.00 0.00 0.00 0.00 0.00
OUTPATIENT	  SERVICES 0.00 0.00 0.00 0.00 0.00
Outpatient	  vaccinations 0.00 0.00 0.00 0.00 0.00
Outpatient	  cough	  triage 0.00 0.00 0.00 0.00 0.00
Outpatient	  screening	  visit 0.00 0.00 0.00 0.00 0.00
Outpatient	  diagnostic	  visit 0.00 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  1 0.00 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  2 0.00 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  3 0.00 0.00 0.00 0.00 0.00
INPATIENT	  SERVICES 0.00 0.00 0.00 0.00 0.00
INSTRUCTIONS:	  DO	  NOT	  ENTER	  DATA	  IN	  THIS	  SHEET.
This	  sheet	  presents	  the	  top-­‐down	  unit	  costs	  of	  service	  outputs.
Summary	  Costs	  -­‐	  TOP-­‐DOWN	  (Economic)
CAPITAL	  
ALL	  Departments
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■n If the values in this row do not match that of the summary values in rows 90 and 
91, check the calculations and values in the preceding cells and related sheets for 
errors such as missing data or broken links.
■n The unit costs of the service outputs and the summary costs for each input should 
be reviewed to assess reasonableness of the calculated values with respect to the 
local context and cost composition.
Summary bottom-up
Total Unit Cost for each service output – bottom-up approach: Step 1 for this 
sheet is an additional step. The subsequent steps follow a similar approach to that of 
steps 1–6 of the Summary top-down sheet.
1. (columns C–J): For each service output, the direct unit costs obtained from the 
bottom-up methods of data collection (observation or interview) are pulled 
in directly for the equipment, staff and supplies input categories (sheets 7b on 
Equipment BU, 10b on Staff bottom-up and 13b on Supplies bottom-up, 
respectively).
2. (columns K–AA): 
a. For the input categories that were not measured using a bottom-up approach, 
the top-down values (Summary top-down, columns C–S) are multiplied by 
the HR bottom-up/top-down capacity adjustment factor
b. For inputs the equipment, staff and supplies inputs, the direct unit costs are 
multiplied by the total unit quantity for each service output. The unit cost for 
the department is the sum of the unit costs for the service outputs provided in 
that department.
3. (columns AB–AR): the admin & management, other overhead and pharmacy costs 
(columns K–AA) are allocated to each department based on the TB versus total 
facility service utilization. Then these department costs for each service output are 
allocated based on the quantity of the service outputs provided in that department 
for the year.
Allocation	  criteria Direct Direct Direct
Observation	  or	  
Interview
Cost	  Centres/	  Services
Laboratory	  and	  
Medical	  
equipment Other	  equipment Furniture Clinical	  staff
OVERHEAD	  AND	  SUPPORT	  	  DEPARTMENTS
Admin	  and	  management	  
Other	  overheads
PHARMACY
OUTPATIENT	  SERVICES 0.00 0.00 0.00 0.00
Outpatient	  vaccinations 0.00 0.00 0.00 0.00
Outpatient	  cough	  triage 0.00 0.00 0.00 0.00
Outpatient	  screening	  visit 0.00 0.00 0.00 0.00
Outpatient	  diagnostic	  visit 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  1 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  2 0.00 0.00 0.00 0.00
Outpatient	  visit	  type	  3 0.00 0.00 0.00 0.00
INPATIENT	  SERVICES 0.00 0.00 0.00 0.00
INSTRUCTIONS:	  DO	  NOT	  ENTER	  DATA	  IN	  THIS	  SHEET.	  
This	  sheet	  presents	  the	  bottom-­‐up	  unit	  costs	  of	  service	  outputs.
Summary	  Costs	  -­‐	  BOTTOM-­‐UP	  (Economic)
DIRECT	  UNIT	  COSTS	  PULLED	  IN	  FROM	  OBSERVATIONS	  /	  INTERVIEWS
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4. (columns AS–BI): direct costs (columns K–AA) and admin & management, other 
overhead and pharmacy costs (columns AB–AR) are summed.
5. (column BJ): ‘unit’ or service output quantities are pulled in from Service 
statistics.
6. (columns BK–CA) – the Unit Costs for each service output is calculated by dividing 
the total unit costs (columns AK–BA) for that output by the total units (quantity).
7. (column CB): Total Unit Cost for each service output is obtained by adding the unit 
cost for each input.
■n There are check cells in row 92 of this sheet. 
■n If the values in this row do not match that of the Summary values in rows 90 and 
91, check the calculations and values in the preceding cells and related sheets for 
errors such as missing data or broken links.
■n The unit costs of the service outputs and the summary costs for each input should 
be reviewed to assess reasonableness of the calculated values with respect to the 
local context and cost composition.
Patient top-down
Calculate unit cost for an average patient – top-down: 
■n This sheet multiplies the top-down unit costs of the service outputs (from 
Summary top-down) by the quantity of each service output (from Service 
description) for an average patient for each of the populations and regimen 
within each intervention type. 
■n The patient costs are provided by phase of treatment and include the costs of drugs 
specific to the regimen and phase.
■n To check the sheet, do a spot check to ensure the formulae are pulling in the correct 
values and that there are no missing or error values due to missing unit cost or 
quantity data.
INTERVENTION	  CLASS VACCINATION
INTERVENTION	  TYPE BCG	  Vaccination
PTB EPTB PTB EPTB PTB
REGIMEN
PHASE
Outpatient	  vaccinations 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  cough	  triage 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  screening	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  diagnostic	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  visit	  type	  1 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  visit	  type	  2 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  visit	  type	  3 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Inpatient	  bed-­‐day	  type	  1 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Inpatient	  bed-­‐day	  type	  2 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  vaccinations 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Com unity	  screening	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  diagnostic	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  treatment	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  other	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  event 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Lost	  to	  follow-­‐up	  tracing	  per	  person	  on	  contact	  list	  
(phone	  calls)
	  	  
-­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
INTERVENTION	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Patient bottom-up
Calculate unit cost for an average patient – bottom-up: 
■n This sheet calculates the bottom-up unit costs for an average patient by pulling 
in the service output bottom-up unit costs (from Summary bottom-up) and the 
quantities of each output per patient (Service description).
■n To check the sheet, do a spot check to ensure the formulae are pulling in the correct 
values and that there are no missing or error values due to missing unit cost or 
quantity data.
Datasets are produced per facility
■n Each data set from a facility will be analysed with traditional statistical packages 
to meet the study objectives.
Dataset output
■n This sheet contains the unit costs of all the service outputs presented by inputs. 
■n The quantities and prices of building space and staff time have also been presented 
for each service output. 
■n They are presented in a dataset format to allow for easy uploading into statistical 
software and for publication in the GHCC database.
INTERVENTION	  CLASS
	  VACCINATI
ON	  
INTERVENTION	  TYPE 	  BCG	  
	  PTB	   	  EPTB	   	  PTB	   	  EPTB	  
REGIMEN
PHASE
Outpatient	  vaccinations 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  cough	  triage 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  screening	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  diagnostic	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatie t	  visit	  type	  1 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  visit	  type	  2 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Outpatient	  visit	  type	  3 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Inpatient	  bed-­‐day	  type	  1 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Inpatient	  bed-­‐day	  type	  2 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  vaccinations 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  screening	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  diagnostic	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  treatment	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
Community	  other	  visit 	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  	  	  	  	  	  	  	  	  	  	  	  	  
TB
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Cost	  per	  patient	  -­‐	  BOTTOM-­‐UP
INSTRUCTIONS:	  DO	  NOT	  ENTER	  DATA	  IN	  THIS	  SHEET.
QUANTITY	  PER	  PATIENT	  (visits,	  beddays	  or	  tests)	  for	  year	  of	  assessment
	  UNIT	  COST	  
PER	  
OUTPUT	  	  
TB	  CASE	  DETECTION	  &	  DIAGNOSIS
	  Passive	  Case	  Finding	  
INTERVENTION	  POPULATIONS
	  Infant	   	  Adult	   	  Child	  
Dataset	  output	  costs
Country Facility	  name
Geography	  1	  -­‐	  
urbanicity	  
(see	  
dropdown) Geography	  2 Geography	  3
Facility	  level	  (see	  
dropdown)
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
COUNTRY	  A 0 0 0 0 0
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Dataset patient 
■n This sheet contains the unit costs for each patient receiving vaccination, TB case 
detection and diagnosis, TB treatment and TB prevention by the service outputs. 
■n Both the top-down and bottom-up costing approaches are presented, along with 
financial and economic costs. 
■n Intervention class, type, populations, regimen and phase for both top-down and 
bottom-up costing approaches, as well as the financial and economic costs, are 
calculated. 
Dataset	  patient	  costs
Country
Facility	  name
Geography	  
(see	  
dropdown)
Facility	  level	  
(see	  
dropdown)
Ownership	  
(see	  
dropdown)
Size	  
(approximat
e)	  of	  facility	  
buildings	  
(m2)
Total	  
hospital	  beds	  
(inpatient)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
COUNTRY	  A 0 0 0 0 0 (all)
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Appendix 9. Non-exhaustive list of unit cost 
per patient per output, top-down and  
bottom-up generated by the data entry tool 
ALT also known as SGPT
Aspirates (EPTB)
AST also known as SGOT
Body fluid analysis PCR-DNA (children)
Bronchial lavage (children)
CD4 count
Creatinine
Creatinine clearance
Culture (liquid media) [e.g.: MB/Bact 
Alert, Bactec MGIT 960]
Culture (solid medium) [e.g.: 
Lowenstein-Jensen, Ogawa or 
Stonebrink]
Digital x-ray
DST – FLD (liquid media) (isoniazid, 
rifampicin, ethambutol, streptomycin)
DST – FLD (solid media) (isoniazid, 
rifampicin, ethambutol, streptomycin)
DST – SLD (liquid media) 
(fluoroquinolone injectables)
DST – SLD (solid media) 
(fluoroquinolone injectables)
ECG
Erythrocyte sedimentation rate
Fine needle biopsy (children)
Full haemogram (red blood cell, white 
blood cell and platelet tests)
Gastric lavage (children)
Glucose (RBS)
HIV confirmatory test
HIV rapid test
IGRA
Lactic acid
LAMP
LF- LAM (rapid antibody or antigen 
detection tests for TB)
Lipase
LPA – FLD
LPA – SLD
Microscopy (ZN)
Sputum induction
Thyroid stimulating hormone
Total white blood cell count
TST or PPD or Mantoux test
X-ray (film)
Xpert® MTB/RIF
Community diagnostic visit
Community event
Community other visit
Community screening visit
Community treatment visit
Community vaccinations (BCG 
vaccination)
Inpatient bed-day
Lost to follow-up tracing (using phone 
calls) 
Outpatient cough triage
Outpatient diagnostic visit
Outpatient screening visit
Outpatient vaccinations (BCG 
vaccination)
Outpatient visit
Patient support during diagnosis
Patient support during treatment 
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Appendix 10. Terms of reference  
for the study team 
The below terms of reference are an example taken from the Value TB Study. 
DATA COLLECTION TEAM DUTIES AND QUALIFICATIONS 
It is anticipated that cost data will be collected from between 15–25 providers of TB 
services and interventions nationally  (both health facilities and laboratories). The 
data collection process involves visits to each site lasting between 1–3 days depending 
on the size and type of provider. The data collection instrument will examine financial 
and TB service records. In addition, all rooms and equipment used for TB will be listed. 
Finally, staff will be interviewed about their time spent on different activities. In some 
cases, activities will be observed. In addition, data collectors will need to collect data 
on local prices of salaries, supplies and equipment costs. The data collection process 
will be piloted in a small number of sites in the first instance  (in approximately 
2 sites). This will be followed by a detailed costing in approximately 5 sites. All data 
will be entered electronically into mobile phones or tablets. 
The study team will comprise of the VALUE-TB principal investigator (PI) and local 
PI  (hereafter referred to as ‘VALUE-TB PI’ and ‘PI’ respectively)  who will joint-
ly lead the study. Due to the large scale of the study, it is envisaged that  at least 
2 research assistants will be required over a period of one year, with a local consult-
ant or member of the National TB Programme (NTP) in a supervisory role (PI). It is 
expected that these 2 research assistants would each collect data from approximate-
ly 15–25 facilities over a period of one year (working full time for 40 hours a week, 
with approximately 1 week per facility). 
Roles/responsibilities of the NTP 
a. Work with the VALUE-TB team to identify local consultants. Specifically, the NTP 
should identify an appropriate local PI and a data collection/analysis team. 
ba. Work with the VALUE-TB team to design the study protocol so that it meets local 
needs. 
c. Host workshops to train data collectors, provide logistical  support, and facil-
itate  access to providers to enable data collection activities  including retrieving 
salary and expenditure data. 
d. Support the process of local ethics submission and provide local oversight for the 
study. 
e. Attend and contribute to a data analysis workshop in Geneva. 
f. Facilitate dissemination of key findings and aid translation of research into policy. 
g. Contribute and where relevant lead the write up of results. 
Country Principal Investigator (PI) (approximately half time position,  
0.5 FTE over 1 year) 
Each national VALUE TB provider cost collection should have a designated principal 
investigator (PI). More than one PI can also be nominated. The PI(s) should be a senior 
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person from the Ministry of Health and/or the contracted external organization 
who has both TB experience and experience in overseeing and managing research or 
health facility-based data collection. The PI assumes overall responsible for all data 
collection  activities and is a nominated person on the protocol and in any ethics 
committee applications. 
If no data collection manager is assigned then the day-to-day management of the cost 
collection is the responsibility of the PI. This entails managing the implementation of 
the cost collection. If possible, this person should be actively involved in the design of 
the study. The PI supervises the work of research assistants who collect the data. For 
this to happen, there needs to be close collaboration between the PI and the research 
assistants in the field via either direct supervision or regular reports from the staff or 
online cost collection tool that allow for quality control. 
If no data manager is assigned  then the PI  is responsible for  flagging quality data 
issues periodically and  managing the data collected by  research assistants. This 
person should have some expertise in data management for cost collection or public 
health research and prior experience in managing data would be highly beneficial. The 
majority of countries will collect data in an online tool. If this is the case, the PI should 
be familiar with the online data collection system and should be able to troubleshoot 
and rectify any data collection problems. 
Roles and responsibilities 
■n Oversees the development of the research protocol and ethical clearance 
■n Acts as a liaison person for communication with partners and stakeholders outside 
the data collection team, with staff from the NTP, the public health service, local 
research institutions and other government departments.  Manages  funding 
for the  data collection and funding reports, ensuring that funds are managed 
according to national procedures 
■n Assembles the data collection team that has all the expertise needed to design, 
implement, and analyse the TB provider cost data
■n Liaises with the research assistants on a frequent basis and oversees their work 
■n Maintains and ensures the quality of the study’s conduct and writes the final study 
report and ensures that it is disseminated to the key stakeholders identified during 
the stakeholder analysis 
■n Convenes jointly with NTP the dissemination of results with stakeholders (health and 
non-health) 
■n Establishes contact with facilities sampled for the study and facilitates the 
welcoming of the research assistant and the key information providers within 
each facility. 
■n Oversees the day-to-day management of the data collection 
■n Assists in the design of the data collection together with the VALUE TB PI 
■n Adapts training manual and cost collection materials 
■n Prepares standard operating procedures 
■n Trains research assistants before data collection and provides retraining if mid-
term review identifies such a need 
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■n Supervises the work of data collection research assistants through on-site visits or 
through periodic reports 
■n Monitors the operational implementation of the data collection 
■n Flags data quality issues periodically (i.e. every two weeks) to  VALUE  TB 
PI and completes regular data management reports 
■n Adapts the electronic data collection instrument (with validation by VALUE TB PI) 
in an effective and feasible manner to support the cost collection 
■n Coordinates data management activities for the  cost collection: receiving, 
batching, cleaning, and merging data from different sources (e.g. NTP regarding 
prices vs data collection for diagnostic tools) 
■n Is responsible for the validation of double-entered data files 
■n Ensures that data are properly stored and backed up 
■n Checks validated data files regularly  (weekly if electronic)  for systematic errors 
(cleaning) 
■n Prepares database to be ready for analysis and data entry screens 
■n Contributes to the analysis of results 
Key tasks 
■n Adapts and develops the protocol  as per methodology developed by VALUE  TB 
team and with input from the VALUE TB PI, NTP and National Technical Advisory 
Group (as needed) 
■n Drafts letter with the NTP manager (and WHO) addressed to facilities involved in 
the study to communicate the purpose of the study and request facility managers 
to share the information requested by the research assistant (which may be listed 
in the letter) 
■n Ensures that  cost data collection  and analysis are conducted according to the 
protocol and the plan 
■n Discusses any problems encountered during the data collection, and then proposes 
and decides on feasible solutions, in collaboration with the data collection team 
and the technical advisory group (if needed) 
■n Endorses the TB provider cost results 
■n Translates study results into policy recommendations 
■n Engages with NTP for results dissemination 
■n Coordinates overall implementation of cost collection in the field 
■n Plans the field implementation and required training, including preparation of 
training materials as appropriate 
■n Contacts and coordinates with local authorities 
■n Ensures quality assurance processes are implemented according to the protocol 
■n Supervises implementation in the health facilities and laboratories 
■n Plans and co-ordinates data collection monitoring visits comprising all partners 
involved in data collection implementation 
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■n Oversees the provision of supplies and required materials 
■n Involved in the analysis of the results 
■n Organizes the writing of activity reports and the final report 
■n Plans the detailed budget of the cost collection and periodically reports to funders 
on funds utilization (as per contract) 
■n Provide any logistic support for the cost collection team 
■n Arrange pilot-testing and its evaluation 
■n Liaise with local officials in the health care facilities and laboratories (during pre-
cost collection visits and actual field work) 
■n Report without delay any major problems in preparation, execution or data 
management of the cost collection 
Qualifications 
■n Preferably at least 5 years of managerial experience in the field of public 
health preferably with costing or health economics experience 
■n Strong managerial skills, including being able to delegate tasks 
■n Extensive knowledge of TB management including the context in which the data is 
being collected 
■n Knowledge of laboratory and facility-based costing 
■n Working within or having access to an organization that has an infrastructure 
that can support 
■n Facility-based costing in the field 
Research assistants (2 FTE over 1 year may cover 15–25 facilities each) 
The  research assistants  will be based at the health facilities and  laboratories  for 
a period of one week per facility and  will conduct  the  data  collection  mostly 
regarding  quantities  of resources used in TB prevention,  diagnosis and care. They 
will need to be employed for the cost collection and cleaning periods and may or may 
not need to be full time depending. The research assistants should have good social 
and communication skills and should be thoroughly trained in costing techniques and 
the  Data Collection Tools. The  research assistants  should also have the ability to 
manage technology if the online Data Collection Tool is used. 
Roles and responsibilities 
■n Carries out interviews with TB  providers  with due respect for privacy and 
confidentiality 
■n Analyses client registers, financial records, pharmacy/laboratory  records, and 
other TB-related documentation and extracts required information from them 
■n Enters, manages, and keeps economic data collected from the field 
■n Participates in data cleaning and analysis with support from the PI 
■n Communicates promptly with study coordinator on any bottlenecks arising 
(technical or managerial) 
Costing guidelines for Tuberculosis interventions110
Qualifications 
■n Prior experiences in cost collection desirable 
■n Demonstrated good computer skills in Microsoft Excel and Word packages 
■n Good knowledge of the Kenyan health system 
■n Fluent in the local language spoken in the cluster or health facility 
■n Good administration and organizational skills 
■n Well-developed social and communication skills, particularly with regards to staff 
■n Prior experience in undertaking field work for public health research or facility 
based costing 
Technical advisory group 
The technical advisory group advises the PI  on all technical aspects of the  cost 
collection  and also  on issues such as the  cost collection  approval and acceptance 
process. It provides technical input (statistical, epidemiological and health economics) 
into all activities for which the PI is responsible and consists of experts in these fields. 
Collaboration with the technical advisory group is substantial during the design and 
adaptation of the protocol, but ad-hoc during actual data collection. Members of the 
technical advisory group perform these activities on a part-time basis. Their workload 
will be different in different phases of the survey, ranging from ad hoc meetings 
during the implementation to more intensive involvement during the design or the 
analysis phase. The technical advisory group may include international experts. The 
suggested composition of the national technical advisory group and terms of reference 
are provided below. 
In the initial stages, for the purpose of the generic TB provider cost collection instru-
ment  and guidelines  and to ensure consistency across  cost collection  conducted in 
different countries with a common methodology, there will also be an international 
technical advisory group which will be coordinated by  the VALUE  TB Team. 
Involve ment of the international advisory group will also be  more  substantial 
when  supporting  the translation of results into policy recommendation and the 
dissemination of results.  Data will become part of the GHCC data repository after 
dissemination. This is an open access database which can be freely accessed. The 
purpose of this sharing is to enable cost to be generalized to other settings where unit 
costs are not yet available. 
Composition of national technical advisory group 
■n Social scientist/epidemiologist/survey expert 
■n Health economist/analyst 
■n Statistician or data analyst 
■n International development agencies 
■n Private sector
■n Civil society
■n Health insurance
■n WHO Country Office
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Terms of reference for the national tuberculosis advisory group 
■n Advise on the cost collection 
■n Advise on the design, pre-testing and production of  costing materials (e-survey 
instrument design, SOP revision, etc.) 
■n Provide technical assistance during training and pilot-testing 
■n Provide ad-hoc advice to data collection co-ordinator during cost collection imple-
mentation based on preliminary data analysis, monitoring missions
■n Support local data manager and PI in analysis of results 
■n Provide feedback on interpretation of results, results dissemination strategy, and 
policy implications and follow-up 
OTHER POTENTIAL TEAM MEMBERS 
Data collection co-ordinator 
The day-to-day management of the  cost collection  is the responsibility of the  data 
collection co-ordinator who may be a Ministry of Health staff member or someone 
from an external organization. The data collection co-ordinator should report to the 
PI. The main work of the data collection co-ordinator is managing the implementation 
of the cost collection. If possible, this person should be actively involved in the design 
of the study. 
The data collection co-ordinator supervises the work of research assistants who collect 
the data. For this to happen, there needs to be close collaboration between the data 
collection  co-ordinator and the  research assistants  in the field via either direct 
supervision or regular reports from the staff or online cost collection tool that allow 
for quality control. The work of the data collection co-ordinator can be substantial, 
and the position may need to be half time or more. 
Roles and responsibilities 
■n Establishes contact with facilities sampled for the study and facilitates the 
welcoming of the research assistant and the key information providers within 
each facility. 
■n Oversees the day-to-day management of the data collection 
■n Assists in the design of the data collection 
■n Adapts training manual and cost collection materials 
■n Prepares standard operating procedures 
■n Trains research assistants before data collection and provides retraining if mid-
term review identifies such a need 
■n Supervises the work of data collection research assistants through on-site visits or 
through periodic reports 
■n Monitors the operational implementation of the survey 
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Key tasks 
■n Coordinates overall implementation of cost collection in the field 
■n Plans the field implementation and required training, including preparation of 
training materials as appropriate 
■n Together with the PI, contacts and coordinates with local authorities 
■n Ensures quality assurance processes are implemented according to the protocol 
■n Supervises implementation in the health facilities and laboratories 
■n Plans and co-ordinates data collection monitoring visits comprising all partners 
involved in data collection implementation 
■n Oversees the provision of supplies and required materials 
■n Involved in the analysis of the results 
■n Organizes the writing of activity reports and the final report 
■n Plans the detailed budget of the cost collection and periodically reports to funders 
on funds utilization (as per contract) 
■n Provide any logistic support for the cost collection team 
■n Arrange pilot-testing and its evaluation 
■n Liaise with the PI on a regular basis, and provide the PI with updates 
■n Liaise with local officials in the health care facilities and laboratories (during pre-
cost collection visits and actual field work) 
■n Report without delay any major problems in preparation, execution or data 
management of the cost collection 
Qualifications 
■n Preferably at least 3 years of research experience in the field of public health 
■n Strong managerial and coordination skills 
■n Knowledge of public health research and health economics 
■n Knowledge of TB 
■n Expertise in field work 
■n Experience in planning and conducting cost data collection or health facility data 
collection 
Data manager 
The data manager is responsible for flagging quality data issues periodically to data 
collection co-ordinator and managing the data collected by research assistants. This 
person should have some expertise in data management for cost collection or public 
health research and prior experience in managing data would be highly beneficial. 
The majority of countries will collect data in an online tool. If this is the case, the 
data manager should be familiar with the online data collection system and should 
be able to troubleshoot and rectify any data collection problems. Depending on the 
composition of the data collection team, the data manager will usually report to the 
PI or the data collection co-ordinator. 
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Roles and responsibilities 
■n Flags data quality issues periodically (i.e. daily/bi-weekly) to  PI  and  completes 
regular data management reports 
■n Adapts the electronic data collection instrument (with supervision  from PI and 
validation by VALUE TB PI) in an effective and feasible manner to support the cost 
collection 
■n Coordinates data management activities for the  cost collection: receiving, 
batching, cleaning, and merging data from different sources (e.g. NTP regarding 
prices vs data collection for diagnostic tools) 
■n Is responsible for the validation of double-entered data files 
■n Ensures that data are properly stored and backed up 
■n Checks validated data files regularly for systematic errors (cleaning) 
■n Prepares database to be ready for analysis and data entry screens 
■n Contributes to the analysis of results (led by PI) 
■n Liaises with the data collection co-ordinator on a regular basis 
■n Reports without delay any problems encountered in data management 
Qualifications 
■n Proven experience in leading and motivating teams 
■n Proven extensive experience with health facility based  costing  or public health 
research 
■n Experience in analysing data to provide summary statistics 
■n Experience in troubleshooting data collection problems including the identification 
of systematic entry and ad hoc errors 
■n Good administrative skills including maintenance of adequate documentation 
for costing or public health research
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Appendix 11. Three Case Studies 
Case study 1: Description of work flow within a Kenyan clinic
Here is an example of a peri-urban clinic that was visited for a morning to understand 
the workflow and flow of patients. 
This clinic is situated in the outskirts of Nairobi on a dirt road (with potholes and 
stones) with market stalls on either side of the road. There are gates to the clinic that 
stand open and are opened further by unarmed security for cars. The area is described 
by the clinic staff as a township and ‘shanty’ (area of informal housing).
The main clinic is a brick and concrete structure with grass outside and a covered 
outdoor waiting area. The small laboratory is housed in a shipping container with wide 
windows and no running water. Lights are on in the corridor. Posters are stuck on the 
walls with health messages, a staff list, diagnostic algorithms etc. 
Patients wait in a separate area outside under a shelter (roof that protects them from 
the sun and rain). The TB clinic is situated in the main clinic building in room that 
is accessed from a separate door. The HIV services are provided in a room diagonally 
across from the TB room and one can see inside when the doors are open. The patients 
hand the staff their yellow TB patient cards through the open windows (through bur-
glar bars). Staff speak to the patient (in Kiswahili) through the open window. The TB 
nurse (deputy in charge (the in-charge sister was absent from the clinic this particular 
morning)) checks the TB register and patient card. The patient enters the facility and 
is weighed in the passageway by a staff member. The patient sits on a chair a metre 
away from the TB nurse. Two counsellors are also involved in TB services (however 
were not present on the initial visit to this facility). A separate patient costing study 
(led by WHO) is underway at the facility and a data collector was present in the TB 
clinic room. 
Patients are given their anti-tuberculosis medication weekly from pre-packed boxes 
which have a unique identifier (patient initiation date) written on the side of the box. 
Boxes are stored on a shelf in the consultation room. The pre-packaging is done a 
central public dispensary. Treatment is observed (daily) at home by a treatment 
support partner or by a community health care worker. Nutrition packages (maize 
flour and peanut butter) are given if a patient’s body mass index (BMI) is below a 
threshold of 18. Masks are used when initiating a patient (although this was not 
observed as no new patients were seen).
A small laboratory is situated outside with two laboratory technicians (only one was 
present). Microscopy specimens are decontaminated, the slides are prepared and are 
then read under an electron microscope (two are available). There is a decontamination 
hood (biosafety cabinet) in the corner with an extraction fan. This was not working 
but was due to be repaired shortly. 
If the TB nurse requests an Xpert® MTB/RIF or culture (DST, LPA etc.) then specimens 
are sent to a nearby facility or reference laboratory respectively. MDR-TB services are 
offered at the clinic however there are very few cases (the TB nurse had attended one 
patient in the recent past). This patient was asked to come to the clinic in the afternoon 
when fewer patients were present and the sister made home visits if the patient was 
too sick to attend the clinic (going on foot) to limit exposure. Children are treated 
for TB in the facility. In the surrounding area, 20 community health care workers are 
assigned to make home visits to patients (with external funding). 
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Case study 2: Data collection in a hospital laboratory in Romania
To obtain the quantities, specifications and some costs for consumables, chemical, 
reagents and equipment used to analyse sputum smear (Ziehl Neelsen (ZN)) and 
culture Lowenstein-Jensen (LJ) samples for TB, a detailed interview was conducted 
with the senior microbiologist who performed the tests. 
The quantities were provided by the microbiologist during the interview and confirmed 
by observation of the analysis processes. The ZN and LJ samples were prepared for 
analysis in batches of 10, so observation of the analysis process occurred by returning 
to the laboratory two days later when there were sufficient samples.
Test-specific capital costs, primarily the equipment used in analysing the ZN and 
LJ tests, were determined by annualising the value of the equipment. This included 
the purchase price when obtained or the current market value, which was divided 
by the life expectancy of the equipment (at a 3% discount rate). The annual cost of 
maintenance was added to this value. The mean capital cost per test utilizing each 
piece of equipment was calculated by dividing the total annualized cost of each piece 
of equipment by the annual number of tests performed.
To obtain recurrent (utilities, insurance, linens and soft inventory, sterilization, 
cleaning, security and general office supplies) and capital (value of buildings and 
land, furniture, computers, general non-medical equipment and vehicles) overhead 
costs an interview was conducted with the financial director of the hospital during 
the following week. For salary and benefits information, the HR manager was called 
into the interview by the financial director and provided this personnel information, 
which was already available from an annual HR report. Additional overhead costs 
that were not readily available in pre-existing reports or in electronic files were later 
obtained by sending spreadsheets with the information required, for completion by 
the financial director.
The mean overhead costs per ZN and LJ tests were calculated by multiplying these 
annual overhead costs by the proportion of the square footage of the respective 
laboratories spaces which were on two different floors of the hospital wing. This was 
then divided by the total annual number of sputum samples analysed by ZN and LJ 
tests for each respective laboratory space. While the square footage of the hospital 
wing with the laboratories was provided by surveyor reports from the financial 
director, the space where the respective tests were performed was measured using a 
tape measure. The annual number of tests performed in each laboratory was obtained 
from the senior microbiologist.
Case study 3: Personnel time in Indonesia
The staff costs associated with IGRA tests in Indonesia were calculated by conducting 
interviews with the resident doctors who drew blood from patients in the clinic and 
time-motion studies to observe the laboratory technicians performing the analysis in 
an immunology laboratory.
The resident doctors were interviewed about the patient flow in the clinic. They were 
asked to estimate the time taken for the full patient consultation as well as the IGRA 
specific activities (talking to patient about the test and taking the blood) for a single 
patient. Data on the total time worked per month, the volume of patients seen at the 
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clinic and the number of patients receiving an IGRA test was obtained from the doctor 
in charge of the clinic.
For the immunology laboratory, the laboratory doctor was contacted and briefed on 
the objectives and methodology of the study which sought to determine the unit 
costs of screening and diagnostic tests for TB at a teaching hospital in West Java, 
Indonesia. Through the laboratory doctor, an appointment was made to meet with the 
two laboratory technicians who performed analysis of the blood samples. During this 
meeting, the technicians were also briefed on the objectives and costing methodology 
of the study. They explained the work flow of the analysis and the equipment used as 
well as some of the challenges of IGRA tests, particularly with maintaining the quality 
of the blood sample when collecting the blood from patients, during transportation 
and in the laboratory. They were then asked to participate in a time-motion study to 
capture the time taken for each task as well as details of the consumables, chemicals 
and reagents used. Since the IGRA test was new to the facility (implemented within the 
last year) the volume of samples was inconsistent and insufficient for daily analysis. 
Therefore, the analysis was done in batches, usually at the end of the week, and the 
time-motion study was scheduled for the following Friday.
On the day of the time-motion study the technicians were asked to review a diagram 
of the sample workflow and a list of the IGRA relevant equipment, consumables, 
chemicals and reagents that had been created after the initial meeting. Edits were 
made to the workflow and lists as needed. Each task was numbered sequentially. For 
the time-motion study data collection, the observer sat in a corner of the laboratory 
that provided a clear view of the processes involved in the analysis of the samples. As 
the technicians performed each task, the digital stopwatch on the observer’s phone 
was used to capture the time of each task by taking the lap time and notes were made 
about the activities in each task as well as the equipment and consumables used. The 
entire process for analysis was timed and annotated without interacting with the 
technicians. Waiting time and recording of results were also included in the time-
motion study. After the study, the technician was again asked to review the workflow 
as well as fill in any gaps with respect to the process or equipment, consumables, 
chemicals or reagents. 
The time-motion study was repeated the following Friday, but with a more junior 
technician. An average of the time taken to perform analysis on an IGRA test was 
used for the unit costs calculation. 
Note 1: Before approaching any of the clinicians or laboratory staff the approval 
letters from the ethics review committee and permission letters were forwarded to 
the persons in charge of the clinic and laboratory.
Note 2: The time taken for administration of the samples (when samples were 
delivered to the laboratory, and storage and disposal after analysis) was obtained by 
interviewing the laboratory doctor and technicians. It was not possible to include this 
in the time-motion study as these processes did not happen at the same time as the 
analysis.
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Appendix 12. Informed Consent Templates
Information Sheet
NAME OF INSTITUTION
Study Title: Costing the delivery of tuberculosis services in country name from a 
health systems’ perspective 
Lay Title: Examining how much it costs to deliver tuberculosis services in country 
name
Lead institutions Investigator
Other Institutions
Who is carrying out this study and what is this study about? 
This study is being carried out by name of lead institution with the Ministry of 
Health’s National Tuberculosis Programme, in collaboration with collaborator name 
(Principal Investigator). 
(Briefly describe lead institution).
Our researchers are visiting health facilities providing services for Tuberculosis 
(TB), to estimate the costs of providing these services. The aim of this research is to 
provide a comprehensive set of unit costs for TB services in country name. This cross-
sectional survey involves (insert number of facilities) healthcare facilities in country 
name sampled from private (for-profit and non-profit) and public facilities of different 
service levels. Your facility is one of those selected through a two-stage stratified 
cluster sampling process. The study will involve interviews with key staff members 
(between three and five individuals) in your facility, document reviews, observations 
and timesheets filled in by some of these staff members.
Why do you want to talk to the staff and what does it involve?
This study would involve key members of clinical staff. We would like to ask a number 
of questions about the running costs of providing TB services, the activities that the 
staff are involved in with regards to TB care, and how much time is taken up by each 
activity. 
If you agree to participate in this research, trained research assistants will perform the 
following: 
■n We will ask some questions about the clinical staff’s knowledge and experiences 
with managing patients with TB, the training and supervision that they have 
received, and the challenges that they encountered while managing TB. 
■n In order to value the type and quantities of inputs used in the staff’s daily clinical 
duties, we will review your facility’s project reports, financial and expenditure 
records, with the consent of the facility in-charge.
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■n We would also like to observe the staff as they carry out their daily clinical 
duties, in order to understand how much time in general it takes to conduct these 
activities. The observations will involve being present at the facility and observing 
and making notes about the conduct of various TB services provided. We will not 
be present during patient consultations but will record the length of time of the 
consultation by observing from a common area adjacent to the consultation area.
■n We would also like the staff to complete a timesheet that covers their activities 
during their working hours over the period of one week in order to have information 
on time spent on various activities.
Are there any risks or disadvantages to participation?
There is no major risk in participating in this study. The interview will take about 60 
minutes, while the observations will be conducted over a working day. We will not 
record the interview or the observations, but we will take detailed notes. All responses 
and observations will be treated confidentially.
The study participants may be uncertain whether they have the correct answers to 
some of the questions and this may make them feel uncomfortable. The participants 
are free to refuse to answer any questions. 
Are there any advantages to participation?
There are no individual benefits to taking part. In talking to us however, the study 
participants will directly help the National Tuberculosis Programme improve its 
services, and will help to plan its spending over the medium term. The overall data 
collected may also help National TB Programmes in other countries estimate the costs 
of their TB services, and plan better for their resources.
Who will have access to the information obtained?
All of our documents are stored securely in locked cabinets and on password protected 
computers. The interview will not bear any names; this way the responses will be 
anonymous. Information on the workload and typical resources used in the process 
of providing TB services will be aggregated into a total estimate of the unit cost per 
TB episode. 
The knowledge gained from this research will be shared in summary form, without 
revealing individuals’ identities, with all participating facilities, the NTP and 
collaborating institutions, and the wider scientific community, for instance through 
policy briefs and scientific publications.
In order to carry out this study, we will also share anonymized individual information 
we collect or generate with the Global Health Cost Consortium (GHCC) in ways that 
do not reveal individual participants’ identities. The cost data from this project will 
be incorporated in the web-based GHCC platform to improve extrapolations of cost 
across settings undertaken by the GHCC.
Who has allowed this research to take place?
All research has to be approved before it begins by several institutional, national 
and international committees who look carefully at planned work. They must agree 
that the research is important, relevant to country name and follows nationally and 
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internationally agreed research guidelines. This includes ensuring that all participants’ 
safety and rights are respected.
What will happen if I refuse to participate? 
All participation in research is voluntary. The staff are free to decide if they want to 
take part or not. If they do agree to participate, they can change their mind at any 
time without any consequences and without the need to give a reason. 
What if I have any questions?
You are free to ask me any question about this research. If you have any further 
questions about the study, you are free to contact the research team using the contacts 
below: 
Name, address, and contact information of lead at the research institute xxx, Telephone: 
+xxx, Email: xxx@yyy.com 
If you want to ask someone independent anything about this research, please 
contact:
Name, address, and contact information of the ethics lead at the research institute xxx, 
Telephone: +xxx, Email: xxx@yyy.com 
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Informed Consent Forms
NAME OF INSTITUTION
Study Title: Costing the delivery of tuberculosis services in country name from a 
health systems’ perspective 
Lay Title: Examining how much it costs to deliver tuberculosis services in country 
name
Lead institutions Investigator
Other Institutions
Who is carrying out this study and what is this study about? 
This study is being carried out by name of lead institution with the Ministry of 
Health’s National Tuberculosis Programme, in collaboration with collaborator name 
(Principal Investigator). 
(Briefly describe lead institution).
Our researchers are visiting health facilities providing services for Tuberculosis 
(TB), to estimate the costs of providing these services. The aim of this research is to 
provide a comprehensive set of unit costs for TB services in country name. This cross-
sectional survey involves (insert number of facilities) healthcare facilities in country 
name sampled from private (for-profit and non-profit) and public facilities of different 
service levels. Your facility is one of those selected through a two-stage stratified 
cluster sampling process. The study will involve interviews with key staff members 
(between 3 and 5 individuals) in your facility, document reviews, observations and 
timesheets filled in by some of these staff members.
Why do you want to talk to me and what does it involve?
As a key member of staff, we would like to ask you a number of questions about the 
running costs of providing TB services, the activities that are you are involved in, and 
how much of your time is taken up by each activity. 
If you agree to participate in this research, trained research assistants will perform the 
following: 
■n We will ask some questions about your knowledge and experiences with managing 
patients with TB, the training and supervision that you have received, and the 
challenges that you encountered while managing TB. 
■n In order to value the type and quantities of inputs used in your daily clinical duties, 
we will review your facility’s project reports, financial and expenditure records, 
with your consent.
■n We would also like to observe you as you carry out your daily clinical duties, in order 
to understand how much time in general it takes you to conduct these activities. 
The observations will involve being present at the facility and observing and making 
notes about the conduct of various TB services provided. We will not be present during 
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patient consultations but record the length of time of the consultation by observing from 
a common area adjacent to the consultation area.
■n We would also like to ask you to complete a timesheet that covers your activities 
during your working hours over the period of one week.
Are there any risks or disadvantages to me of taking part?
There are no major risks in participating in the study. The interview will take about 
60 minutes, while the observations will be conducted over a working day. We will not 
record the interview or the observations, but we will take detailed notes. All responses 
and observations will be treated confidentially.
You may be uncertain whether you have the correct answers to some of the questions 
to be asked and this may make you feel uncomfortable. You are free to refuse to answer 
any questions. However, in order to have good results from the study, it is important 
that you try to answer all questions correctly.
Are there any advantages to me of taking part?
There are no individual benefits to taking part. In talking to us however, you will 
directly help the National Tuberculosis Programme improve its services, and will help 
to plan its spending over the medium term. The overall data collected may also help 
National TB Programmes in other countries estimate the costs of their TB services, 
and plan better for their resources.
Who will have access to the information I give?
All of our documents are stored securely in locked cabinets and on password protected 
computers. Your questionnaire will not bear your names; this way your responses 
will be anonymous. Information on your workload and typical resources used in the 
process of providing TB services will be aggregated into a total estimate of the unit 
cost per TB episode.
The knowledge gained from this research will be shared in summary form, without 
revealing individuals’ identities, with all participating facilities, the NTP and 
collaborating institutions, and the wider scientific community, for instance through 
policy briefs and scientific publications.
In order to carry out this study, we will also share anonymized individual information 
we collect or generate with the Global Health Cost Consortium (GHCC) in ways that 
do not reveal individual participants’ identities. The cost data from this project will 
be incorporated in the web-based GHCC platform to improve extrapolations of cost 
across settings undertaken by the GHCC.
Who has allowed this research to take place?
All research has to be approved before it begins by several institutional, national 
and international committees who look carefully at planned work. They must agree 
that the research is important, relevant to country name and follows nationally and 
internationally agreed research guidelines. This includes ensuring that all participants’ 
safety and rights are respected.
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What will happen if I refuse to participate? 
All participation in research is voluntary. You are free to decide if you want to take 
part or not. If you do agree to participate, you can change your mind at any time 
without any consequences and without the need to give a reason. 
What if I have any questions?
You are free to ask me any question about this research. If you have any further 
questions about the study, you are free to contact the research team using the contacts 
below: 
Name, address, and contact information of lead at the research institute xxx, Telephone: 
+xxx, Email: xxx@yyy.com
If you want to ask someone independent anything about this research, please contact:
Name, address, and contact information of the ethics lead at the research institute xxx, 
Telephone: +xxx, Email: xxx@yyy.com 
CONSENT FORM
I have had the study explained to me. I have understood all that has been read/
explained and had my questions answered satisfactorily. Please write your initials next 
to each of the following three statements to provide consent.
____________ Yes, I agree for the interview/discussion to be conducted 
____________ Yes, I agree to take part in the observational research
____________ Yes, I agree to fill in a working timesheet over one week
I understand that I can change my mind at any stage and it will not affect me in any 
way.
Signature:  Date: 
Participant/guardian name:  Time: 
 (please print name)   
[Following section is recommended where verbal consent is obtained, and must be signed by 
person undertaking informed consent.]
I have followed the study’s standard operating procedure to obtain consent from 
the participant. S/he appeared to understand the nature and purpose of the study 
and consents to participation in the study. S/he has been given opportunity to ask 
questions which have been answered satisfactorily.
Designee/investigator’s signature: Date: 
Designee/investigator’s name:  Time: 
 (please print name
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